|
|
·|û¡Ghung120110149413 µoªí®É¶¡:2020/6/24 ¤U¤È 02:11:23
|
¥«³õº¨£·sÃÄ(¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸) Àø®Ä¤ÀªR p=0.009 6634 ªYÄ£ ªÑ¥»: 3.832»õ ¥Dn·~°È: ¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo ¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤) ¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤) Ä~Äò©¹¤U¬Ý...! ============================================================================= ²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ) ¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢ ²£«~Àu¶Õ: 1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ« 2.¥«³õº¨£·sÃÄ(First-in-class) 3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x 4.µL¦w¥þ©Ê°ÝÃD ¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C Ävª§¤O: 1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢ 2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯× 3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x ¬ãµo¶¥¬q: 1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á 2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ Àø®Ä¤ÀªR¡G 1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n 2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009) ============================================================================= ²£«~02¡GSNP-630 ¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢ ²£«~Àu¶Õ: 1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE) 2.¥«³õº¨£·sÃÄ(First-in-class) 3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x 4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~ ¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C Ävª§¤O: 1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢ 2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯× 3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡ 4.µL¦w¥þ©Ê°ÝÃD ¬ãµo¶¥¬q: 1.Á{§É«e 2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C 3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C Àø®Ä¤ÀªR¡G 1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05 ============================================================================= ²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯) ¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯) ²£«~Àu¶Õ: 1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê 2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs) 3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q ¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ Ävª§¤O: 1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ« 2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^ 3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O ¬ãµo¶¥¬q: 1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç 2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D 3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç ============================================================================= ²£«~04¡GSNP-830/ SNP-840 ¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh) ²£«~Àu¶Õ: 1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è 2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q ¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ Ävª§¤O: 1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è 2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä 3.¦³¨Ï¥Î±M§Q¡A¥iקï©Î§R°£FDA¨x¬rĵ»y 4.¥i¼W¥[¤AñQÓi×ô¾¯¶q ¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î 5.¤GªÌ¾Ü¤@±ÂÅv 6.¥i¼W¥[¥«¦û²v ¬ãµo¶¥¬q: 1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ ============================================================================= ***************************************************************************** SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G 1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005 1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005 ============================================================================= ***************************************************************************** ¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G 1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv 2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv 3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv ============================================================================= ***************************************************************************** ¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º §Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó ¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄÆªÑ ----------------------------------------------------------------------------- ¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×) |
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/4/20 ¤W¤È 07:40:59²Ä 3109 ½g¦^À³
|
¬O»¡§Ú¦b³Ì±`µe¤j»æ? ¦^¥h¬Ý¥J²Ó. §Ú³Ì¬D¾Ô¥»¸sºô¤Íªº¤j»æ§a. n§åµû§O¤H, ¤]n¬Ý²M·¡¦³ÃÒ¾Ú. ¤½¥q810Á{3°µ§¹,±ÂÅv±q2020´N¦b½Í¨Sµ²ªG. ²{¦b¤S¦³¤H«÷©R¦b±À610Á{2§¹±ÂÅv. 630§ó´Î´Î...³£¦³¥»ª©ºô¤Í»¡¬O¹Ú¨ìªº¤F... |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/4/20 ¤W¤È 12:44:11²Ä 3108 ½g¦^À³
|
³Ì±`µe¤j»æªº¤£´N¬O§A¶Ü¡H¡K |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/4/19 ¤U¤È 07:22:14²Ä 3107 ½g¦^À³
|
²{¦b810Á{3°µ§¹,±ÂÅv¤]½Í¤F»á¤[¨S®ø®§. ¤S¦A»¡610Á{2°µ§¹µo°Ê±ÂÅv. ¬O§_610Á{2°µ§¹¤Sµ¥Á{3? 610Á{3§¹¦Aµ¥630? ©Î¦A·d1Ó910? ¤£Â_µe¤j»æ? |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/4/19 ¤W¤È 09:16:19²Ä 3106 ½g¦^À³
|
¤H¤H³£º¦¡A´NªYÄ£¤£º¦~ §Q¦h => ¶^ §QªÅ => ¶^ ¤H®aº¦ => Ä~Äò¶^ ¤H®a¶^ => ¤@°_¶^ ¾ãÓ´N³Qª±Äê¤F~¸Ì±¦Ñ¤HÌÀ³¸Ó¤]°µ¦n¥´ºâ¤F~ °µ¦n°¸º¸©ñ©ñ¦n®ø®§¡AµM«á¦b¤½¥q°®»â°ªÁ~¨ì°h¥ðªº¥´ºâ~ |
|
|
·|û¡GJames10139245 µoªí®É¶¡:2023/4/18 ¤U¤È 12:03:39²Ä 3105 ½g¦^À³
|
§äºô¬õ¨Ó½æ¡A¥´¥Xª¾¦W«×¡A±ÂÅv¶O·|«Ü¦n½Í |
|
|
·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2023/4/17 ¤U¤È 08:26:17²Ä 3104 ½g¦^À³
|
¤T¤ë¥÷¦¶¸³¼W¥[65±i,ºµ°ÆÁ`´î¤Ö44±i,¦ó¨ó²z¼W¥[118.5±i¡C 6786ªä´ú 110/03/08¨ú±o¸gÀÙ³¡¤u·~§½¥X¨ã¤§¡u«YÄݬì§Þ¨Æ·~¤Î²£«~¶}µo¦¨¥\¥B¨ã¥«³õ©Ê¡v¤§·N¨£®Ñ¡C¦]¬G¹O´ÁµL´£¥X¤WÂd¥Ó½Ð 112/04/17¦A«×¨ú±o·N¨£®Ñ¡A¦A«×¬D¾Ô¤W¥«Âd |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/17 ¤U¤È 08:02:25²Ä 3103 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/16 ¤W¤È 07:35:00²Ä 3032 ½g¦^À³ 2023.3.8 FDA ±j¨î½Õ¾ã´¶³q Rx(³B¤èÃÄ)¤îµhÃÄ¥i¯à®¾±Ï¥Í©R ...... OTC[«D³B¤è]ªºAPAPªº¦í°|²v¦b¦P¤@®É´Á¤º¹ê»Ú¤W«D¦ý¨S¦³´î¤ÖÁÙ[¼W¥[][¼W¥[][¼W¥[]¡C OTC[«D³B¤è]ªºAPAPªº¦í°|²v¦b¦P¤@®É´Á¤º¹ê»Ú¤W«D¦ý¨S¦³´î¤ÖÁÙ[¼W¥[][¼W¥[][¼W¥[]¡C OTC[«D³B¤è]ªºAPAPªº¦í°|²v¦b¦P¤@®É´Á¤º¹ê»Ú¤W«D¦ý¨S¦³´î¤ÖÁÙ[¼W¥[][¼W¥[][¼W¥[]¡C ------------------------------------------------------------------------------------------------ Ä~¿D¬w¤§«á¡A¥i¹w´Á¬ü°êFDA¤]·|¹ï[«D³B¤è]APAP°µ¥X¥]¸Ë¨î! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/17 ¤U¤È 07:56:48²Ä 3102 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/29 ¤U¤È 12:56:11²Ä 2563 ½g¦^À³ ¿D¬wTGAªº±M®a¿Ô¸ß©eû·|¦b11¤ë±N¨M©w§ïÅÜ¥Á²³Àò±o´¶®³¯kªº¤è¦¡! ¦b¤@¥÷¿W¥ß±M®a³ø§iºÙ«C¤Ö¦~ÀݥΡ§¥O¤H¾á¼~ªº¼W¥[¡¨«á¡A¼³¼ö®§µh¦b¿D¤j§Q¨Èªº¾P°â¥i¯à·|¨ü¨ì¨î¡C ------------------------------------------------------------------------------------------------- 2023.2.3-TGA °µ¥X´î¤Ö¼³¼ö®§µh³Ì¤j¥]¸Ë¤Ø¤oªºÁ{®É¨M©w www.tga.gov.au/news/media-releases/tga-makes-interim-decision-reduce-maximum-paracetamol-pack-sizes TGA¤µ¤Ñµo¥¬¤F¤@¶µÁ{®É¨M©w¡A¥H´î¤Ö¦UºØ¼³¼ö®§µh²£«~ªº³Ì¤j¥]¸Ë®e¶q.... |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/4/16 ¤U¤È 10:33:46²Ä 3101 ½g¦^À³
|
45·³³¯©m¤k¤l¡A¦]¬°¦Y¹L¶q´¶®³¯k¡A²rÃz©Ê¨xª¢¡A¨x«ü¼Æöt°ª124¿~~ JP²o½u¨ì¤¤°ê·íÄd¸ôªê?? |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/4/15 ¤U¤È 12:41:31²Ä 3100 ½g¦^À³
|
ªYÄ£¬O²£©x¾Ç²Õ¦¨¹Î¶¤¡A«e±¶K¤å¦³Jp¾Ç¸g¾ú¤¶²ÐªÅ«eÄ£²´¡A¤]¬OªYÄ£ÆF»î¤Hª«¡F¦¶¸³¦³»¡¹L¡A610¤G´Á«án±ÂÅv¥X¥h¡F¶È³Ñ³Ì¬Ã¶Q¡B»ùȪº630¡A§Æ±æ¯à¨«§¹3´Á»ùȽ¿¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/15 ¤W¤È 08:23:41²Ä 3099 ½g¦^À³
|
¤½¥q²¤¶-¹Î¶¤¦X·ÓJP´NºÝºÝ¥¿¥¿§¤¦bC¦ì |
|
|
·|û¡Gª÷¨©¨©10153227 µoªí®É¶¡:2023/4/15 ¤W¤È 01:25:21²Ä 3098 ½g¦^À³
|
¤½¥qºô¯¸¨S§ä¨ìJP¡A¹õ«á¶Â¤â¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/14 ¤U¤È 01:07:38²Ä 3097 ½g¦^À³
|
2022.9.28-¯q¥Íµß§í¨î¨x²ÓM¯S²§©Ê PTEN ºV°£¤p¹«ªº«D°sºë©Ê¯×ªÕ©Ê¨xª¢©MÀùÅܶi®i www.nature.com/articles/s41598-022-20296-3 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/14 ¤U¤È 01:01:34²Ä 3096 ½g¦^À³
|
2022.6.24-¯q¥Íµß¡G§@¬°¹ï§Ü¹ï¤A酰®ò°ò×ô»¤¾Éªº¨x¬r©Êªº¼ç¦bªvÀø¿ï¾Üµo®iwww.ncbi.nlm.nih.gov/pmc/articles/PMC9312935/ --------------------------------------------------------------------------------------------- ¬ã¨sªí©ú¡A¯q¥Íµß¸É¥R¾¯¥i§í¨î»P APAP »¤¾ÉªºµÇ¬r©Ê¬ÛÃöªº³sÄò¨Æ¥ó¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/14 ¤U¤È 12:50:18²Ä 3095 ½g¦^À³
|
¡u¨x¸z¶b½u¡v ¬°¦ó¸z¹Dµß»P¨xŦ¦³Ãö¡H¨xŦ»P¸z¹D¤§¶¡¦³Ó¡u¸z¡X¨x¶b½u¡v¡A³z¹L¨xªùÀR¯ß»PÁxºÞ³s±µ©¼¦¹¡C¸z¹D©Ò§l¦¬ªºÀç¾i·|³z¹L¨xªùÀR¯ß¶Ç°e¨ì¨xŦ¡A¦Ó¨xŦ¤]·|¦X¦¨¡uªì¯ÅÁx»Ä¡v¡A´£¨Ñµ¹¸z¹DµßÂà¤Æ¦¨¡u¦¸¯ÅÁx»Ä¡v¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/14 ¤U¤È 12:45:39²Ä 3094 ½g¦^À³
|
1.¡u¨x¸z¶b½u¡v www.top1health.com/article/84967 ¬ã¨s¡G¸É¥R¯S©w¯q¥Íµß¥i¼vÅT¨xŦ¥NÁ¡A´î½w¯×ªÕ¨xÄY««× ®Ú¾Ú¤@¶µ¨Ó¦Û¦ÌÄõ¤j¾Ç¤@¯ë¯f²z¥Í²z¾Ç»P²¾´Ó¾Ç¨t¡]Department of Pathophysiology and Transplantation, Università degli Studi di Milano¡^ªº°¨¨½¥d・±öù¥§±Ð±Â¡]Dr.Marica Meroni¡^¤Î¨ä¬ã¨s¹Î¶¤©Ò¶i¦æ¡A¨Ãµoªí¦b¡mÀç¾i¾Ç´Á¥Z¡n¡]Nutrients¡^ªº¬ã¨s«ü¥X¡A¾A¶q¸É¥R¯S©w¯q¥Íµß¡A¦ü¥G¥i¥HÂǥѼvÅT¨xŦªº¥NÁÂ¥\¯à¡A¥H´î½w¯×ªÕ¨xªºÄY««×¡C ¬ã¨s¤Hû«ü¥X¡A·í¸z¹Dµß¸s¥¢¿Å¡A¥i¯à·|¾ÉP¸z¹Dl¥Íªº²Óµß©M¤º¬r¯À¶i¤J¨x¸z¶b½u¡A¥i¯à¶i¤@¨B¾ÉP«D°sºë©Ê¯×ªÕ©Ê¨xª¢¡]NASH¡^¡B¨xÅÖºû¤Æ¡]Liver fibrosis, LF¡^¡B¨xµw¤Æ(Liver cirrhosis, LC)¡A¬Æ¦Ü¬O¨xÀù(Liver cancer)ªºµo¥Í¡C 2.¡u¨x¸z¶b½u¡v 2022.8.14-¦Y¯q¥Íµß[¨xŦ]¤ÆÁw¦í°|¡I(¤å³¹¦Û·j) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/14 ¤U¤È 12:37:16²Ä 3093 ½g¦^À³
|
2022.1.12 ¸z¹Dµß ¦p¦ó¼vÅT[¨xŦ]»P¥þ¨°·±d¡H www.liver.org.tw/journalView.php?cat=73&sid=1054&page=1 ·LµßÂO»P¨xŦ°·±dÃö«Y±K¤Á |
|
|
·|û¡G¤p¨k¤H10151116 µoªí®É¶¡:2023/4/14 ¤U¤È 12:15:53²Ä 3092 ½g¦^À³
|
°¸µM¬Ý¨ì¼Æ¦r»È¦æªºÂ¾¯Ê¡A·Q½Ð±Ð¤j®a«ç»ò¬Ý¡HÂ૬¯q¥Íµß¦n¶Ü¡H ¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡×¡× ¬ã¨sû(¯q¥ÍµßÀ³¥Î¬ã¨s, ¨xŦ¯e¯f¬ãµo³B) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/13 ¤U¤È 02:10:41²Ä 3091 ½g¦^À³
|
¥¿¤j¤Ñ´¸[¯S别¬O¨Ì¦«¥x¥_医学¤j学开®i¤H¤~发®i°ö训] §Æ±æ¦³¦n®ø®§! ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/25 ¤W¤È 09:19:37²Ä 2540 ½g¦^À³ SNP-610Àu©óElafibranor (PPAR£\/£_¿E动剂) Genfit»PIpsen (¶R¤U´¼Àº¯ØŦÀùÃĪ«)¦b2021¦~ñ4.8»õ¬ü¤¸±ÂÅvElafibranorªvÀøìµo©ÊÁx¥Ä©ÊÁxºÞª¢(PBC)¸ÕÅç VS. ¥¿¤j¤Ñ´¸ªá3.07»õ¬ü¤¸ªº[PPAR]¿E动剂Lanifibranor ¡A¥i¿E¬¡PPARªº¥þ³¡3Ïú亚«¬£\¡B£^¡B£_¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/13 ¤U¤È 02:00:06²Ä 3090 ½g¦^À³
|
ªYÄ£I«á¬OJP! www.facebook.com/linkingpros/videos/315346746891378 2:54:00 ~JP¦ÛӨ໡¥¥x(SNP810/SNP610§Þ³N¥¥x)I«á¬O¥L.... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/13 ¤U¤È 01:32:50²Ä 3089 ½g¦^À³
|
¶W3亿¬ü¤¸¡I¥¿¤j¤Ñ´¸¤Þ进¤fªANASH·s药 2022¦~9¤ë21¤é¡AInventiva«Å¥¬¡A¨äÉO¤¤国¥Íª«¨î药ªº¤l¤½¥q¥¿¤j¤Ñ´¸药业¶°团¦³¤½¥q达¦¨¦X§@协议¡A¦@¦P开发©M°Ó业¤ÆInventiva¦Û¥D¬ã发ªºªxPPAR¿E动剂lanifibranor¡A¥Î¤_ªv疗«D°sºë©Ê¯×ªÕ©Ê¨xª¢¡]NASH¡^©Mýͦbªº¨ä¥L¥N谢¯e¯f¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/13 ¤U¤È 01:26:32²Ä 3088 ½g¦^À³
|
ªYÄ£I«á¬OJP! JP(¥x¥_Âå¾Ç¤j¾ÇÁ¿®y±Ð±Â)¨üÁÜ¥X®u¡A§Æ±æ¦³¤õªá![¦X§@备§Ñ录¬O¨Ì¦«¥x¥_医学¤j学开®i¤H¤~发®i°ö训] ¥¿¤j¤Ñ´¸«点¥´³y肿½F¡B¨x¯f¡B©I§lµ¥产«~¶°¸s¡A35个¦~销°â过亿¤¸产«~§Î¦¨¡§亿¤¸产«~¸s¡¨¡C°£¨x¯f领°ì¥~... ------------------------------------------------------------------------------------------------ 2023.3.28-®ü峡两©¤医药卫¥Í¥æ¬y协会ÉO«n¨Ê¥¿¤j¤Ñ´¸¨î药¦³¤½¥q签¸p战²¤¦X§@备§Ñ录www.acsme.org.cn/xwdt/202303/t20230331_12522960.html 2023¦~3¤ë25¤é¡A®ü峡两©¤医药卫¥Í¥æ¬y协会ÉO«n¨Ê¥¿¤j¤Ñ´¸¨î药¦³¤½¥q¦b®ü¤f¥«¥l开2023¦~®ü峡两©¤医°|药学¤j会º[®ü峡两©¤医药卫¥Í¥æ¬y协会医°|药学专©e会²Ä¤届学术¦~会¤§际签¸p战²¤¦X§@备§Ñ录¡C 双¤è¦b医°|药学领°ì学术¥æ¬y¦X§@¤è±达¦¨¦@识¡A[¯S别¬O¨Ì¦«¥x¥_医学¤j学开®i¤H¤~发®i°ö训] 签¸p仪¦¡¤W¡A®ü峡两©¤卫¥Í¥æ¬y协会¯µ书长¥Ð伟¡B«n¨Ê¥¿¤j¤Ñ´¸¨î药¦³¤½¥q±`务°Æ总µô张¾_°®¤À别¥Nªí双¤è签¸p战²¤¦X§@备§Ñ录¡AÁÜ请¤F®ü峡两©¤卫¥Í¥æ¬y协会会长¤ý¥ß°ò¡B®ü医会医°|药学专©e会¦W誉¥D©e¡B¥x¥_医学¤j学±Ð±Â[J¥®®E] ------------------------------------------------------------------------------------------------- 1.¥¿¤j¤Ñ´¸开¬E¤F¡I61´Ú1类·s药¡B7个«½S单§ÜÅQ«Ìm.antpedia.com/news/2842209.html 2.2019.2.28-«n¨Ê¥¿¤j¤Ñ´¸ÉOAbpro达¦¨40亿¬ü¤¸ªº±Â权¤Þ进协议 3.2022.12.30-¤é¥»塩³¥¸q·s«a¤fªAÃÄ Ensitrelvir¡I¿W®a±ÂÅv¤¤°êÃÄ·~¥¿¤j¤Ñ´¸³c°â |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/4/13 ¤W¤È 11:44:57²Ä 3087 ½g¦^À³
|
¥Í§Þ¤½¥q³W¼Ò¨ì¤@µ{«×, ´Nn±M·~¤Æ¤Î¥ø·~¤Æ. ±M·~¤Æn¸u½Ð°ê»Ú¤Æ°Ó·~½Í§P¤H¤~. ¥ø·~¤Æ§ä¦³°ê»Ú¤H¯ß½Í¦X§@¤Þ¶iµ¦²¤¹Ù¦ñ¤Î±ÂÅv¹ï¶H. ¤j®a¥i°Ñ¦Ò¥þºÖ¤µ¦~ªº²Õ´«²Õ§G§½. ªYÄ£ÁÙ¦b¬ãµo³Õ¤h¥´¤Ñ¤U, ¤S¬OxÂå¾Ç°|³Õ¤h. |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/4/13 ¤W¤È 09:57:22²Ä 3086 ½g¦^À³
|
¨þ¨þ¡A¼é¤ô°hÅo~~ ¤â¸}³£³Q¬Ý¯}Åo~~ ³Ñ¤U°¸º¸µoµo¬Y°ê±M§Q¤S³q¹Lªº¤½§i¦Û¶Ù¤@¤U~ µM«á¤º³¡¥DºÞ³£»â°ªÁ~µ¥µÛ°h¥ð~ ¤£·\¬O¤@°ï°ê¨¾Âå¾ÇI´º¥X¨Óªº±M®a~ °µ¨Æ±¡³£«Ü°ê¨¾~¤£EY¤F~ |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/4/9 ¤U¤È 05:48:35²Ä 3085 ½g¦^À³
|
ì¨Ó810°µ¤Fp3°Ú¡Kªøª¾ÃÑ¡C ¥Í§Þ¤½¥qªºº¦¶^¸ò¥¼¨Óªºcatalyst¦³Ãö¡A6¨t¦C¤G´Á¨S¶}©l¦¬®×¡A°ê¥~Nash¤½¥qº¦¸òªYÄ£¤]µLÃö¡C µu´Á¥u¯à¬Ý810¦³¨S¦³·s¶i«×¡AJeff¤j¦ôp¤]¬O¬Ýª¯ªº¸ÕÅç®Éµ{¹w¨¥ªº§a¡H |
|
|
·|û¡GBear10152946 µoªí®É¶¡:2023/4/9 ¤W¤È 11:47:16²Ä 3084 ½g¦^À³
|
¶^¨ì³o¡A±ÂÅv¸ò¬ãµo¬O¤£¦¨¥\¤F¡H «e¦~¤w¥Ó½Ð¼Ï¯Ã¸ÕÅç¡A FDA«o¥¼®Ö·Ç¡A¹ê¦b¬O«Ü©Ç¡A ¬O¦³¤°»òºÃ¼{ªº¶Ü¡H ¨S³B¤èÃÄÃÒ¡A³æotc ³\¥i¡A¬O§_´N¨S¦³»ùȤF°Ú¡H |
|
|
·|û¡G¤p¨k¤H10151116 µoªí®É¶¡:2023/4/9 ¤W¤È 09:11:18²Ä 3083 ½g¦^À³
|
½Ð°Ý¦³¤Hª¾¹D³Ç¤Òªº¤£t³d²q´úì¦]¶Ü¡H |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/4/8 ¤U¤È 07:37:22²Ä 3082 ½g¦^À³
|
810²{¦b¬O±ÂÅv¦X§@¨óij¶i¦æ¤¤¡A¦p¯à³Ç¤Ò±¡³ø¤@Ӥ릳®ø®§«Ü¦n¡IY¨S¦³®ø®§¤]¥Nªí§ó¾aªñ½µPªº¤é¤l¤F¡G830¦]µL¬r¥i¥H¥[ÃĶq¡A¦¨¥\¨ÓÁ{´N¾a®É¶¡¡Fr¤j¶K¤å¨xª¢ÃÄ«ü«n2¡B3Á{§Én12¨ì18Ó¤ë¡A6¨t3Ӥ볣°¦Ê¤À¤§29¤F¡A®É¶¡¥[ªø°´T·|§ó¤j¡I¥¼¨Ó¤]¬O¼ÖÆ[¡IÁ`»¡¯à°í«ù§ë¸ê5¨ì7¦~ªºªÑªF¥²¯à°ª³ø¹S¡I¤j®a¦@«j¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/4/7 ¤U¤È 12:12:36²Ä 3081 ½g¦^À³
|
810Á{3³£°µ§¹¤FµLªk±ÂÅv. ¤S¦A´Á«Ý610Á{2§¹±ÂÅv? §ó¤£¥Î»¡630¤F. |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/4/7 ¤W¤È 08:51:36²Ä 3080 ½g¦^À³
|
¤j®a³£¬Oªø´Á§ë¸êªÑªF¡A¥u¬OÂà¶Kµy®¶¾Ä¶K¤å¡A·í°Ñ¦Ò´N¦n¡F·Å¬Gª¾·s¡A¦A¬Ý«e±¶K¤å¸ê®Æ¡A¦¶¸³¹ï610¬On¦b2´Á§¹¦¨±ÂÅv¥X¥h¡F630¤ñ¸û·m¤â¡A¤½¥q¤]´Á«Ý°ª¡I§Æ±æ«e±¦³ÃıÂÅv¥X¥h¡A¸êª÷¥R¨¬¯à«÷3´Á»ùȽ¿¡C |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/4/6 ¤W¤È 09:21:29²Ä 3079 ½g¦^À³
|
¬°Ô£·|¦³¤H¥h¬Û«H¦P¾Ç·|JEXX³oºØ¨S®Ú¾Úªº²q´ú? ¦pªG¥u¬O³æ¯Â¥Î¤é´Á¥h±Àºâ¡A¤j®a³£¥i¥H»¡¤@®M»¡µü¡A §Ú¤]¥i¥H»¡®Ú¾Ú¤£t³d¥ô¤ÀªR¨âÓ¤ë«á¥i¯à·|¦³®ø®§¥X¨Ó¡A ³oºØ»¡µü¤H¤H³£¯àÁ¿¡A ¦pªG¯u³Ñ¤U¤@Ӥ릴N¤ÏÀ³¦bªÑ»ù¤F! ´²¤á³Ì©Èªº´N¬O³o¼Ë~¶^¨ì«á±¶}©l¦UºØ¸£¸É¸ò¦Û§Ú¦w¼¢~ µM«á©¿²¤¤F³Ì¯u¹ê±ªºªF¦è~ |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/4/2 ¤W¤È 07:31:19²Ä 3078 ½g¦^À³
|
810ªº®ø®§¦pªG¤£¬O±ÂÅv¦³¬ð¯},¥u¬O¼Ï¯Ã¶i«×©Î¤SÀò±M§Q¤]¨S¬Æ»ò¤j¥Î. 810¤w¸g¨ì¸Ó¹ê²{¹ê½èÀò§Q§Q¦h®ÉÔ. ¥t¥~§Q¦hÁ`¦³¤H¥ýª¾¹D,ªÑ»ù¤]·|¥ý¤ÏÀ³. ¦pªG¯u¦³¹ê½è§Q¦h,ªÑ»ù4¤ë¸Ó«ªð100. |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/4/1 ¤W¤È 09:49:05²Ä 3077 ½g¦^À³
|
ªYÄ£µL¨xµÇ¬r©Ò¥H¥[¶q¤AñQ¦w×ô¦b°¾ÀYµh©Î¨ä¥L¦UºØ¤j¤pµh¡A³£¯à«Ü¦³®Ä¥B¦w¥þ¡FªYÄ£¸ô¦h¥B¼s¡A¦n¦n¥[ªo¡IÂà¶K¹j¾À³ø®Æ¦P¾Ç·|³Ç¤Ò¶K¤å¡G¡u®Ú¾Ú¥L·j¶°ªº¸ê°T¡A810¤@Ӥ뤺¥i¯à·|¦³®ø®§¡A¥L¬O¤£t³dªº¡C¡vÁÂÁÂ¥Lªº¸ê°T´£¨Ñ¡C¤j®a¥i¥H¥[¤j´Á«Ý·í°Ñ¦Ò¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/1 ¤W¤È 09:44:44²Ä 3076 ½g¦^À³
|
2018¦~---ªA¥Î«D³B¤è¼³¼ö®§µh¥i¦³®Ä½w¸Ñ«æ©Ê»´«×¦Ü¤¤«×¯kµhªº[¾¯¶q] Charly Gaul 1 , * , # , Alain Eschalier 2 , # Königstein °¾ÀYµh©MÀYµh¶E©Ò¡A61462 Königstein im Taunus¡A¼w°ê §JµÜ»X¶ø¥±¯I¤j¾Ç¡AUMR Inserm Neuro-dol¡AÂíµh¬ã¨s©Ò¡Aªk°ê§JµÜ»X¶O®Ô openpainjournal.com/VOLUME/11/PAGE/12/FULLTEXT/ I´º¡G ¼³¼ö®§µh¡]¹ï¤A酰®ò°ò×ô¡^¬O³Ì¼sªx¨Ï¥Îªº«D³B¤è (OTC) ÂíµhÃĤ§¤@¡A¥Î©ó¦Û§ÚªvÀø»´«×¦Ü¤¤«×«æ©Ê¯kµh¡C¤£¦Pªº°ê®a¨Ï¥Î¤£¦Pªº¾¯¶q¡A¦b¨ä¤¤¤@¨Ç°ê®a¡A«Ü¤j¤@³¡¤À¦¨¦~¤H¨Ï¥Î§C¾¯¶q¡]325 ²@§J¦Ü 500 ²@§J¡^¡C ¥Ø¼Ð¡G ¸Ó¬ã¨sªº¥Øªº¬O¦^ÅU¤wµoªí¬ã¨sªº«H®§¡A¥H¦^µª¥H¤U°ÝÃD¡G¼³¼ö®§µh¦bªvÀø»´«×¦Ü¤¤«×«æ©Ê¯kµh¤è±¬O§_¨ã¦³¾¯¶q¨Ì¿à©ÊÂíµh§@¥Î¡H ¤èªk¡G ¹ï²{¦³¨t²Îµû»ù¡BîPµÑ¤ÀªR©M³æ¤@ÀH¾÷¸ÕÅ窺¸Ô²Óµû¦ô¬O®Ú¾Ú¹q¤l¤åÄm·j¯Á¶i¦æªº¡A«ÂI¬O¤ñ¸û°ª¾¯¶q©M§C¾¯¶q¼³¼ö®§µhªvÀø»´«×¦Ü¤¤«×«æ©Ê¯kµhªº¬ã¨s¡C µ²ªG¡G ¼f¬d©M¤ñ¸û¸ÕÅç´¶¹Mªí©ú¡A»P§C¾¯¶q¡]500 ²@§J©Î 650 ²@§J¡^¬Û¤ñ¡A°ª¾¯¶q¼³¼ö®§µh¡]1000 ²@§J¡^¦b¹ê²{Á{§ÉÅãµÛ¯kµh½w¸Ñ¤è±¨ã¦³§ó¤jªºÀø®Ä¡A¨Ã¥B¹ï¤£¦PÃþ«¬ªº¯kµh¨ã¦³¥i¤ñªº@¨ü©Ê¡C µ²½× ¯kµhªº©Ê½è©M±j«×¬OªvÀø¿ï¾Üªº¨âÓÃöÁä¦]¯À¡C ¸û°ª¾¯¶qªº³tÄÀ¼³¼ö®§µh (1000 mg)¡A¨Ï¥Î®É¶¡¸ûµu¡]4-5 ¤Ñ¡^¡A¨Ã¿í¦u¼ÐÅÒ¤º°w¹ï·ÀI¤H¸sªº«Øij¡A»P»´«×¦Ü¤¤«×¦¨¤Hªº§C¾¯¶q¬Û¤ñ¡A¥i´£¨Ñ¦w¥þ¥B§ó¦³®ÄªºÂíµh®ÄªG«æ©Ê¯kµh¡C ---------------------------------------------------------------------------------------------- ¥L̬ã¨sµ²ªGªº¹ê»Ú·N¸q¬O¡A»P§C¾¯¶q¬Û¤ñ¡A¸û°ª¾¯¶qªº¼³¼ö®§µh¥i¬°§ó¦h±wªÌ´£¨Ñ¨¬°÷ªºÂíµh®ÄªG¡C ´X¶µ¬ã¨s³ø§i¤F¹ï¤A酰®ò°ò×ôªº¤£¨}©Î¬r©Ê§@¥Î¡A§Ú̦b¤W±´£¨ì¤F¨x¬r©Êªº·ÀI¡A¨Ã«Øij¹ï¦³¤£¨}¤ÏÀ³·ÀI©Î¯S®í±¡ªpªº¨ü¸ÕªÌÂÔ·V¨Ï¥Î¡C ¨º»ò¥i¥H¬I¥Î§ó°ª¾¯¶qªºµL¨x¬rSNP-810ªºÂíµh®ÄªG??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/4/1 ¤W¤È 09:24:11²Ä 3075 ½g¦^À³
|
ªvÀYµhÃĪ«È¿ú¤£? 2021½÷·ç¯{ 12.4»õ¬ü¤¸¬O¤£¥]§t¬ü°ê¥«³õ(Biohaven¦ÛÓ¨à½æ) 2022½÷·ç¥H116»õ¬ü¤¸²{ª÷¦¬ÁÊ°¾ÀYµhÃÄ°ÓBiohaven ------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/2/28 ¤U¤È 10:14:42²Ä 1756 ½g¦^À³ SNP-810±ÂÅv«á¦A°µ´XÓ°¾ÀYµhÁ{§É¹êÅç¡A°£¤F»´¯g¡A©Î³\¤¤«¯g¤]¯à¦¨¬°¤@½uÃĪ«! 1.2021.11.10 ½÷·ç¯{ 12.4»õ¬ü¤¸¶R°¾ÀYµhÃĪ«Rimegepant(°ß¤@¤ä¤fªACGRP药ª«) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/31 ¤U¤È 11:40:20²Ä 3074 ½g¦^À³
|
Last week Teva Pharmaceuticals colleagues took part in the European Headache Federation EHF congress, ... ... --------------------------------------------------------------------------------- Krisztina Gyimes, (§ô¤O¶®) 3Ó¤ë«e´N¬O²Ä 16 ©¡¼Ú¬wÀYµh¤j·|®É¶¡ ... ... On behalf of Sinew Pharma, we would like to join you in your discussion and potentially collaborate. Our Team¡¦s hepatotoxicity-free, significantly safer, acetaminophen might hold the key to tackling migraine. §ÚÌ¥NªíªYÄ£Âå·~¡AÄ@·N¥[¤J§A̪º°Q½×¨Ã¶i¦æ¼ç¦bªº¦X§@¡C§Ú̹椪ºµL¨x¬r©Ê¡B©úÅã§ó¦w¥þªº¹ï¤A酰®ò°ò×ô¥i¯à¬O¸Ñ¨M°¾ÀYµhªºÃöÁä¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/31 ¤U¤È 11:34:25²Ä 3073 ½g¦^À³
|
2022 ¦~ 12 ¤ë 7-10 ¤é ²Ä 16 ©¡¼Ú¬wÀYµh¤j·|·|ijºKnthejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01527-4 P181 ¥ÎParacetamol¡]Acetaminophen¡^ªvÀø«æ©Ê°¾ÀYµhªº¹ê½î«ü«nªººtÅÜ ¥Øªº¡G ¹ï«æ©Ê°¾ÀYµh¤¤¨Ï¥Î¼³¼ö®§µhªº¤£¦P«ü«nªºªø´ÁºtÅܶi¦æ©w©Êµû¦ô¡C ¤èªk¡G ¹ï¨Ó¦Û5Ó¬ì¾Ç¨ó·|ªº10Ó¤wµoªíªº«ü«n¶i¦æµû¦ô¡A¥]¬A¬ü°êÀYµh¨ó·|¡]AHS¡^¡B«e¬ü°ê¯«¸g¯f¾Ç·|¡]AAN¡^¡Bªk°êÀYµh¨ó·|¡^¡B¥[®³¤jÀYµh¨ó·|¡]CHS¡^¡B¼Ú¬w¯«¸g¾Ç·|Áp¦X·|¡]EFNS¡^©M¼Ú¬wÀYµhÁp¦X·|¡]EHF¡^¡C .... µ²½×¡G [¦b³Ì·sªº«ü«n¤¤¡A¹ï¤A酰®ò°ò×ôªº«Øij¦³¤F¿n·¥ªºµo®i¡C²{¦b¡A¤j¦h¼Æ«ü«n³£«Øij¹ï»´«×¦Ü¤¤«×¯kµh¨Ï¥Î¼³¼ö®§µh¡C] ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/12 ¤U¤È 12:34:05²Ä 1979 ½g¦^À³ ½÷·ç±q·s«aÃĪ«Áȱo¬Öº¡²Úº¡¡A°®¯Üª½±µ¦Y±¼! 2022.5.11 ½÷·ç¥H116»õ¬ü¤¸²{ª÷¦¬ÁÊ°¾ÀYµhÃÄ°ÓBiohaven(°¾ÀYµhÃĪ« Rimegepant) news.cnyes.com/news/id/4870079 ªvÀø«æ©Ê°¾ÀYµh¤@½uÃĪ«¤AñQ®ò×ô¡]acetaminophen¡^. ----------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/2/28 ¤U¤È 10:14:42²Ä 1756 ½g¦^À³ SNP-810±ÂÅv«á¦A°µ´XÓ°¾ÀYµhÁ{§É¹êÅç¡A°£¤F»´¯g¡A©Î³\¤¤«¯g¤]¯à¦¨¬°¤@½uÃĪ«! 1.2021.11.10 ½÷·ç¯{ 12.4»õ¬ü¤¸¶R°¾ÀYµhÃĪ«Rimegepant(°ß¤@¤ä¤fªACGRP药ª«) www.taiwanlab.com.tw/news/show.asp?id=24440 |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/31 ¤U¤È 05:05:16²Ä 3072 ½g¦^À³
|
810 ±ÂÅvª÷§Y¨ÏµLªk¹F$10»õ¬üª÷. ±H±æ¥¼¨Ó¤À¼íª÷¥¨¤j§Q¯q,6-8»õ¬üª÷±ÂÅvª÷¤]¥i±µ¨ü. »P¤jÃļt双Ŭ°¤Wµ¦. ¤d¸U¤£n·d¨ìn¦Û¦æ¾P°â¹ï¾Ô¤jÃļt. ¨º¬O双¿é§½±. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/31 ¤U¤È 04:56:30²Ä 3071 ½g¦^À³
|
¦ý¨ä¹ê§Ú³Ì´Á±æªº¬O: 810¥þ°Ï¥H$10»õ¬üª÷±ÂÅv¦¨¥\. ªÑ»ù¥ß°¨¤W500-1000. 2¦~«áÃÄ«~¤W¥«,¤À¼íª÷¦¬¤JÅýªÑ»ù¦Ü¤Ö¤W1000-2000. ©¡®É610/630/830 ¤]¦¨¥\±ÂÅv. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/31 ¤U¤È 01:35:46²Ä 3070 ½g¦^À³
|
§ÚÁÙ¯u§Æ±æ¦pªO¤W¤j¤j©Ò·Qªº: 1. ¥h¬ü°ê¤W¥«,ªÑ»ù¬üª÷$200-300-500; 2. ¤À°Ï±ÂÅv810, ¨C°Ï¦¨¥\±ÂÅv$6»õ¬üª÷; ©Î 3. ¦Û¦æ¾P°âµL¬r°h¿N/¤îµhÃÄ. ºÙÅQ¦~¾P°â¬ü¬z$200»õ¥H¤Wªº¥«³õ; 4. 610/630 ¤]¦³°ê»Ú¤jÃļt·mµÛ°ª»ù¨D±ÂÅv. µ²ªG©Ò¦³ªÑªF³£Ãz´I¼Ö¶}Ãh. À³¸Ó¬O¬ü¹Ú§a. «Øij¤j®a°Ñ¥[ªÑªF·|, ¦n¦n½è°Ý¸³¨Æªø. ·d²M·¡801±ÂÅvµ¦²¤¤Î¶i«×. ÁÙ¦³Ó²£«~¬ãµo¶i«×. |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/29 ¤U¤È 12:48:49²Ä 3069 ½g¦^À³
|
¦^¹LÀY¬Ý¦X¤@5¡B3»õ¬ü¤¸±ÂÅv®×³ø¾É¸ê®Æ¡A¦X¤@n§¹¦¨2a«á¥æµ¹³Q±ÂÅvÃļt¡A¥i¨£§¹¦¨2´Á¤]¨ã¬Û·í»ùÈ¡I¤§«e¨S§C»ù®³¨ì3196ªºÃļt¡A²{¦b3196¤w°ª¤£¥iÃk¡A·|Âà¦V·mÀø®Ä¦n3¿ªº6¨t¡A¶}¥Xªº±ø¥ó¦ÛµM¤£·|®t¡F§Æ±æªYÄ£¯à®¼¦í¤£¨ü»¤´bn¥þ¤O½Ä3´Á¡IY¯à¨ì3´Á¶¥¬q¦A±ÂÅv¡A¨ºªÑªFÓÓ³£¯º¨þ¨þ¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/28 ¤U¤È 06:11:24²Ä 3068 ½g¦^À³
|
ªYÄ£630¤]pµe¶i¤J2´ÁÁ{§É¡A·í6¨t2Ãħ¹¦¨2´ÁÁ{§É«á¡A¤~¦³±ÂÅvÂú§Î¡F³Ì¦n¦A¾Ô3´ÁÁ{§É¦A¨Ó½Í±ÂÅv¡CY2´Á´N¦³Ãļt·mµÛ±ÂÅvªí¥Ü¼Æ¾ÚÀu¶V¨ü«C·ý¡F6¨t¦n¹³¤]¤@ª½¦³¨ü¨ì¤jÃļtÃöª`¡CY¯àª½½Ä3´Á¹LÃö«á¤S¦Û¦æ½æÃÄ¡A¥u¯à¥ÎªÑªFº¡¤â¶r²¼¨Ó§Î®e¡I |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/28 ¤W¤È 08:59:54²Ä 3067 ½g¦^À³
|
¯uªºÆZ´d«sªº.... ªYÄ£²{¦b³Ñ¤U¨C¹L¤@¬q´Á¶¡´Nµoµo¥Ó½Ð¬Y°ê±M§Q³q¹L¤½§iªº¥\¯à¡A ²{¦b«ÂI´N¬O®³¤F¤@°ï±M§Q¡A¦ý¬O¤j¼t´N¤£¶R³æ¡A ¦pªG¤§«e»¡ªº¡A§A¤@Ó¨D¾ªÌ¸ò±¸Õ¤½¥q»¡§A¤S¦Ò¤F¤@°ïÃÒ·Ó¡An¨D¶W°ªÁ~¹S¡A ¦ý¥D°ÊÅv¬O¦b±¸Õ¤½¥q¡A¥L¥i¥H¶±¥Î¨ä¥L©Ê»ù¤ñ§ó°ªªºû¤u~ ¦R¼Ñ¨ì³£¤£ª¾¹Dn»¡Ô£¤F~ |
|
|
·|û¡GÂæÃz10149029 µoªí®É¶¡:2023/3/27 ¤U¤È 07:20:39²Ä 3066 ½g¦^À³
|
¡i¤½§i¡jªYÄ£¯×ªÕ¨xª¢·sÃÄSNP-630¨ú±o¤é¥»±M§Q ¤¤¥¡ªÀ2023/03/27 16:35 ¡]¤¤¥¡ªÀ2023¦~3¤ë27¤é¹q¡^ ¤é¡@¡@´Á¡G2023¦~03¤ë27¤é ¤½¥q¦WºÙ¡GªYÄ£(6634) ¥D¡@¡@¦®¡GªYÄ£¯×ªÕ¨xª¢·sÃÄSNP-630¨ú±o¤é¥»±M§Q µo¨¥¤H¡G¦¶³Í¥Á »¡¡@¡@©ú¡G 1.¨Æ¹êµo¥Í¤é:112/03/27 2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q±µÀò©e¥ô±M§Q¨Æ°È©Ò³qª¾¡A¥»¤½¥q¯×ªÕ¨xª¢·sÃÄSNP-630¨ú±o¤é¥»±M§Q¡A ±M§Q¦WºÙ: ¡u¦³®Ä©óªvÀø¨x¬r©Ê¤Î¯×ªÕ¨x¯e¯fªº¤Æ¦Xª«¤Î¨ä¥Î³~(Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof)¡v¡C 6.¦]À³±¹¬I:¤£¾A¥Î 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ(Y¨Æ¥óµo¥Í©Î¨Mij¤§¥DÅé«YÄݤ½¶}µo¦æ¥H¤W¤½¥q¡A ¥»«h«¤j°T®§¦P®É²Å¦XÃÒ¨é¥æ©öªk¬I¦æ²Ó«h²Ä7±ø²Ä9´Ú©Ò©w ¹ïªÑªFÅv¯q©ÎÃÒ¨é»ù®æ¦³«¤j¼vÅT¤§¨Æ¶µ): ¤@.¥»¤½¥q¯×ªÕ¨xª¢·sÃÄSNP-630¥ý«e¤wÀò±o¬ü°ê¡B¿D¬w¡B¼Ú¨È¡B«n«D¡B¤¤µØ¥Á°ê¡B °¨¨Ó¦è¨È¡B¾¥¦èô¡B¤Ú¦è±M§Q¡A¤µ¤SÀò±o¤é¥»±M§Q¡A¦Ü¤µ¤wÀò±o16°ê±M§Q¡A¥Ø«e ©|¦³7°ê±M§Q¥Ó½Ð®×¥¿¿n·¥¼f®Ö¤¤¡C ¤G.¥»±M§Q¦³®Ä´Á©|¦³13¦~¡A³Ì¦h¥i¦Ü¦è¤¸2041¦~¡C ¤T.¥»¤½¥qªø´Á±Mª`©ó¯×ªÕ¨xª¢ªvÀø»â°ì¡ASNP-630ªº¦³®Ä¥NÁª«¤w§¹¦¨²Ä¤G´ÁÁ{§É ¸ÕÅç°ª¡B§C¨â¾¯¶q²Õ¦@36¦W¨ü¸ÕªÌ¡A´Á¤¤¤ÀªRµ²ªGÅã¥Ü¦bÁ{§ÉÀø®Ä«ü¼Ð»P¥¼ªAÃÄ«e ¤ñ¸û¡A§e²{·¥ÅãµÛªvÀø®ÄªG¡A¦¨¥\¹F¦¨¦b¯×ªÕ¨xª¢ªvÀø¤Wªº¥Ø¼Ð¡CSNP-630¥ç¤w§¹¦¨ ¥xÆWÁ{§É¤@´Á¸ÕÅç¡A¼Æ¾ÚÅã¥ÜSNP-630¦b¤HÅé¤W¨ã¦³°ª«×¦w¥þ©Ê¡A¥¿³W¹ºÁ{§É¤G´Á¡C SNP-630¬°Àu¤Æ·s¤Æ¾Ç¹êÅé¯×ªÕ¨x·sÃÄ¡A°£¥»¨ÃIJz¬¡©Ê§ó±j¥~¡ASNP-630¥t¦³4Ó ¥H¤W¬¡©Ê¥NÁª«¤w¦bÅ餺¸ÕÅç¤WÃÒ¹ê¥iªvÀø¯×ªÕ¨xª¢¥B¨ã°ª«×¦w¥þ©Ê¡A¥iª½±µ§@¥Î ©ó¨xŦ¡A°§C¨x¯×¨Ã§ïµ½¯×ªÕ¨xµoª¢¡C ¥|.¥Ø«e¡u«D°sºë©Ê¯×ªÕ¨xª¢¡v©|µL¼Ð·ÇªvÀøÃĪ«¡A¼ç¦b°Ó¾÷Ãe¤j¡A¥þ²y©Ò¦³«n ¤jÃļt§¡¤w¿n·¥§ë¤J¬ãµo·sÃÄ¡A¦Ó¥Ø«e¶È¦³¼ÆÓ«~¶µ¶i¤JÁ{§É¤T´Á¸ÕÅç¡A¦ýNASH ¥«³õ¥¨¤j¡A¥i¦P®É®e¯Ç¦hÓ·sÃÄ¡C®Ú¾ÚGlobalData 2017¦~5¤ëªº³ø§i¹w´ú¡A¥]¬A ¬ü°ê¡A¼Ú·ù¤¤j°ê®a¡]ªk°ê¡A¼w°ê¡A¸q¤j§Q¡A¦è¯Z¤ú©M^°ê¡^©M¤é¥»ªºNASH¥«³õ¡A ¦b¥¼¨Ó¤Q¦~ªº½Æ¦X¦~¼Wªø²v¹F45¢H¡C¥t®Ú¾Ú¼w·N§Ó»È¦æ¤ÎEvaluate Pharmaªº¹w´ú¡A ¥þ²yNASHÃĪ«ªº¥«³õ³W¼Ò¦b2025¦~¤W¬Ý350»õ~400»õ¬ü¤¸¡C¥Ø«e¥»¤½¥q¥¿¿n·¥´M¨D»P °ê¥~¦h®a¥Dn¤j¼t¦@¦P¦X§@©Î±ÂÅvµ¥¨Æ©y¡C ¤.·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI ¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/24 ¤U¤È 07:08:52²Ä 3065 ½g¦^À³
|
§ÚÓ¤H¤ñ¸û¬Û«H«D±MÄݤÀ°Ï±ÂÅv¬OªYÄ£»P¤jÃļt°Q½×¥X¨Óªº°µªk¡A¹ï¤T¤è³£¦n¤]´î¤Ö¼r±þ¨ý¡C´N¬O2¤jÃļt§¡¯à§â¦Û¤v´¶®³¯k¡B®õ¿Õ©Î³B¤èÃĶi¶¥¬°µL¬r¡A±ÂÅvª÷©M¤À¼íª÷§¡¬°¦æ±¡»ù6§é¡AªYÄ£Á`¦¬¤J¦h2¦¨¡C³o§¹¥þ¬O±À²qªº¡A¯u¥¿µª®×¥¼¨Ó·|©ú¥Õ¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/24 ¤U¤È 04:18:24²Ä 3064 ½g¦^À³
|
ªYÄ£¥Ø«e°ÝÃD¤£¬OÄw½X°ÝÃD. ¦Ó¬O¯à§_»P¤jÃļt¦X§@¦¨¬°¦X¹Ù¤H,ÁÙ¬O¦¨¬°¼Ä¤â°ÝÃD. ¦pªG810±ÂÅv¦¨¥\,¦@¦PÄâ¤â¿WÅQ¤îµhµo¿NÃÄ¥«³õ«h¬°ÂùĹ. §_«h¨â±ÑѶË. ¤jÃļt¤p¶Ë,ªYÄ£¤j¶Ë. ±ÂÅvª÷¬O¤@µ§Àò§Q,¤À¼íª÷À³¸Ó§ó¬O¦n¦h¿. Ä묹¤@¨Çªñ§Q,´«¨úÂùŤΫáÄò¥¨¤j¤À¼íª÷§Q¯qȱo. |
|
|
·|û¡Gª÷¤pD10153198 µoªí®É¶¡:2023/3/23 ¤W¤È 09:48:43²Ä 3063 ½g¦^À³
|
¦P·Ndk¤j»¡ªk ÁöµM¤£¨£±o¬O¤j¤á©Î¬O¥D¤O¬~½L,¦ý¬OÅý¨S«H¤ßªº§ë¸ê¤H¦¦¤U¨®¤]¬O¤@¥ó¦n¨Æ(´î¤Ö¤Wº¦®Éªº½æÀ£) ±qgoodinfoªº«ùªÑ¤À¯Å¨ÓÆ[¹î,¤W¶g200±i¥H¤W¤j¤á¤w¸g¸û¤W¤W¶g¼W¥[¤F600¦h±i (±µÄòÆ[¹î¬O§_¦³©µÄò©Ê) ¨S¦³¼z®Ú¬O§_n·|¸ò?? ¤U¶^¨S¤°»ò¶q,ªÅ¤è¤OºÜ,¦¹»ù¦ì¤w¸g±µªñ¥ý«e¼W¸êªº$75¤¸,¬O§_¥[½X¬ÝÓ¤H«H¤ß+¸êª÷ «ÂI¬O ¦³¿ú¶R ³{§C¶R(«e´£¬O¦³«H¤ß) |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/22 ¤U¤È 10:45:36²Ä 3062 ½g¦^À³
|
换个·Qªk¡A¤jªÑ东¬O«ç·Qªº?? ´I¨¹亏¤@裤¤l¡A还¤£·Q¤è设ªk卖¦nɲ钱?还©ñ¥ô·s药乱来!!!¤¤¤Ñ¤]¤£¬O¦Y¯Àªº¡A§â¤pªÑ东¬~¤@¬~ ¤â贱±µ¤F¤L张¦^来 |
|
|
·|û¡G´MÄ_10151381 µoªí®É¶¡:2023/3/22 ¤U¤È 03:34:06²Ä 3061 ½g¦^À³
|
ªG³»²Ä¤G¡H |
|
|
·|û¡GBear10152946 µoªí®É¶¡:2023/3/22 ¤U¤È 01:49:28²Ä 3060 ½g¦^À³
|
½Ð±Ð¦U¦ì¤j¤j¡A¤p§Ì©`¦Ì¤á¡A¦ý¦³ª`·N¨ì ªYÄ£ªº810¥Ó½Ð¬ü°êFDA¼Ï¯Ã¸ÕÅç À³¸Ó¬O¦³1-2¦~¤F§a¡H ¸ÕÅç¨ì²{¦b³£ÁÙ¨S¦³®Öã¬O¥¿±`ªº¶Ü¡H ©Î¬O¦³ºÃ¼{¡AÀ³¸Ó¬O¤£·|ã¤F¡H |
|
|
·|û¡Gªiªi10151449 µoªí®É¶¡:2023/3/22 ¤U¤È 12:57:45²Ä 3059 ½g¦^À³
|
¯uªº«ÜÄê.¤j¼t¤£¦b¥G§A³o®a.¦pªG¯u¦³»ùÈ.¤jÃļt·|±·µÛ¤j¶r²¼¨Óñ¬ù¤F |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/22 ¤W¤È 10:18:41²Ä 3058 ½g¦^À³
|
2¦~±ÂÅvn¤U¨Ó¬O«ü2023/24. ¨ä¹ê1¦~´N®t¤£¦h¨M©w. 1¦~ñ¤£¤U¨Ó¤j¬ù¤jÃļt´N¤£±µ¨üªYÄ£±ø¥ó. §Ú¤]»{¬°¤À°Ï±ÂÅv¤jÃļt«ÜÃø¦P·N. ¨ä¹ê³oÃÄ¥DnÀò§Q¤]³\¸Ó©ñ¦b¤À¼íª÷, ±ÂÅvª÷¥i¾A«×Åý§Q. »P¤jÃļt§Î¦¨¦X¹Ù¤HÆ[©À. |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/22 ¤W¤È 10:15:08²Ä 3057 ½g¦^À³
|
¦b°Ó¨¥°Ó¡A·sÃĬãµo¿N§ë¸ê¤Hªº¿ú¡A´Nn°l¨DªÑªF³Ì¤j§Q¯q¡C n·Q²M·¡¡A¤j¼t¥u¦³¡u³æ¿W±ÂÅv¡v¤~¯à¿W¦û¥«³õ¡A¤~¦³¦n»ù¿ú¡C ªYÄ£¤£¬O·Oµ½¹ÎÅé¡A¬O®³ªÑªFªº¿ú¦b¿N¡A¤°»ò¥s¥@¬É¤½½Ã¡H ¨ì©³¸ÕÅ禳¨S¦³¦b°µ¡H·F·F·F¤°»òn°µ³o¼Ë¤[¡H ¥xÆW¼Ï¶s¤~´X¤H¡A¥ÎÃĤ~´X¤Ñ¡A·d¨º麽¤[ÁÙ°µ¤£§¹¡C ¯u¬O¤í½|¡I ¨C¤Ñ°²É¡u¶}·|¡B¥~¥X¡v¤£²z¤£¸B¤pªÑªFÌ¡C ´N¬O¤í½|¡I |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/22 ¤W¤È 09:31:57²Ä 3056 ½g¦^À³
|
¦¥ý´N»¡¤F¡A ªYÄ£³oºØ¤£·Y¤£¤õªººA«×¡A¦A¥[¤W¤Ó¹L°ª¦ô¦Û¤v¡A °ò¥»¤W«ÜÃø¦³¤j§@¬°¡A¥Ó½Ð¤F¤@°ï±M§Q¤S¦p¦ó? ´N¸ò¨D¾¤@¼Ë¡A¦Ò¤F¤@°ï¬Ý¦ü«ÜÎxªºÃÒ·Ó¡A¸ò°ê»Ú¤j¤½¥q»¡§An¦~Á~1000¸U¬üª÷¡A µM«á°ê»Ú¤j¤½¥q»¡³Ì¦h¶}¨ì500¸U¬üª÷¡AµM«á¨D¾ªÌı±oµLªk±µ¨ü¡A¹ï¥~©ñ¸Ü»¡¦Û¤v¤£¥i¯à±µ¨ü³o»ù®æ! ³Ì«á¹L¤F¥b¦~«á¡A¦b¬Y¶¡¥»¤g¥ø·~¤º¬Ý¨ì¸Ó¨D¾ªÌ¡A°µ¦~Á~100¸U......¥x¹ôªº¤u§@¡A ³o¨D¾ªÌ´N¸ò²{¦bªºªYÄ£¤@¼Ë¡A¥H¬°¦Û¤v¦³±M§Q´N«Ü¤F¤£°_¡A ©êºp¡A¤H®a¤j¤½¥q(Ãļt)®Ú¥»¤£©È¤Ö§A¤@Ó¤H¡A¦]¬°¤H®a¦W®ð°÷¤j¡A¤£¯Ê§A¤@¤H! |
|
|
·|û¡G¤p¨k¤H10151116 µoªí®É¶¡:2023/3/22 ¤W¤È 08:49:05²Ä 3055 ½g¦^À³
|
½Ð°Ý¤g¤j¡A2¦~¬O«ü2020/12©M2021/5¨Ó¦ôºâ¶Ü? ¥t¥~¦³¤H¬Ý¨ì§¹¾ãÀɮת©ªº2022¦~°]°È³øªí¶Ü? ----------------------------------------------------------------------------------------------------- ¦pªG2¦~¤º,810µLªk©M¤j¼tñ±ÂÅv. ¨º»ò°ÝÃD´N«Ü¤j.ªí¥Ü¤j¼t¤£·|ñ. ¥i¯à¥Î¨ä¥L¤èªk»P810¶}¾Ô.¨ä¹ê1¦~¤º¤j¬ù´N¥i¬Ý¥XºÝÙ. ´N¬ÝªYÄ£ºÞ²z¶¥¼hµ¦²¤. ¦³®ÉÄ묹¤p§Q´«¨úÂùŤ~¬O¤Wµ¦. |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/21 ¤U¤È 10:54:21²Ä 3054 ½g¦^À³
|
40¦~³£¨S¯à¸Ñ¨M¦³¬r°ÝÃD¤F¡Aªí¥Ü¤£®e©ö¡Iªp¥BªYÄ£³Ì¼ô±xªºµL¬r±M·~¡A¤§«eµy¤£¯d¯«µL¬r®ÄªG´N¤£²z·Q¡A«á¨Ó§äì¦]¤~¸Ñ¨M¡Aªí¥Ü«Ü±M·~¥©§®¡I¦nÃa¤µ¦~À³¸Ó·|掲¾å¡A·í²Ä¤@Ó±ÂÅv®×§¹¦¨¡A´N¯à¦ô¥X810³B¤è¡B«D³B¤èÁ`»ùÈ¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/21 ¤U¤È 08:34:38²Ä 3053 ½g¦^À³
|
¦pªG2¦~¤º,810µLªk©M¤j¼tñ±ÂÅv. ¨º»ò°ÝÃD´N«Ü¤j.ªí¥Ü¤j¼t¤£·|ñ. ¥i¯à¥Î¨ä¥L¤èªk»P810¶}¾Ô.¨ä¹ê1¦~¤º¤j¬ù´N¥i¬Ý¥XºÝÙ. ´N¬ÝªYÄ£ºÞ²z¶¥¼hµ¦²¤. ¦³®ÉÄ묹¤p§Q´«¨úÂùŤ~¬O¤Wµ¦. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/21 ¤W¤È 05:46:18²Ä 3052 ½g¦^À³
|
¦P¾Ç·|Jeff¦³¶K¥Xקï[«e]ªº¤º®e¥i¹ï¤ñ¡CSNP-810¤ÆÁc¬°Â²±¹Ãã§óÄYÂÔ¡ASNP-610»PSNP-630¦³¼Ð¥XP2©Û¦¬¤H¼Æ¡ASNP-610(P2b)¸ÕÅç¥Dn¬O¶i¦æªø´ÁÀø®Ä(¦h¤[?)ªºÅçÃÒ¡A¾ãÅ骩±¸û©ú®Ô¡C SNP-630¨ú±oÁ{§É¤@´Á³Æ¬d®Öã¨ç«á¡A±N³W¹º¶i¦æ¬dÅçµn°O¥ÎÂùª¼¹ï·ÓÁ{§É¤G´Á(2a)¸ÕÅç¡Aªì¨B³Wµe¥Dn¬O¶i¦æÀø®Ä©M¦w¥þ©ÊªºÅçÃÒ¡A¹wp¦¬®×80¤H--->ªí¥ÜSNP-630ªº¦X¦¨Àu¤Æ¤w¦³¬ð¯}??? ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/12 ¤U¤È 05:35:38²Ä 2908 ½g¦^À³ ¤£ª¾¹D2®a©e°U¦X¦¨»PÀu¤Æ¦³µL¬ð¯}? SNP-610²{°µªºP2¬dÅçµn°O¥ÎÁ{§É¡A¤£¬O«§@¤G´Á! ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/12 ¤W¤È 09:52:26²Ä 2236 ½g¦^À³ ¦³¤Ö¼Æ¤p¤À¤lÃĦX¦¨¨BÆJ¦h¥B²£²v·¥§C¡A¦¨¥»°ª©ó¤j¤À¤lÃÄ!(SNP-630«ÜÃø¦X¦¨!!!)... -------------------------------------------------------------------------------------- 1.©e°U¬ã¨s °]¹Îªk¤H¤¤µØ´º±dÃľǰòª÷·|110/5/1~111/4/30 SNP-630ÃÄ«~¤Æ¦Xª«(¦X¦¨Àu¥ý)©e°U§Þ³NªA°È 2.©e°U¬ã¨s »OÆW¤j¾Ç 110/7/1~111/6/30 SNP-630¦X¦¨ÃÄ«~¬ã¨spµe®Ñ SNP-630«ÜÃø¦X¦¨¬OÁô¼~¡A§Æ±æ¦³¬ð¯}! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/21 ¤W¤È 05:16:01²Ä 3051 ½g¦^À³
|
2023.3.13-辉·ç«Å¥¬将¥H¨CªÑ229¬ü¤¸ªºÉ²®æ¦¬购Seagen¡A总ɲ约430亿¬ü¤¸ ¥h¦~Àq¨F东´¿¥´ºâ¦¬购这®a¤½¥q¡A¦ý¦]为ɲ®æì¦]³Ì终没¦³谈拢¡C §K¬Ì¥\§{? -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/24 ¤U¤È 12:18:37²Ä 2755 ½g¦^À³ §K¬Ì¥\§{? 2022.12.22--总ª÷额¶W100亿¬üª÷¡I¬ì伦³Õ®õÉOÀq¨F东´N¦h个¥Î¤_ªv疗Àù¯gªº§ÜÊ^°¸联ª«药ª«(ADCs)达¦¨¦X§@协议 finance.sina.com.cn/stock/enterprise/cn/2022-12-22/doc-imxxpvnp1675472.shtml ..¬ì伦³Õ®õ将¤_¡m¦X§@协议¡n¥Í®Ä¦Z¤@¦¸©Ê¦¬¨ì¦X计1.75亿¬ü¤¸¤£¥i°h还ªºº¥I´Ú¡A¨½µ{¸O¥I´Ú¦X计¤£¶W过93亿¬ü¤¸¡C -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/7 ¤U¤È 02:00:43²Ä 2200 ½g¦^À³ ¤µ¦~ªº«½S¥æ©öÀq¨FªF±ý¦¬ÁÊADC?(¥Ø«e¦è¶®¹Ï°ò¦]¥«È325»õ¬ü¤¸) ..... µ²½×: ¥iª`·N±i¤l¤å³Õ¤h¦¨¥ßªº§K¬Ì¥\§{(¸òÀH¤j¤û¨«¿ù¤£¤F) www.immunwork.com/edcontent_d.php?lang=tw&tb=1&id=14 ÃĪ«§ôªº¨Ò¤l (ADC¬O¥Ñ³æ§Ü¡B¬r¯À¡A³s±µ¤l¤T³¡¤Àºc¦¨ªº½ÆÂøµ²ºc)¥xÆW¥[ªo! |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/20 ¤U¤È 11:58:02²Ä 3050 ½g¦^À³
|
¤jÃļt±N¨Ó«a¤WµL¬r¤îµh¾¯¨C¤@Áûº¦¤@¤¸¥x¹ôµ¹ªYÄ£·í±ÂÅvª÷©M¤À¼íª÷¡A¤p¼tªYÄ£´N¦Y±o¹¡¹¡ªº¡C8¨t2¦~¤º10»õ¬ü¤¸±ÂÅvµû¦ô¡A«Ü¹ê¦bªº¡C¨º¦X²zªÑ»ù¬O2000¤¸¡A¹ê»ÚªÑ»ù¥«³õ¨M©w¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/20 ¤U¤È 10:32:04²Ä 3049 ½g¦^À³
|
¦pªG2¦~810±ÂÅvÁٽͤ£¤U¨Ó,°ÝÃD´N«D±`¤j. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/20 ¤U¤È 09:14:57²Ä 3048 ½g¦^À³
|
5¦~¬O²£«~¤W¥«¤À¾P°â¤À¼íª÷. ±ÂÅvª÷À³¸Ó1-2¦~´N¸Ó½Í¤U¨Ó. |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/20 ¤U¤È 07:35:54²Ä 3047 ½g¦^À³
|
ªº©ì¤Ó¤[¤F©È³Q½|¡I·sªº¬ü¦h¤F¡IÓ¤H¬Ýªk¡GªÑ²¼©ñÓ5¦~¤~¥i¯à¹FÅq®p¡I |
|
|
·|û¡G¤p¨k¤H10151116 µoªí®É¶¡:2023/3/20 ¤U¤È 07:18:11²Ä 3046 ½g¦^À³
|
§Ú¬Ý¨ìªº®t²§¬O©ã¤é´Á¡A3/17,¦³¤H¬Ý¨ì¤°»ò§Oªº®t²§¶Ü¡H |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/20 ¤U¤È 05:34:27²Ä 3045 ½g¦^À³
|
²£«~¶i«×קï«á¤S¤W¬[¤F ²³¥ý¶i̦p¦ó¸ÑŪ¡H |
|
|
·|û¡GJames10139245 µoªí®É¶¡:2023/3/20 ¤W¤È 10:26:58²Ä 3044 ½g¦^À³
|
²{¦b³\¦h°Ó«~³£§äºô¬õ¦b½æ¡A§ä´XÓ±E±x¼Ú¬ü¾Þ§@ªº¡A¦bOTC¥«³õ¥´¶}ª¾¦W«×¡A¡A±ÂÅvª÷ÃB·|©Ô°ª«Ü¦h |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/20 ¤W¤È 10:10:12²Ä 3043 ½g¦^À³
|
³o½×z¥»¨´N¬O¥Ù¬Þ¡A¯u´¶¤Î¤Æ¡A¹ï¤jÃļt¨Ó»¡®Ú¥»¤£¬O¦n¨Æ¡A¤]¤£¬O´î»´t¾á¡A ¦]¬°¦p¦¹¤@¨Ó¡A¦³¥i¯à´î¤Ö¤jÃļt¿W¦û¥«³õªºÀu¶Õ¡A °Ó¤H¬Ýªº¬O§Q¯q¤£¬O¤½¯q¡A¦pªG¤j¤½¥q³£¬O¥H¤½¯q¬°¥XµoÂI¡A¨º¤]¤Ó¹L¯Q¦«¨¹ªÀ·|¤F¡ã ©Ò¥H§Ú¦pªG¬O¤jÃļt¡A¤µ¤Ñ¦³·sªº§Þ³N§ÚµLªk¿W¦û¡A¨SÃö«Y¡A «Ü²³æ¡A§Ú´N¥´À£§A¡A¥´À£¨ì§A¥Ã»·µLªk¥XÀY¡A¼É¤O¤S²³æªº¤è¦¡¡C µ²½×ÁÙ¬O¤@¥yªYÄ£¤£n¤Ó¹L°ª¦ô¦Û¤v¤F¡A¤£µM¤j¤½¥q¤@¼Ë¦³¤j¤½¥qªºª±ªk¥i¥Hª±¦º§A¡ã ========================================== «D±MÄݱÂÅv¬O´¶¯Å¤Æ·§©À¡A¯à§â´¶®³¯k¡B®õ¿Õ§Þ³N±ÂÅvÅܵL¬r¡A³£¯à¥HµL¬r¥þ²y¤W¥«¡A2¤jÃļtt¾áÅÜ»´¡AªYÄ£Á`¦¬¤J§ó°ª¡C¯à¤£¯à§â¦w®õ®³¯kÃÄÃÒ»P¥¬¬¥×ôÃļt¦X§@¡H³o³¡¤À¬O°Ó¾÷¤]¬O¤HÃþ¤§ºÖ¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/18 ¤U¤È 12:53:35²Ä 3042 ½g¦^À³
|
«D±MÄݱÂÅv¬O´¶¯Å¤Æ·§©À¡A¯à§â´¶®³¯k¡B®õ¿Õ§Þ³N±ÂÅvÅܵL¬r¡A³£¯à¥HµL¬r¥þ²y¤W¥«¡A2¤jÃļtt¾áÅÜ»´¡AªYÄ£Á`¦¬¤J§ó°ª¡C¯à¤£¯à§â¦w®õ®³¯kÃÄÃÒ»P¥¬¬¥×ôÃļt¦X§@¡H³o³¡¤À¬O°Ó¾÷¤]¬O¤HÃþ¤§ºÖ¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/18 ¤W¤È 11:43:26²Ä 3041 ½g¦^À³
|
¹ï¤ñ¤@¤UÃĵإӽЬü°ê/¤é¥»ÃÄÃүӮɴX¦~? ¦X¤@¤j³°ÃÄÃÒ´X¦~? ¤@¥¹¤½§i±ÂÅv¡A²Ä1®a±ÂÅv°ê»Ú«e10¤jÃļtªºÃzµo¤O±N¦h¤j?§Ú¤]¤£ª¾! ------------------------------------------------------------ ÁÂÁÂR¤jªº°T®§¾ã²z¥H¤Î¸Ñ»¡. §Ú«ù¦³¶W¹L40±i. ´N«ö·Ó즳pµe«ù¦³2¦~µ¥¤½¥qÀç¹Bºì©ñ. ·í§@·ÀI©Ê§ë¸ê¼Ö³zªÑ. ²z½×¤W³oªÑ¸Ó¦³ªÑ»ù1000ªº¦æ±¡, ´N§â¥Ø¼Ð»ù2¦~q500§a. ·íµM·ÀI¬O¤]¥i¯à2¦~«áÁÙ¬O³o»ù¦ì. ªÑªF·|®É¤j®a¤]³\¥i¥H¬Û¬ù¨£±»{ÃѤ@¤U, ¦n¥H«á¦h¥æ¬y. ¦]¬°³£¬O¥Í§Þ·ÀI³Ð§ë«¬§ë¸ê¤H. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/18 ¤W¤È 10:57:36²Ä 3040 ½g¦^À³
|
ªYÄ£¤îµh·sÃĸÑÂê40¦~¨x¬r©Ê°ÝÃD °ê»Ú¤j¼t±ÂÅv¦b±æ ...¦¶³Í¥Áªí¥Ü¡A¥Ñ©ó¦³®ÄÃIJzªº¥D¦¨¤À¨S¦³§ïÅÜ¡AY¦¨¥\±NSNP-810±ÂÅvµ¹¥Ø«e¾P°â¤AñQÓi×ô¦¨¤À¤îµhÃĪº¤j¼t¡A¤£¥Î«·s°µÁ{§É¥Ó½ÐÃÄÃÒ¡A¥u»Ýn§ó§ï¥]¸Ë¤Î¥é³æ¡A´N¯à¥H³Ì§Öªº³t«×¾P°â¶i¶¥ª©¡]¤£¶Ë¨x¡^²£«~¡C ----------------------------------------------------------------------------------------------- ¹ï¤ñ¤@¤UÃĵإӽЬü°ê/¤é¥»ÃÄÃүӮɴX¦~? ¦X¤@¤j³°ÃÄÃÒ´X¦~? ¤@¥¹¤½§i±ÂÅv¡A²Ä1®a±ÂÅv°ê»Ú«e10¤jÃļtªºÃzµo¤O±N¦h¤j?§Ú¤]¤£ª¾! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/18 ¤W¤È 10:40:58²Ä 3039 ½g¦^À³
|
2022.10.30ªYÄ£¤îµh·sÃĸÑÂê40¦~¨x¬r©Ê°ÝÃD °ê»Ú¤j¼t±ÂÅv¦b±æ ...¦Ü©ó±ÂÅv¼Ò¦¡¡A¦¶³Í¥Á»¡....¦]¦¹¥¼¨Ó±N±Ä[«D±MÄÝ]¡B[¤À°Ï±ÂÅv]µ¦²¤..... ñq«O±K¨óij(CDA©ÎºÙNDA)--µû¦ô§Þ³N±M§Q±ÂÅv«e¤§«n¾÷¨î enews2.nhri.org.tw/enews_list_new2_more.php?volume_indx=435&showx=showarticle&article_indx=8837 ...¾÷ºc»P¾÷ºc¤§¶¡¤§©Ò¥H[ñq«O±K¨óij¡A¨ä¥Dn¥Øªº¬Onµû¦ô±µ¦¬¤è¬O§_¦³·NÄ@±µ¨ü§Þ³N±ÂÅv]¡A ...¦Ò¼{¤¤ªº§Þ³N±ÂÅv¿ï¶µ¥i¬°[±MÄݱÂÅv]©Î[«D±MÄݱÂÅv]¡A³Ì°_½X¡A¿ï¶µÀ³©w¸q§Þ³N±ÂÅv¿ï¶µªº©Ê½è¡B·Ç³Æ¦æ¨Ï¡A¤Î¦p¦ó¦æ¨Ïµ¥¡C.... ©¹©¹¡A¦b§Þ³Nµû¦ô¤§«e¡A±ø¥ó½Í§Pªº¿ð©µ±N³y¦¨Âù¤è¥u¯à¦P·N¬Y¨Ç°ò¥»±ø¥ó¡A¨Ò¦p¡A°ò¥»¿ï¶µ¥i¥]¬A¡G 1. ¦b¬Y¨Ç¦a°Ï¡]¨Ò¦p¥_¬ü¦a°Ï¡^¬°±MÄݱÂÅv¡A¨ä¥L¦a°Ï¬°«D±MÄݱÂÅv 2. ±ÂÅvª÷ªº¤ñ¨Ò½d³ò¬°¨Ï¥Î±ÂÅv§Þ³N²£«~²b¾P°â»ùªº 3 - 6% 3. ±ÂÅv´Á¬°³Ì¤Ö10¦~ --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/14 ¤U¤È 06:30:34²Ä 3018 ½g¦^À³ 2022.9.20¤½§i....ÃÒ¹êSNP-810µL¨x¬r©Ê¡C -------------------------------------------------------------------------------------------------- 2022.10.30ªYÄ£¤îµh·sÃĸÑÂê40¦~¨x¬r©Ê°ÝÃD °ê»Ú¤j¼t±ÂÅv¦b±æ ¦¶³Í¥Á±µ¨ü¤¤¥¡ªÀ°OªÌ±M³X®Éªí ------------------------------------------------------------------------------------------------ 2022 ¦~9 ¤ë - ¥Ø«e7 Ó¤ë.....signed a CDA ----------------------------------------------------------------------------------------------- ±q®É¶¡¤W¦êÁp°_¨Ó¡A¦n¨Æ±Nªñ¤~¬O!? |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/17 ¤U¤È 09:23:53²Ä 3038 ½g¦^À³
|
·Pı³o¤½§i³£¬Oª©¤W¥ý¶iªº¸ê°T¾ã¦X°_¨Ó¡A¨S¤°»ò«GÂI?? 810 1¡B¹wp¦¬®×36¦ì¨ü¸ÕªÌ¡A¸ÕÅç²{¥¿¶i¦æ¤¤===>¬O§¹¦¨¦¬®×¦b¸ÕÅç¤F? 2¡B650²@§J¸ÕÅç«ùÄò¦¬®×¤¤¡K¡K 3¡Bª¯ 610/630 GG~PENDING? |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/17 ¤U¤È 09:11:40²Ä 3037 ½g¦^À³
|
new use indication new claim ´M§A¤d¦Ê«× |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/17 ¤U¤È 07:28:51²Ä 3036 ½g¦^À³
|
~1:45°_JP:...¤£¯àÁ¿¤Ó¦h] Á¿¤Ó¦h±N¨ÓÄvª§¹ï¤â..... ------------------------------------------------------------------------------------------------ ´ê¥©¬Ý¨ì¤@®×¨Ò¶K¤W¡C ½Þ¶¤¤ÍMGI Pharma[´£¦]¤½¶}¤F¦X¬ùÃÄ«~¤º®e¡AÅýÄvª§¹ï¤â(Teva)¨£Á_´¡°w¡A¾ÉP³à¥¢·s¿o©Ê¦Ó±M§QµL®Äªº°ÝÃD¡C www.giant-group.com.tw/law-detail-707.html Helsinnªº·sÃĹwÁʤèMGI Pharma¹H¤Ï«O±K¦X¬ù¤Î³c°â¦X¬ùªº«O±K±ø´Ú¡A´£¦¤½¶}¤FHelsinnªº¦X¬ùÃÄ«~¤º®e¡Aºc¦¨³c°âªý«o¡B¾ÉP³à¥¢·s¿o©Ê¦Ó±M§QµL®Äªº°ÝÃD¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/17 ¤U¤È 04:03:30²Ä 3035 ½g¦^À³
|
ªYÄ£¥ÍÂå¥Dn¬ãµo²£«~¶i«× 2023/03/17 (µù): CMC, Chemical Manufacture and Controlªí¥ÜÃÄ«~«~½è¤w¸g³q¹L¡A¥¼¨Ó¥HÁ{§É¸ÕÅç¥Ó½Ð·sÀø®Ä (µL¨x¬r©Ê)§Y¥i¡C ---------------------------------------------------------------------------------------------------- Ãö©óSNP-810¬ü°êOTCÃÄÃÒ www.facebook.com/100064104724409/videos/443452154155295?__so__=permalink ~1:45°_JP:...¹³§Ú̥ӽШºÓ¬ü°êªºlicense¡A¥ý¥Ó½Ð¨ì´N¬O¥ý§âCMC¸Ñ¨M±¼¡A´NÅܦ¨¬O¤@Ó¤W¥«ªºÃÄ §Ṳ́W¥«ªºÃĦA¥h°µ¤@Ónew use indication new claimªº¸Ü ´N²³æ¦h¤F...[¤£¯àÁ¿¤Ó¦h] Á¿¤Ó¦h±N¨ÓÄvª§¹ï¤â..... |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/17 ¤U¤È 03:48:27²Ä 3034 ½g¦^À³
|
©ã¿ùÄ_¤F ¥É®i¦n´Î´Î ============================== ¦P´Á 111/03/21¨ú±o¬ì§Þ¨Æ·~¥B¨ã¥«³õ©Ê¤§·N¨£®Ñ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/16 ¤W¤È 08:01:12²Ä 3033 ½g¦^À³
|
www.tn.gov/tbi/crime-issues/crime-issues/opioids.html FDAªº±j¨î¤âªkÅýAPAP³B¤èÃľP°â¶q»Pª÷ÃB¤j´î70%¡A¦pªGÁÙ¤£¯àÅýRx³B¤èÃĪº¤¤¬r¦í°|²v´î¤Ö¡A´N¯u¬O¯«©_ªº³Ç§J¤F! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/16 ¤W¤È 07:35:00²Ä 3032 ½g¦^À³
|
2023.3.8 FDA ±j¨î½Õ¾ã´¶³q Rx(³B¤èÃÄ)¤îµhÃÄ¥i¯à®¾±Ï¥Í©R www.lowellgeneral.org/health-and-wellness/health-library/fda-mandated-tweak-to-common-rx-painkillers-may-have-saved-lives ³ø§iµoªí¦b 3 ¤ë 7 ¤éªº¬ü°êÂå¾Ç·|Âø»x¤W¡C ....¬ü°ê°ê®a¿}§¿¯f©M®ø¤Æ¹D¯e¯f¬ã¨s©Ò¨x¯f¤À³¡Á{§É¨x¯f¬ã¨s¬ì¬ìªøMarc Ghany³Õ¤h»P¤H¦XµÛ¤F¸Ó¬ã¨sªº¤@½gªÀ½×¡C Ghanyªí¥Ü¡AŲ©ó¹ï¤A酰®ò°ò×ô-ªü¤ùÃþ½Æ¤è»s¾¯¥u¥e¬ü°ê¹ï¤A酰®ò°ò×ôÁ`¥Î¶qªº20%¡AFDAªº±ÂÅv¥u¯à¨«¨ì³o¤@¨B¡C ¥L«ü¥X¡A¬ã¨sµo²{ ¨Ï¥Î«D³B¤èÃÄ¡B«D³B¤èÃĪº¯Â¹ï¤A酰®ò°ò×ô²£«~ªº¤Hªº¦í°|²v¦b¦P¤@®É´Á¤º¹ê»Ú¤W¦³©Ò¼W¥[¡C Ghany»¡¡A²{¦bªº¬D¾Ô¬O¦p¦óÀ³¹ïµ´¤j¦h¼Æ¨Ï¥Î«D³B¤èÃĪº¯f¤Hªº¬r©Ê·ÀI¡C Ä~Äò§V¤O§ïµ½¹ï¤A酰®ò°ò×ô¶Ë®`·ÀIªº®ø¶OªÌ±Ð¨|¡A¨Ã¦b²£«~¼ÐÅÒ¤W´£¨Ñ²³æ©M©ú½Tªº¨xŦ¶Ë®`·ÀI«H®§¡C¦ýŲ©ó®ø¶OªÌ´¶¹M»{¬°«D³B¤èÃĬO¦w¥þªº¡A¶È¦¹¤@ÂI¥i¯àÁÙ¤£°÷¡A¥L«ü¥X¡C¨¾¤î»P¹ï¤A酰®ò°ò×ô¦³Ãöªº¨x·l¶Ë©M¦º¤`ªº°ß¤@¤èªk¡AGhany»¡¡A±N¬O¶}µo§ó¦w¥þ¡B§ó¦³®Äªº¤îµh¾¯¡C ------------------------------------------------------------------------------- µ²½×: 1.¬ã¨sµo²{¡AFDAªº±j¨î¤âªk¥u¹ï³B¤èÃĦ³®Ä¡AOTC[«D³B¤è]ªºAPAPªº¦í°|²v¦b¦P¤@®É´Á¤º¹ê»Ú¤W«D¦ý¨S¦³´î¤ÖÁÙ[¼W ¥[][¼W¥[][¼W¥[]¡C 2.¨¾¤î»P¹ï¤A酰®ò°ò×ô¦³Ãöªº¨x·l¶Ë©M¦º¤`ªº°ß¤@¤èªk--±N¬O¶}µo§ó¦w¥þ¡B§ó¦³®Äªº¤îµh¾¯¡C |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/3/15 ¤W¤È 09:35:04²Ä 3031 ½g¦^À³
|
»¡¤¤¤Ñ¶°¹Î¦bªYÄ£¨S¦³¥D¾ÉÅvµ´¹ï¬O·d¤£²M·¡ª¬ªp |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/15 ¤W¤È 09:26:57²Ä 3030 ½g¦^À³
|
¤£¤WÂd¡A¤£¨£±o¬OÃa¨Æ¡C ¦ý¬O¡A·íªì´N¬°¤Fn¤WÂdÁÙ¶}¤FÁ{®ÉªÑªF·|¡A³o´N»¡¤£¹L¥h¡C ®ö¶O§ë¸ê¤Hªº¿ú¡A¸Ón¦³¤Ht³d¡C ¦X¤@¤~«ùªYÄ£8¦Ê±i¡A¤¤¤Ñ¦b¦¹µL¥D¾ÉÅv¡A¨ÖÁÊ¡Hªù³£¨S¦³¡C ¦Ñ¦Ñ¹ê¹êªº§â»OÆW¼Ï¶s¸ÕÅç»°§Ö§¹¦¨§a¡I¦¶¸³¡I ¤£n»¡¤F¤@¤j°ï¡A«oÀt³tºCºCª¦¡C ³oӮɥN¡A®É¶¡´N¬Oª÷¿ú¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/15 ¤W¤È 09:11:47²Ä 3029 ½g¦^À³
|
¨Æ«á½Ñ¸¯ªºµ²ªG½×¨Ó»¡¡A2023/1/31¤½§i¤º³¡½]®Ö¸g²zÃ㾡A¦ôp¬O¦]¹LÂ÷¾!!! |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/3/15 ¤W¤È 08:50:42²Ä 3028 ½g¦^À³
|
I«á´I¨¹¦Ñ¤j¤£¦P·N°Ú¡A¤WÂd«á«ç»ò³Q¦X¤@¶°¹Î¤j¤f¨Ö§]¡ã |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/15 ¤W¤È 08:39:37²Ä 3027 ½g¦^À³
|
·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2023/3/3 ¤U¤È 09:44:22²Ä 2981 ½g¦^À³ ¦P´Á 111/03/21¨ú±o¬ì§Þ¨Æ·~¥B¨ã¥«³õ©Ê¤§·N¨£®Ñªº6785¤w¥X¨ã¤º±±±M¼f³ø§i¡A ----------------------------------------------------------------------------------------- 2023/03/06 ¤½¶}¸ê°TÆ[´ú¯¸«¤j°T®§¤½§i6785¬R®i·sÃĦ]À³¤WÂd¥Ó½Ð»Ýn¡A¨ú±oñÃÒ·|p®v¤º±±±M¼f³ø§i 2023/03/06 ¬R®i©Ý°Ó¾÷ ÃÄ«~±ÂÅvÀò500¸U¬ü¤¸Ã±¬ùª÷ 2023/03/07 ¬R®i·sÃÄ(6785)°e¥ó¥Ó½ÐªÑ²¼ÂdÂi¶R½æ¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/15 ¤W¤È 07:49:07²Ä 3026 ½g¦^À³
|
±ÂÅv¦X¬ù§Ú¤]¬Û«H¦³¦b½Í¡A¥u¬O¤º®e¬°¦ó¡H ¦pªG¨«¡u³æ¿W¡v±ÂÅv¡A§Y¨Ï±ÂÅvª÷«Ü¤Ö¤]¬O¤j§Q¦h¡C ¡u¤£¶Ë¨x¡vªº¤îµhÃÄ¡A·|¥´¶}ªYÄ£ªº¥þ²yª¾¦W«×¡C ¦pªG¤À°Ï±ÂÅv¡A±N±Á{¤j¼t¥i¥Î¡A¤]¥i¥H¤£n¥Îªº±¡ªp¡C °ª¾¯¶qªº³B¤èÃÄ¡A¨S¦³Ävª§ªÌ¡A¨º¤~È¿ú¡C ´Á±æ¤½¥q¥[§Ö°µ§¹»OÆWªº¼Ï¶s¸ÕÅç¡A¦pªG¹F¼Ð¡AªYÄ£¤~¦³¥i¯à¤jº¦¡C ¤WÂdªù²¼³£®³¨ì¤F¡A¬°¤°»ò¤£¥Ó½Ð¤WÂd¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/15 ¤W¤È 05:38:29²Ä 3025 ½g¦^À³
|
www.facebook.com/100064104724409/videos/1202540343488971/?__so__=watchlist&__rv__=video_home_www_playlist_video_list 16¤À10¬í~ [¯u¥¿ªº±¡ªp¥Î2±i¹Ï¨Ó¬Ý...±z¤@©wn§â³Ì«nªº»\°_¨Ó...¥Ln¸ò±zÄ~Äò¨«¤U¥hªº®ÉÔ ¥L³q±`·|ñ¦n´XÓ¬ù³á ±z¤£n»{¬°Ã±¤@Ócooperation agreement´N¥i¥H¤F³á ±z¨ºÓ¬Ogeneral³á ±zn©ñ¥X¨Ó§ó¦hªF¦èµ¹¥Lª¾¹Dªº®ÉÔ ¤£¬O¦b±M§Q¤W¦³ªº³á ¨º»ò±znn¨Dnon-competen¥[¶i¥h....¤£¬O¥L¹ï±z«Ü¦³¿³½ì ¥Lµ´¤£ªÖñCDA...¤@¶}©l¥L¤°»òCDA³£¤£¸ò±zñ...µM«á±zñ²Ä2ÓCDA¶i¥h«á....] ------------------------------------------------------------------------------------------------ 109¦~12¤ë¤½§i ¥»¤½¥qSNP-810·sÃÄ»P°ê»ÚÃļtñq·sÃĬãµo[¦X§@¨óij]¡A«S¦X§@§¹¦¨¡AÂù¤è°ò©ó¦X§@¨óij¡A¦A¨ó°Ó«áÄòÂX¤j¦X§@µ¥¬ÛÃö¨Æ©y¡C µ²½×:JP:[±z¤£n»{¬°Ã±¤@Ócooperation agreement´N¥i¥H¤F³á] [¤£¬O¥L¹ï±z«Ü¦³¿³½ì ¥Lµ´¤£ªÖñCDA]¡A¦³Ã±CDAªí¥Ü»P°ê»ÚÃļt¦X§@¦³¶i®i¦ýÀt³t! |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/14 ¤U¤È 10:13:25²Ä 3024 ½g¦^À³
|
3/10ªº4Ó¤½§i³£¤£¬O¤WÂd©Ò»Ýªº¤½§i ¤u·~§½°ª¬ì§Þ¦P·N¨ç¤w¥¢®Ä¡I ²³æ»¡¡An¤WÂd¥²¶·«·s¦V¤u·~§½¥Ó½Ð ©Ò¦³ºÃ°Ý¡A³£¥u¯à¦bªÑªF¤j·|¤W°Ý¦¶¸³¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/14 ¤U¤È 09:42:43²Ä 3023 ½g¦^À³
|
¿Õ©M¿Õ¼wªºSemaglutide(GLP-1)ÃĤý¹ÚÂ_»î®ø!!! 灵»î¬åɲ¡v²v¥ý¥X®ü¡A¬ü国¯Ø岛¯À¤T¥¨头³Q¡u¹G宫¡v¡K¡K Orz www.drugtimes.cn/2023/03/03/linghunkanjiashuaixianchuhaimeiguoyidaosusanjutoubeibi/ 2023¦~3¤ë1¤é¡A¬ü国³Ì¤jªº¯Ø岛¯À¥Í产°Óþ÷来«Å¥¬¡A¯Ø岛¯À类药ª«É²®æ¥þ线¤U°70%.... -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤U¤È 07:24:51²Ä 2305 ½g¦^À³ 2021¦~¿Õ©M¿Õ¼wGLP-1ÃþÃĪ«ºâ¤W´îªÎ»â°ì¦Xp°^ÄmÀ禬¹F95»õ¬ü¤¸! Y¦bNASH¤]®³¨ìÃÄÃÒ¡A¿Õ©M³o¤äGLP-1ÃÄ(¿}§¿¯f+´îªÎ+NASH)°ª®pÀ禬µ´¹ï¯}200»õ¬ü¤¸¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/14 ¤U¤È 09:27:46²Ä 3022 ½g¦^À³
|
r¤j ²]Á«¦Ût°Õ~~ÁȤF¨Ó426³o½Ð±z¦YӲʹ¡ ¿é¤F¦Û»{©R®t |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/14 ¤U¤È 08:23:52²Ä 3021 ½g¦^À³
|
D¤j¡AÓ¤H¤£t³d¥ôÂ_³¹¨ú¸q¦a¡C [Within the first 6 months on the job, signed a CDA agreement with a top 5 pharma company.] §ô¤O¶® ·~°È©M°Ó·~µo®i¡U¤Hû¹B§@©M¤½¥q³W¼ÒÂX¤j¡U·|»¡^»y¡B¦I¤ú§Q»y¡B¤¤¤å©M¼w»y Sinew Pharma 2022 ¦~ 9 ¤ë - ¥Ø«e7 Ó¤ë Taipei City, Taiwan • Responsible for short, medium, and long-term business strategy planning and due diligence. Formulate and implement the use of Objectives and Key Results (OKRs). • Prioritize tasks in managing multiple complex projects simultaneously, and take full ownership of the outcome of the tasks below: • Develop business development strategies and plans, and analyze and formulate pricing strategies. Assist in the company¡¦s IPO process. • Manage the sales pipeline, from acquisition to long-term partnership. Arrange business meetings with prospective clients, cross-culturally understand and translate each party¡¦s needs and negotiate contract terms. Develop and negotiate with international partners, including but not limited to technology transfer, drug licensing, and related cooperation cases, and extend the strategy for follow-up negotiations. Within the first 6 months on the job, signed a CDA agreement with a top 5 pharma company. • Develop domestic and international cooperative licenses, develop and negotiate contracts, all confidential and non-confidential partnering materials, and evaluate the relevant pharmaceutical markets. • Manage company image and related marketing and public relations. Establish and cultivate relationships with the pharma community, associations, and key opinion leaders to support business development efforts. • Project management, support, and coordination of internal and external collaborations among R&D units, and confirmation of implementation progress to assist in out-licensing and commercial development. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/14 ¤U¤È 08:08:40²Ä 3020 ½g¦^À³
|
°Ó·~¶}µo¥D¥ô:§ô¤O¶®. ³o¾¦ì¤Ó§C. §O®a³q±`¬Oµ¦²¤ªø¥D½Í. |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/14 ¤U¤È 06:59:11²Ä 3019 ½g¦^À³
|
Å¥¸s¤@®u¸Ü ©ú¤Ñ¨Ó¦^¸É |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/14 ¤U¤È 06:30:34²Ä 3018 ½g¦^À³
|
2022.9.20¤½§i ...¥»¤½¥qµL¨x¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k)¤w¨ú±o²Ä¤T¤èÅçÃÒ³æ¦ì¬ü°êµÛ¦W¬r²z¸ÕÅ礽¥qCharles River Laboratoriesªº¥¿¦¡¸ÕÅç³ø§i¡A¸ÕÅç½s¸¹¡GNo.8003774¡AÃÒ¹êSNP-810µL¨x¬r©Ê¡C -------------------------------------------------------------------------------------------------- 2022.10.30ªYÄ£¤îµh·sÃĸÑÂê40¦~¨x¬r©Ê°ÝÃD °ê»Ú¤j¼t±ÂÅv¦b±æ ¦¶³Í¥Á±µ¨ü¤¤¥¡ªÀ°OªÌ±M³X®Éªí ------------------------------------------------------------------------------------------------ §ô¤O¶® 2022 ¦~9 ¤ë - ¥Ø«e7 Ó¤ë.....Within the first 6 months on the job, signed a CDA agreement with a top 5 pharma company. ----------------------------------------------------------------------------------------------- ±q®É¶¡¤W¦êÁp°_¨Ó¡A¦n¨Æ±Nªñ¤~¬O!? («e5¤j´N¬OJNJ?) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/14 ¤U¤È 05:23:49²Ä 3017 ½g¦^À³
|
CDA ¨óij---³o¬O¤°ºN? «ö®É¶¡±Àºâ À³¸Ó¬O²Ä2ÓCDA! JP¦b³o«á¥b¬q¦³¸Ñ»¡ www.facebook.com/100064104724409/videos/1202540343488971/?__so__=watchlist&__rv__=video_home_www_playlist_video_list ....¤£¬O¥L¹ï±z«Ü¦³¿³½ì ¥Lµ´¤£ªÖñCDA..... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/14 ¤U¤È 05:08:39²Ä 3016 ½g¦^À³
|
¸gÀç¤Î¬ãµo¹Î¶¤·s¼W°Ó·~¶}µo¥D¥ô:§ô¤O¶® §ô¤O¶® 2022 ¦~9 ¤ë - ¥Ø«e7 Ó¤ë .....Within the first 6 months on the job, signed a CDA agreement with a top 5 pharma company. ¦b¤u§@ªº«e 6 Ӥ뤺¡A»P¤@®a±Æ¦W«e 5 ªº»sÃĤ½¥qñ¸p¤F CDA ¨óij---³o¬O¤°ºN? ---------------------------------------------------------------------------------------------- ¬ãµo¨½µ{¸O¤Î¹wq®Éµ{»PQ&Aºû«ù¸U¦~¤£ÅÜ! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/14 ¤U¤È 04:07:12²Ä 3015 ½g¦^À³
|
¦¶s¬O°ê¨¾Âå¡A¦³°h¥ðÄ?©Ò¥H¤£»{¯u?¤½°Èû¤ßºA?? |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/13 ¤U¤È 06:14:29²Ä 3014 ½g¦^À³
|
ªYÄ£¦³Àu¶V¬ãµoÃĪ«¯à¤O©MÁZ®Ä¡A¹ï©ó4ÁûÃĪº¥X¸ô¡A§Æ±æ°ª¼hn¦³´¼Ån¹Î¡A¹ï©ó±ÂÅvµ¦²¤n¦³¨F½L±Àºt®M³N¡A§â§Q¼í©¹³Ì¤jȱÀ¤É¡FÁöµM¤pªÑªF¬¶Án¶©¶©¡IÓ¤HÁÙ¬O«Ü¼ÖÆ[´Á«Ý¡AªYÄ£¥[ªo¡I¦h¼Æ¤pªÑªFÁ`¬OÀqÀq¤ä«ù¤½¥q¡A§Æ±æ¶Ì¤H¦³¶ÌºÖ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/13 ¤U¤È 01:16:22²Ä 3013 ½g¦^À³
|
Åý¦¶¸³·P¨üªÑªF¤w»W¿n¤£º¡±¡ºü¡A°PÃ×µh駡«Å¬ª¤£¥þµM¬OÃa¨Æ¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/13 ¤U¤È 12:29:24²Ä 3012 ½g¦^À³
|
Á`¾÷¥u¬O¦Y¤HÀY¸ô¡A±µ¤F¹q¸Ü¥u¯à³QªÑªF©ê«è¡B®Á½|¡C ¯à¸Ñ¤j®aªººÃ°ÝªÌ¡H±©¦³µo¨¥¤H¦¶¸³¡I¥L¥Ø«e¬O¤£·|±µ¨ü³X°Ýªº¡C ·Q¸ÑºÃ¡H¥u¯à¦bªÑªF¤j·|¤F¡I ¤½¥q¦³3¤jªÑªF¡A¦U¦³¨ÓÀY¡A·|ºÊ·þ¤½¥q¸gÀç¡C ¹ïªYÄ£ªº·sÃĦ³«H¤ßªº´N¯d¤U-ÀR«Ý¨Îµ ¨S«H¤ßªº´NÂ÷¶}§a¡I |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/13 ¤W¤È 11:07:19²Ä 3011 ½g¦^À³
|
²{¦b³s³Ì°ò¥»ªº±µªÑªF¹q¸Ü°µ°µ¼Ë¤l³£¤£°µ¤F¡A¯º¦º! ¸Ó¤£·|¥´ºâ»âÓ10¦~°ªÁ~¹S±e¶O«á¡Aª½±µ°h¥ð¥æ±µµ¹¤U¤@Ó¤HÄ~Äò·d~ ¦³¤@ºØ¦ÑX·|ªº¬Jµø·P~~ |
|
|
·|û¡GEric10153189 µoªí®É¶¡:2023/3/13 ¤W¤È 10:48:30²Ä 3010 ½g¦^À³
|
·Q½Ð°Ý¦³¤Hª`·N¨ì¤½¥q¥Ó½Ð¤WÂd®É¶¡¤w¶W¹L¤@¦~¡A¦ý¤½¥q«oµL¥ô¦ó¦^À³¶Ü¡H |
|
|
·|û¡GEric10153189 µoªí®É¶¡:2023/3/13 ¤W¤È 10:41:41²Ä 3009 ½g¦^À³
|
¤j®a¦n¡A ¤µ¤Ñ9:00¡ã10:30¤§¶¡¥´¤F³\¦h³q¹q¸Ü¡A³£µL¤H±µÅ¥¡A ½Ð°ÝªYÄ£¤½¥q¤W¯Z®É¶¡¬°´XÂI¡H ¥Ø«eÁÙ¦³¦bÀç¹B¶Ü¡H |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/13 ¤W¤È 08:38:56²Ä 3008 ½g¦^À³
|
·Pı¤½¥qª½±µ¤£ºt¤F¡A Â\Äê¡B¤£§ó·s¸ê°T¡B¤£¦^À³¼Ë¼Ë³£¨Ó¡A ·Qª¾¹D¦¶¥ý¥ÍªºÁ~¹S¬O¦h¤Ö? ·Ó¥Ø«e°]³ø¨Ó¬Ý¡AÀ³¸Ó¥i¥H¦A²n»âÓ8.9¦~¤£¬O°ÝÃD¡A ¨ì®ÉÔ¦A¸ò§ë¸ê¤H¼W¸ên¿ú~~ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/9 ¤U¤È 02:50:43²Ä 3007 ½g¦^À³
|
¬Ý¨ÓºÞ²z¼h¦³¦bª`·N³oÃä¶K¤å¡C ¦¶¸³¸Ó§ó·s¬ãµo¨½µ{»PQ&A¤F! ¦¶¸³¸Ó§ó·s¬ãµo¨½µ{»PQ&A¤F! ¦¶¸³¸Ó§ó·s¬ãµo¨½µ{»PQ&A¤F! ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦p¯u¦³¬Ý¨ì¥»ª©¶K¤å ¦¶¸³ªº¹Ú¬O§_¸ò§Ú°µªº¤@¼Ë¡H ·Ð½Ð¦¶¸³¦^·Q¤@¤U¡IÁÂÁ¡I |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/9 ¤U¤È 12:11:00²Ä 3006 ½g¦^À³
|
¤jÃļtY¤À°Ï±ÂÅv¥u¯à¦b¸Ó°Ï½æµL¬rÃÄ¡A¨ä¥L°Ï¥u¯à½æ¦³¬rÃÄ¡A³o¼Ë¤]«Ü¬°Ãø¡C«Øij¤½¥q§â810§ï¬°¥þ²y¤@¦¸±ÂÅvµ¹n±ÂÅvªº¤@Ó¤jÃļt¡A³o¼Ë¯à±o¨ìÃe¤j¸êª÷¦n¦n±À®i6¨t¡F¤½¥q¥¿½T¤è¦V¬O¤j§Q¡Iû¤u¸Ó¦³ªººÖ§Q¡B¦Y»³Ü»¶ok°Õ¤p¿ú¡A¤]¬OÀ³¸Óªº¡CªÑªF½|¤@½|¤½¥q¤]«Ü¦n¡A¤½¥q¯àª`·NªÑªFªº¤ßÁn¡A³£¬O§Æ±æ¤½¥q§ó¦n¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/9 ¤W¤È 10:39:59²Ä 3005 ½g¦^À³
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/9 ¤W¤È 08:01:01²Ä 3003 ½g¦^À³ ...ÃD¥~¸Ü:³Q¤H´¦º|®³§ë¸êªÌªº¿ú¶}§À¤ú¦Y¦Y³Ü³Ü¦n¤£³p»»«á¡A´N§â¤å³¹¥þºM±¼¤F¡A¨þ¨þ¡C ---------------------------------------------------------------------------------------- ¬Ý¨ÓºÞ²z¼h¦³¦bª`·N³oÃä¶K¤å¡C ¦¶¸³¸Ó§ó·s¬ãµo¨½µ{»PQ&A¤F! ¦¶¸³¸Ó§ó·s¬ãµo¨½µ{»PQ&A¤F! ¦¶¸³¸Ó§ó·s¬ãµo¨½µ{»PQ&A¤F! |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/9 ¤W¤È 10:02:06²Ä 3004 ½g¦^À³
|
ªYÄ£¤½¥q«ÅºÙªº610¤Î810¨º»ò¦nªºÃÄ®Ä 75¤¸¼W¸ê¤]¶Ò¤F12»õ¤¸¡A¥H¥Ø«eªº¸ÕÅç610-2¡B810¼Ï¶s³£¨¬°÷¡C ¥H¨º¤Ñ¤W¤S¤U¬[ªº¸ê®ÆÅã¥Ü 810¼Ï¶s¸ÕÅç¥ÎÃĤ~7¤Ñ 610-2¥ÎÃĤ~12¶g ¦Ó¥B¸ÕÅç¤H¼Æ³£«Ü¤Ö ¯u·Q¥Î¤ß°µ¸ÕÅ禴N°µ¥Xµ²ªG¤F Ãø©Ç¥¢±æªºµu½uÄw½X±þ¥X ¹ï©óªø½u§ë¸ê¤H·íµMµL©Ò¿× ¥u¬O¤u·~§½ªº¤WÂd¦P·N¨ç´Á¤w±NºÉ ¬°¤°»ò³£ÁÙ¨S¦³n¥Ó½Ðªº¸ñ¹³¡H |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/9 ¤W¤È 08:01:01²Ä 3003 ½g¦^À³
|
¨Ã¤£¬O¤°»òªÑ»ù¶^¤~¥X¨Ó°Û°I¡A¦Ó¬O¨Æ¹ê´NÂ\¦b²´«e¡A ¦ý¶R¥Í§ÞªÑªº¤H«Ü®e©ö¥Î¹Ú·Q¸ò¤j»æ¨Ó¶Ê¯v¦Û¤v¡A ªÑ²¼¥«³õ»Ýnªº¬O¸êª÷¡B¤H®ð¸ò´x´¤®É¾÷¡A ¦ýªYÄ£¶Ò¶°¨ì¤F¸êª÷¡A«o¤£À´±o´x´¤®É¾÷¡A¤Ï¦Ó©]¦¦Û¤j¡B¬G¨B¦Û«Ê¡A §Y¨Ï²{¦b½T¹ê¦³Àu¶Õ¡A¤§«á«Ü§Ö´N·|³Q¨ú¥N±¼¤F¡A ¨ú¥N¤£¤@©w¬On°µ¥X¸ò§AªYÄ£¤@¼ËªºªF¦è¡A¦Ó¬Oª½±µµLµø§A¡A·í§Ná¤p¤¡! ÃD¥~¸Ü:³Q¤H´¦º|®³§ë¸êªÌªº¿ú¶}§À¤ú¦Y¦Y³Ü³Ü¦n¤£³p»»«á¡A´N§â¤å³¹¥þºM±¼¤F¡A¨þ¨þ¡C |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/3/8 ¤W¤È 11:46:58²Ä 3002 ½g¦^À³
|
µuµøªñ§Q¥u·|±o¤£Àv¥¢¡AªÑ»ù¶^¤°»ò°¸Ü³£»¡±o¥X¨Ó¡C |
|
|
·|û¡Gonly10135877 µoªí®É¶¡:2023/3/8 ¤W¤È 11:13:12²Ä 3001 ½g¦^À³
|
¨º´µ¹F§J¤W¥«? ¨º¤U¿³Âd«eªÑ»ù¥ý¶^¤@¥b,µM«á¦Aµ¥ ¤G¦~¨º´µ¹F§J¤£ª¾¥i¤£¥i¥H¤W¥«·Ç³Æ´Á(¤£¯à¥æ©ö) µM«á¸I¤F¤@»ó¤l¦Ç |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/8 ¤W¤È 10:10:15²Ä 3000 ½g¦^À³
|
¥H«eªºªYÄ£µ¹¤Hªº·Pı¡G¥Rº¡¥Ø¼Ð¤@ª½·Q©é¥XÂI¦¨ÁZ¡A¸ê°T³£¤½¶}³z©ú¡C ²{¦bªºªYÄ£µ¹¤Hªº·Pı¡G·L¦³ÂI¶i®i«á¶}©l¦Ûµø¬Æ°ª¡A³sºt³£¤£·Qºt¡AÂ\Äêµ¹§A¬Ý¡ã ²ö¦WªºÄ±±o´d«s¡ã ¡°¤½¥q³s¥X¨Ó¸ÑÄÀ©Î¦w¼¾¤u§@³£¤£·Q°µ¡A¤Ï¥¿I«á§ë¸ê¤½¥qµ¹ªº¿ú°÷¤º³¡û¤uÌ»âÁ~¤ô¾i¦Ñ¤@½ú¤l¤F¡ã |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/7 ¤U¤È 02:57:10²Ä 2999 ½g¦^À³
|
§Ú·|¥X®u¦~«×ªÑªF¤j·| ¨Ã·|«Ø½Ð¤½¥q¨ì¨º´µ¹F§J¤W¥« ¥HªYÄ£¤pªÑ¥»¤½¥q Y¦b¨º«ü¤W¥« ·d¤£¦n¥un²{ª÷¼W¸ê1»õªÑ¥» ´N¨¬°÷3´Á¸ÕÅç¸êª÷ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/7 ¤U¤È 02:33:18²Ä 2998 ½g¦^À³
|
Ó¤H¬Ýªk 810³B¤èñ¦p¸gFDA®ÖãÃÄÃÒ ·íµM®ø¶OªÌ·|¶R³æ¡uµL¬r¡A¤£¶Ë¨x¡v¤îµhÃÄ ©Ò¥H³B¤èñ«D±`È¿ú ¬ü°ê¼Ï¶s¸ÕÅç¥Ó½Ð¡A¬°¦ó¿ð¿ð¤£®Öã¡H µL¥L¡A¦]ªYÄ£¤£¬O¬ü°ê¤½¥q¡A¤£²Å¦X¬ü°ê§Q¯q¡C ©Ò¥H¡A°e¥ó¼f¬d«án¨D¡u¤j¹«¡v¸ÕÅç¡C ¤j¹«°e¤F¡A¤S¦An¨D¡uª¯¡v¸ÕÅç¡A©úÅã¬O¦b©ì©µ®É¶¡¡C ³£¤w¼f¬d³q¹Lµ¹OTCÃÄÃÒ¤F¡AOTCªºÃÄÃø¹D¤£¬Onµ¹¤H¦Yªº¶Ü¡H ¥Ó½Ð¼Ï¶s¸ÕÅç¡AÁÙn¨D¥ý¡u¹«¡Bª¯¡v¥ý¦Y¡A¤£¬O¥»¥½Ë¸m¶Ü¡H ¤µ¤Ñ¦pªG¬OJ&J¬ü°ê¤½¥q¥Ó½Ð¡AÁÙ·|¦p¦¹¶Ü¡H ¥H¤W¶È¨Ñ°Ñ¦Ò¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/7 ¤U¤È 12:14:07²Ä 2997 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/7 ¤W¤È 10:12:44²Ä 2994 ½g¦^À³ ....³Ìªñªº³ø§i«ÂIÃöª` TRPV4 ¦b TGF-£] »¤¾É (2017¦~) -------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/19 ¤W¤È 10:17:40²Ä 2941 ½g¦^À³ ...TGF-£]1 ¬O诱导纤维胶ì(¥Dn¬OI«¬©MIII«¬)¡B£\-SMA¡B ....¾Ú¦¹2018¦~Gileadªá15»õ¬ü¤¸±ÂÅvTGF£]ÃĪ« ------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/7 ¤W¤È ....§Ú̥ثeªº¹êÅç¡]¦P®É¨Ï¥ÎÅé¥~©MÅ餺¬ã¨s¡^´¦¥Üªºµ²ªG¤ä«ù³o¤@·s·§©À¨Ã´£¨Ñ¤F¤@ºØ¾÷¨î¡A§Y TRPV4 ¤¶¾Éªº³q¹L NOS3 ½Õ¸` CYP2E1¡C --------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 04:55:45²Ä 2974 ½g¦^À³ CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21 -------------------------------------------------------------------------------------- §í¨îCYP2E1¯àÅýÅÖºû¼Ð»xª«£\-SMA¡BCol1a1¡BCol3a1©MTimp-1§¡ÅãµÛ°§C¡C ÀôÀô¬Û¦©¦a¤E³sÀô¾÷¨î¡A CYP2E1¯à§_¦¨ÃÄ?ÀHµÛ®É¶¡¹L¥h¤]®t¤£¦hn´¦¾å¤F¡C |
|
|
·|û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2023/3/7 ¤W¤È 11:12:52²Ä 2996 ½g¦^À³
|
JP¡Aªº±M§Qµ¦²¤¬OÀHµÛ®É¶¡¤@¼h¼hÅ|¤W¥hªº¡A¥Øªº¬O©µªø±M§Q«OÅ@ªº®É¶¡¡C JP»¡³o¦³·ÀI¡A·~¬É¤]¹ï³o¤è¦¡¦³©Ò½èºÃ¡A¦ý¤Æ¾ÇÃľǦWÃĪºªùÂe¤£¤ñ¤j¤À¤lÃÄ¡A±M§Qªº«OÅ@®É¶¡«Ü«n¡C ©Ò¥H¡A¦b±ÂÅv¥¼½Í§´«e¡AY¬OÅý±ÂÅv¤è¹ï©ó²Ó³£¤@²M¤G·¡ªº¸Ü¡A¬O¦³¥i¯à³Q¨ä¥Ó½Ð¬Y³¡¥÷ªº±M§Q¡A¶i¦Óºã¦í¤Î«d®z½Í§PªºÄw½X¡A·d¤£¦n³Ì«á¾ã¸J³Q®³¨«ªº¡A¼Æ¤Q¦~ªº¬ãµo¦¨ªG´N«ý¤âÅý¤H¡C SNP-810 °ª¾¯¶q³B¤èºà¥«³õ½T¹ê¤~¬O¼É§Qªº¡A¯S§O¬O·í FDA ¡y©Ó»{¡zµL¬r©Ê®É¡A«áÄò³B¤èºàÁ{§É²Õ¦Xªº¦h¼Ë©Ê¶}µo¬O«D±`¦³·Q¹³ªÅ¶¡ªº¡A©Ò¥H¡A¨ú±o FDA ªº»{¦P¬O«D±`ÃöÁ䪺ÂI¡C©Ò¥H¡AÓ¤Hı±o«ùÄòªº¦³®Ä¸ò FDA ·¾³q¡A§âÃöÁäÁ{§É¼Æ¾Ú°µ¥X¨ÓÃÒ©ú¤HÅéªA¥ÎµL¬r¡A¶i¦ÓÅý FDA µo®Ñ±ÃÄÃÒ¦P·N¨äµL¬rªº¥\®Ä¡A«áÄòªºl¥Í²Õ¦X¥ÎÃĪºÁ{§É¤~¯à®üÁï¤ÑªÅ¡C ¤£n¥H±ÂÅv¬°¾É¦V¥h°µÁ{§É¡An¥HÃÄ«~¤W¥«¬°Á{§É³]p±À¶i¡A±ÂÅv¬Oªþ±a¦Ó¨Óªº¡CSNP-810 µL¬rÁ{§ÉÀø®Äªº®i²{¥B¬O³B¤èºà°ª¾¯¶qªº°ß¤@¿ï¾Ü®É¡A±ÂÅv½Í§Pºò±iªº´N¤£·|¬OªYÄ£¡C ¥t¥~¡A¸Óªá¿ú¨ì¬ü°ê°µÁ{§É´N°µ¡A¤£n¤Ó¹L¬Ù¿ú¡A²¦³º·sÃĬãµo time is money ¡A³t«×¤ÓºCªº¼vÅT¡A¨ä·l¥¢¥i¯à¤ñÂi±¤W¬Ùªº¿ún¤j¦h¤F¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/7 ¤W¤È 11:12:01²Ä 2995 ½g¦^À³
|
´N¦pS¤j©Ò»¡¤@¼Ë¡A¦Û¤v¦æ¾P¤£¬O¨º»ò²³æ¡C ´N®³´¶®³¯k¦b¥xÆWªº¼s§i¡A¶O¥Î¶}¾P´N«ÜÅå¤H¡C ¤j®a³£¦³¦b½æªº¤îµhÃÄ¡A¨S¦³±j¤O¼s§i«Å¶Ç¡u¥u¦³§Úªº¤£¶Ë¨x¡v¡C ®ø¶OªÌ¤£·|¿ï¾Ü¦W¤£¨£¸g¶Çªº¤p¼t¡A¹ç¿ï´¶®³¯k¡C ªYÄ£µLªk¸ò²{¦³ªº¼t°ÓÄvª§¡A±©¦³±ÂÅv¤j¼t¡C ¦ý¬O¡A¤j¼t¦b©ó¥i¥Î»P¥i¤£¥Î¤U¡A·íµM¤£·|µ¹¦n»ù¿ú¡C ©Ò¥H¡A¦Ñ¥jªOªº¾ÇªÌ¥²¶·§ïÅÜ«äºû¡A¤£¯à¥H¤½½Ã·§©À½Í±ÂÅv¡C ¦Ó¬O¥H¥þÅéªÑªFªº³Ì¤j§Q¯q¡A½Í¥þ²y¡u³æ¿W¡v±ÂÅv¡A¤~¯à¦³¦n»ù¿ú¡C ¤£µM¥u¯à¥ô¾Ì¤j¼té«d¡A¥ô¾Ì®_³Î¡I 810³B¤èñÃĤ]£¸¼Ë¤£¯à¦Û¤v½æ¡An³æ¿W±ÂÅv¡A¥²¦³¦n»ù¿ú¡C ÃľìÃĦۤv½æ¡A·QnÁÈ¿ú¨S¨º»ò®e©ö¡A¦æ¾P¶O¥ÎÅå¤H·|¦Y±¼µ´¤j³¡¤ÀÀç§Q¡C ¥H¤½¥q¹ï©ó6¤Î8¨t¦C«ÅºÙªºÃĮġA¥[¤WNASH¦b¨º«üªº´X¿¤jº¦¤U¡C ¦pªG¦b¨º«ü¤W¥«¡AªÑ»ùÀ³¸Ó¤£·|¤Ó«K©y¡A¦Ü¤Ö·|°ª©ó¥xÆW´X¿¡C ªYÄ£ªº6¨t¦C¦pªGn´Â3´Á¨«¡A±NnÃe¤jªº¸êª÷À³¹ï¡C ¨ì¨º«ü¤W¥«¶Ò¶°Ãe¤j¸ÕÅç¸êª÷§ó®e©ö¡I ´N¬Ý¦Ñ¥jªOªº¾ÇªÌÆ[©À¡B°µªk·|¤£·|§ïÅÜ¡H ¥H¤W¡A¶È¨Ñ°Ñ¦Ò¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/7 ¤W¤È 10:12:44²Ä 2994 ½g¦^À³
|
Ãö©óCYP2E1 §í¨î 1. ¤@²Õ°µ¤F¤@¨Ç¦³½ìªºµ²ªG www.facebook.com/100064104724409/videos/298211662214622?__so__=permalink 2:50~JP: ¦Ó¥BNASH§Ú̱q¨Ó¨S¦³·Q»¡ §Úì¨Ó¤£·|¿ïNASHªº ¬O§Ú¤@Ó¬ã¨s¥Í¥L¦b¤Q´X¦~«e¥L¬ã¨s©Ò°µªº §Ú¨S¦³n°µNASHªº·sÃÄ³á ¦ý¬O§Ú̵o²{°µ¤F¤@¨Ç¦³½ìªºµ²ªG¥X¨Ó¤F ¨S·Q¨ì³Ìªñ³o56¦~ «õ NASH¬õªº¤£±o¤F ©Ò¥H¤H®a´NPUSH§ÚÌ°µ ©Ò¥H§Ú¤~°µ¦a 2.¤@²Õ»¡TRPV4 is [THE Obelix of the hepatic Gaul] www.youtube.com/watch?v=fClRftUGZhQ Dr. Saurabh Chatterjee: TRPV4 is [THE Obelix of the hepatic Gaul] ...³Ìªñªº³ø§i«ÂIÃöª` TRPV4 ¦b TGF-£] »¤¾Éªº¨x¬Pª¬²ÓM (HSC) ¼W´Þ¤¤ªº§@¥Î¡A³o¬O²Õ´¦A¥Íªº«n¼Ð»xª«©M¶i¦æ©Ê NAFLD ªº¯f²z¥Í²z¨Æ¥ó.... ¾¨ºÞ³o¨Ç³Ìªñªº¬ã¨s«Ü¦³½ì¡A¦]¬°¥¦Ì´¦¥Ü¤F»P HSC ¼W´Þ¬ÛÃöªº¨xŦ TRPV4 ªº½Õ¸`ªí¹F¡A¦ý¥¦Ì¨Ã¥¼©w¸q TRPV4 ³q¹L«nªº CYP450 ³~®|¦b«O¨x©Î·l¶Ë¤¤ªº§@¥Î¡C§ÚÌ°²³] TRPV4 ³q¹L¿E¬¡¬\§_²ÓM NOS3 ¨Ã¥H®Ç¤Àªc¤è¦¡ÄÀ©ñ NO ¨Ó [ªýÂ_ ]CYP2E1 ¥\¯à.... §Ú̥ثeªº¹êÅç¡]¦P®É¨Ï¥ÎÅé¥~©MÅ餺¬ã¨s¡^´¦¥Üªºµ²ªG¤ä«ù³o¤@·s·§©À¨Ã´£¨Ñ¤F¤@ºØ¾÷¨î¡A§Y TRPV4 ¤¶¾Éªº³q¹L NOS3 ½Õ¸` CYP2E1¡C ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 01:28:36²Ä 2969 ½g¦^À³ ¬ü°ê«n¥dù¨Ó¯Ç¤j¾Ç2016¦~½×¤å--ªýÂ_CYP2E1]¤¶¾ÉªºROS TRPV4 ¿E¬¡¤º¥Ö¤@®ñ¤Æ´á¦X酶³q¹L [ªýÂ_CYP2E1]¤¶¾Éªº®ñ¤ÆÁÙì¬r©Ê¨Ó©è§Ü«D°sºë©Ê¯×ªÕ¨x www.ncbi.nlm.nih.gov/pmc/articles/PMC5989309/ |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/7 ¤W¤È 09:54:08²Ä 2993 ½g¦^À³
|
¤£»ÝnÁ`¬O¥H©ÈÄvª§¹ï¤âª¾¹D¡A©È¤j¼t«ç¼Ë¡A©È¤°»ò¤°»ò¤§Ãþªº»¡µü¦Û§Ú¦w¼¢ ¦pªG¯uªº¦³«H¤ß¡A±M§Q³£¥Ó½Ð¤F¡AÁ٩ȪF©È¦èªº¤£¬O«Ü¿Ø¨ë¶Ü? ¯uªº³o»ò¼F®`¤S¨ã¦³«e¤©Ê®ÄªG¤S³o»òÎx¡A¤H®a¤j¼t¦´N±·µÛ¤j§â¤j§â¶r²¼¤Wªù¤F~ ¦Ñ¸Ü¤@¥y¡A§AµLªk¦Û¤v¶q²£³c½æ¡B¨S¦³³q¸ô¥«¥e¡B¸êª÷¤S¦³¡A ´«¦ì«ä¦Ò¡A§A¯¸¦b¤j¼tªº¨¤«×¡A§Anªá¤j¿ú¸ò¹ï¤â¶R¡AÁÙ¬Oµ¥¥L¦Û¤v¼µ¤£¦í°»ù¨D°â~ ´N¸òNBA²y¬P¤@°ï¥H¬°¦Û¤v«ÜÎx¡A§Æ±æ²y¶¤¶}¦~Á~4000¸U¬üª÷¡AµM«á²y¶¤³Ì¦h¶}¨ì3000¸U¬üª÷¡A ²y¬P¦b¨ºÂ\¬[¤l¤£Ä@·N±µ¨ü¡A³Ì«áµo²{³£¨S¤Hnñ¬ù¡A·Q¸ò²y¶¤§CÀY»¡Ä@·N±µ¨ü3000¸U¬üª÷®É¡A ²y¶¤¦^§A¤@¥y:¨S¹wºâÅo¡A1500¸U¬üª÷¤@¥y·Rn¤£n¡A¤£n©ÔË! §Aı±oź¶Æªº¤£·Q§CÀY¥i¥H¡A¥hSBL»â¤ëÁ~10¸U....¥x¹ô¡C ======================================== Ãö©óSNP-810¬ü°êOTCÃÄÃÒ www.facebook.com/100064104724409/videos/443452154155295?__so__=permalink ~1:45°_JP:...¹³§Ú̥ӽШºÓ¬ü°êªºlicense¡A¥ý¥Ó½Ð¨ì´N¬O¥ý§âCMC¸Ñ¨M±¼¡A´NÅܦ¨¬O¤@Ó¤W¥«ªºÃÄ §Ṳ́W¥«ªºÃĦA¥h°µ¤@Ónew use indication new claimªº¸Ü ´N²³æ¦h¤F...[¤£¯àÁ¿¤Ó¦h] Á¿¤Ó¦h±N¨ÓÄvª§¹ï¤â..... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/7 ¤W¤È 09:37:54²Ä 2992 ½g¦^À³
|
Ãö©óSNP-810¬ü°êOTCÃÄÃÒ www.facebook.com/100064104724409/videos/443452154155295?__so__=permalink ~1:45°_JP:...¹³§Ú̥ӽШºÓ¬ü°êªºlicense¡A¥ý¥Ó½Ð¨ì´N¬O¥ý§âCMC¸Ñ¨M±¼¡A´NÅܦ¨¬O¤@Ó¤W¥«ªºÃÄ §Ṳ́W¥«ªºÃĦA¥h°µ¤@Ónew use indication new claimªº¸Ü ´N²³æ¦h¤F...[¤£¯àÁ¿¤Ó¦h] Á¿¤Ó¦h±N¨ÓÄvª§¹ï¤â..... |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/6 ¤U¤È 08:03:57²Ä 2991 ½g¦^À³
|
´°½Ð¥»ª©´X¦ì«ÜÀ´¤Î¦³¬Ýªkªº¤j¤j°Ñ¥[ªÑªF·|, ª½±µ»P¸³¨Æªø¹ï¸Ü, «Ø¨¥¨Ã¼á²M¬ãµo¤Î±ÂÅvµ¦²¤¶i«×. |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/6 ¤U¤È 01:41:03²Ä 2990 ½g¦^À³
|
S¤j ¥H¤U¬O§Ú°µ¹Ú¹Ú¨ìªº¡A¶È¨Ñ°Ñ¦Ò¡I OTCÃÄÃÒ´N¦p±z©Ò»¡¡A¥H¥@¬É¤½½Ãºc·Q½Í±ÂÅv¡C ´N¤£·|¦³¦n»ù¿ú¡A¤½¥q¥H¦¹¤è¦¡½Í·íµM¤£·|¦³°ªÃB±ÂÅvª÷¡C ¦Ó¥B¡u¤½¥q¤]ª¾¹D¡v³o¼Ë¥u¯àñ¤p¦X¬ù¡A¨Ã¤£¬O±z©Ò²q´ú¤½¥qn¨D¡u°ª±ÂÅv¡v¡A¦Ó½Í¤£§´¡C ³oÂI§Ú°µ¹Ú¥i½T»{¡A©Ò¥H§Ú¤~»¡OTCÃÄÃÒ¤£È¿ú¡C 810¶W¹L¼Ð·Ç¾¯¶qªº³B¤èñ´N¡u¥þ¥@¬É¿W¤@¡v ³B¤èñ¥«³õ¶W¹L20»õ¬ü¤¸¡A³o¶ô«D±`È¿ú¡C ³o¶ô¤½¥q·Q¦Û¤v½æ¡A¦pªG¤£¬O¦Û¤v½æ¡A¨âªÌ£¸°_½Í±ÂÅv¨Æ©y¡A¨º±ÂÅvª÷´N¥iÆ[¤F¡I Y¬O¦Ò¶q¥þÅéªÑªFªº³Ì¤j§Q¯q¡A«h±Ä¡u¿W®a¡v±ÂÅv¡A¨º¤j¼tÄv¼Ð¡A¤£¬O§ó¥iÆ[¶Ü¡H ¸Ó±´°Qªº¬O¨ì²{¦b¬°¦óÁÙ¤£¥Ó½Ð¤WÂd¡H ¦b¥h¦~NASH±Ú¸sÁÙ¥¼¤jº¦´X¿®É¡A´¿¹Ú¨ì¡u»ù®æ¤£²z·Q¡vªº²z¥Ñ¡C ²{¦b³o±Ú¸s¥«È¤w¸g°÷¤j¡AªYÄ£«ÅºÙªº¤ñM¤½¥qªºÃĮħó¦n¡AªYÄ£ªº»ùÈÀ³¸Ó¤]n¤ôº¦²î°ª§a¡I ¸Ó¨ì¨º´µ¹F§J¤W¥«¤F§a¡H¦¶¸³¡H ·Qªk»P°µªk¬O§_¤w¦³§ïÅÜ¡H ¨â¤j¼t³£¯Ê610¤Î810¡A¦¹®É¦pªG°÷Áo©úªº¸Ü¡A¶}¥XÅý¤HµLªk§Ü©Úªº»ù½X¨ÖªYÄ£¡A¬O«Ü¦Eºâªº¡C ¥H¤W¬O¬~¸£©Î¬O¸É¸£¤å¡A¦Û¦æ¸ÑŪ¡I |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/3/6 ¤W¤È 11:56:36²Ä 2989 ½g¦^À³
|
810¤À°Ï±ÂÅv¥i¯à±a¨Ó§ó¤j§Q¼í¡F°µ¥Í·NÁ`¬O¦bÅÜ¡A¤À°ÏY¦³¤£¶¶¤]¥i¯à¥þ²y¤@¦¸Àu´fµ¹¥t¤@®a¤j¼t±ÂÅv¡F¦A½Í¤£Ãl°®¯Ü¦Û¤v§ä»sÃļt¥N¤u¦Û¤v³c½æ¡A§Q¼í8¦¨¤£¥²ªá¿ú¼s§i¡A¤@¦~À禬¤@»õ¬ü¤¸´N¦n«¥ªYÄ£¬O¤p¤½¥q¦Y¹¡¹¡¡A¤£¥²Åý¤j¼tn¤£nªº¡C¾Ç¾Ç¦X¤@¡BÃĵØÃÄ¡AªÑ»ù°ª¤S¦nÁÈ¡I |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/6 ¤W¤È 09:24:03²Ä 2988 ½g¦^À³
|
¦V¥S±zÁ¿¨ì«ÂI¤F¡A ¨ä¹ê·í¦¶³Í¥Á»¡¨ì¡G¥@¬É¯Å¤jÃļt³£¬O¥H¡u¤½¦@½Ã¥Íªº»ùÈ¡v¬°³Ì¤j©v¦®¡A¦]¦¹¥¼¨Ó±N±Ä«D±MÄÝ¡B¤À°Ï±ÂÅvµ¦²¤ ¤j®a´N¸Óª¾¹D¡A¨ä¹ê±ÂÅvÀ³¸Ó³£¬O¦³¦b½Í¡A ¬Æ¦Ü§Ú¤jÁx²q´ú¼t°Ó³£¦³´£¥X±ÂÅvª÷³ø»ù¤F¡A ¦ý¬OªYÄ£¤½¥q¤è´N¬O¹L«×³g±oµL¹½¡A·Qn®³°ª±ÂÅvª÷¡A¤S¥u·Q¤À°Ï¡A¤°»ò³£·Q®³¦n®³º¡¡A ¾ÉP¤j¼t¤£²n¤U¹çÄ@¦Û¤v¯{¿ú¬ã¨s¤]¤£·Qµ¹ªYÄ£ÁÈ¡I ²{¦bªYÄ£·d¨ì¦Û¤vµL¸ô¥i¨«¡A¤S¤£Ä@·N§CÀY°§C쥻¤j¼t¯à±µ¨üªº±ÂÅv±ø¥ó¡A ©Ò¥H¥u³Ñ¤U¦bì¦aªÅÂà¡A¯º¦º¡Ë ¤j¼t¦³ªº¬O®É¶¡¸ò§A±Î¡A¦ý¬OªYÄ£¸êª÷¦³¡A¨ì®ÉÔ¼µ¤£¤U¥h¡A¤H®a¤j¼tÁÙ¥i¥HÂǾ÷¦A¬å§ó¦h±ÂÅv±ø¥ó¡ã ¤@½L¦n´Ñª±¨ì¿é¡I¡I ÃD¥~¸Ü¡A¤H®aªYÄ£¦~ªì®ÉÁÙ°ª½Õªº¦b¢Ô¢Ð¤W¢Þ¢Ý¤@°ï¦~²×¼y¥Í·|ªº¹Ï¤å¡ã ®³§ë¸ê¤Hªº¿ú¥h¦Y¦Y³Ü³Ü´N¬O²nªü¡ã |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/6 ¤W¤È 08:51:42²Ä 2987 ½g¦^À³
|
To S¤j ¥¿¦p±z©Ò»¡¡A810ªºOTCÃÄÃÒ¤£È¿ú¡A¤j¼t¥i¥Î¤]¥i¤£¥Î¡C ªYÄ£¤]µL³q¸ô¡AµL¯à¤Oªá¤j¿ú¼s§i¡A¥B¤p¼tªºÃÄ®ø¶OªÌ¤£¨£±o·|¥Î¡C ¤j¼t¼Ð·Ç¾¯¶qÁÙ¬O·Ó½æ¡A®Ú¥»¤£»ÝnªYÄ£ªº¤£¶Ë¨x¡C ªYÄ£ªº¦¶¸³À³¸Ón§ï¡u¿W®a±ÂÅv¡v¡A¤~¯à¥´¶}ª¾¦W«×¡C 810È¿úªº¬O¶W¹L¼Ð·Ç¾¯¶qªº³B¤èñ¥ÎÃÄ¡A¦pªG¦¨¥\¹F¼Ð¡I ¥ô¦ó¤@®a¤j¼t¨ú±o¿W®a±ÂÅv¡A±N·|¦Y¤U©Ò¦³¤wñQÓi×ôOTC¤Î³B¤èÃÄ¥«³õ¡C NASH¤~¬OªYÄ£ªº¶W¯Å¤jÃÄ¡A610ªº¥ÎÃĤ~12¶g¡A¦pªGÃĮįu¦p¤½¥q©ÒºÙ¡I ¡u¦n¡v¹LM¤½¥qªº¼Æ¾Ú¡A¥[³t¦A°µ¤@Ó2´Á¡A¦h°µ´X²Õ¸ÕÅç¡C §ä¥X³Ì¦nÃĮIJէO¡Aµu®É¶¡´N·|¨ì3´Á¡C ÁÙ¬O¥i¥H»°±o¤WNASH³oªi®ö¼é¡I ´N¬Ý¦¶¸³¥L̪º°µ¬°¤F¡I |
|
|
·|û¡GStockMaster10153183 µoªí®É¶¡:2023/3/6 ¤W¤È 08:17:53²Ä 2986 ½g¦^À³
|
»¡¹ê¸Ü¡A¯u¤ß¤£À´¬°¤°»ò¤@°ï¤H¤@ª½¦b¸£¸É~~ »{¬°¨â¤j¼t¤@©wn¸ò§AªYÄ£¶R³æ? Á¿¥Õ¤F¡AªYÄ£³oÓ¦³±M§Q¤S¦p¦ó? ¤H®a³£ÃbÂ_¥«³õ¤F¡A§A¤µ¤Ñ¥h¸ò¤H®a»¡§AªºÃĦh¼F®`¡AµL¨x¬r¡AÎx¥´¤H®a´¶®³¯k...µ¥¦U¤jÃļt µ²ªG©O?¤j®a³Ì«áÁÙ¬O·|¿ï¾Ü¦³Å¥¹Lªº´¶®³¯k! ©Ò¥H¤H®a¤j¼t¨S¦³¤@©wn¸ò§A¶R³æ¦n¶Ü? §A¦Û¥H¬°¬O·Qn°ª»ù±ÂÅvª÷¡A¨º§A´NºCºCµ¥¡A¤Ï¥¿§Ú¤£¸ò§A¶R³æ§Ú¤@¼Ë½æªºÀ~À~¥s~ ªYÄ£³Ì¦n¥ý·d²M·¡¦Û¤vªº¥ß³õ¡A¬O¨S¦³Ô£©³®ð¸ò¤H¶æÁnªº¡A ·PıªYÄ£´N¹³¬O¹¥j¤£¤Æªº¾ÇªÌ¡A³Ì«áµ²ªG´N¬OÀHµÛ®É¶¡³Q²^¨O¦Ó¤w~ ¦Ûµø¬Æ°ªªº¤U³õ³q±`³£¤£¬O¤Ó¦n¡A ´N¸ò¾³õ¤W¡A©¹©¹¯àª¦¤W¥hªº¤H³£¤£¬O¯à¤O³Ì¦nªº¡A¦Ó¬OÀ´±o¦p¦ó°µ¤Hªº! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/5 ¤U¤È 09:00:33²Ä 2985 ½g¦^À³
|
¨ä¹ê§Ṳ́pªÑªF¨S¥hªÑªF·|½è¸ß¤@¤U¡A¤£µMªÑªF·|¥b¤p®É´N¤£·|µ²§ô¤F¡C ¦¶¸³À´¤£À´~ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/5 ¤U¤È 06:36:35²Ä 2984 ½g¦^À³
|
110¦~²{¼W»ù75¤¸¡A¶WÃB»{ÁÊ5¤d±i¡C ¥h¦~©³¨º´µ¹F§JNASH±Ú¸s¤jº¦´X¿ «Ü¿ò¾ÑªYÄ£¨S¦³¸òµÛº¦¡A¤Ï¦Ó¤U¶^¡C ÁöµMªYÄ£¸ÕÅç¶i«×½½¤û¨B¡A¦pªG¦³¤ßn°µ¡C 610ªº2´Á¦A°µ¤@¦¸¡A12¶g«Ü§Ö´N·|µ²§ô¡C ¬Æ¦ÜÁÙ¥i¦h´X²Õ¸ÕÅç¡A24¶g³£¦æ¡A¬°3´Á¾Q¸ô¡C M¤½¥q¤]¬O©µªø¸ÕÅç®É¶¡¤~¥X²{¦n¦¨ÁZ Ãø¹DªYÄ£¯uªºµLªk¸ò¤W±Ú¸s¤jº¦¶Ü¡H ªYÄ£ªº¦¶¸³¸¬Äªùب쩳½æ¤°»òÃÄ¡H |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/5 ¤U¤È 05:00:44²Ä 2983 ½g¦^À³
|
§Ú¤T¤£¤®ÉÁÙ¬O¦bÃö¤ß¡A©Î¬O¤£¥Ì¤ß!!¥i±¤¤F³o¤ä ¨ä¥¦³£º¦¤@¿¦h¤F ¦pªG¶^¦^80§Ú¦A¨Ó¬Ý¬Ý |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/4 ¤U¤È 07:20:42²Ä 2982 ½g¦^À³
|
dk¤j¦³ªÅ±`¦^¥»ª©¬Ý¬Ý²á²á.¤]³\¦³Âà¾÷¦A¶R¦^. §Ú¬O¥´ºâ«ù¦³2¦~. ¤£¹L¦pªG1¦~«á¦bÁ{§É/±ÂÅv/IPO¤è±³£¨S¦³¥ô¦ó¶i®i,´N·|«·s¦Ò¼{«ùªÑµ¦²¤. |
|
|
·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2023/3/3 ¤U¤È 09:44:22²Ä 2981 ½g¦^À³
|
¦P´Á 111/03/21¨ú±o¬ì§Þ¨Æ·~¥B¨ã¥«³õ©Ê¤§·N¨£®Ñªº6785¤w¥X¨ã¤º±±±M¼f³ø§i¡A §Æ±æ6634¯à¹³¨ú±oOTCªº¼Ò¦¡¡AÅý¤j®a¯à¦³¥X¥G·N®Æ¤§¥~ªº¤@µ§¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/3 ¤U¤È 02:05:56²Ä 2980 ½g¦^À³
|
¤p§Ì¥ý°h¥X §ë°¿é¤@¥b! ¯¬¤j¼wÁÈ¿ú |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/3 ¤W¤È 11:53:24²Ä 2979 ½g¦^À³
|
¤µ¤Ñ¦³¤H¨è·N¥Î¹sªÑ1ªÑ¦b¥´À£ªÑ»ù »s³y¤U¶^ªº®£·W±¡ºü ¬Ý¬Ý3ÂI¦¬½L¡A¯à¤£¯à¯}©³Â½¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/3 ¤W¤È 11:38:51²Ä 2978 ½g¦^À³
|
2023.2.17-°ªÒ¾«ù仓ªºNASH¡§§Ö鱼¡¨¡G两¦~¥bIPO¡A¥|¦~°µ¥XýͦbBest-in-Class药ª« www.vbdata.cn/1518897234 2018¦~5¤ë¡AAkero从¦w进¤Þ进¤FAMG876¡A¤@´ÚFc¿Ä¦Xªº长®ÄFGF21类¦üª«¡A这¬OAkero¦bNASH领°ìªº°_点¡C Akero¤Þ进ºÞ线时¡AFGF21©|¥¼¦¨为NASH领°ìªº¥D¬y -------------------------------------------------------------------------------------------- Akero¦b2018¦~ªá500¸U¬ü¤¸±qamgen¶R¤J(Á`¨½µ{ª÷7500¸U¬ü¤¸¡A¤£¬O¥D¬y¤è¯à«K©y¶R¨ì)¡AÀø®Ä¼Æ¾Ú¬OFGF21ÅD¬°¥D¬yÃöÁä¡C ³t«×¤ñ©éªYÄ£(ºñø¿Àt)¹ï¤WAkero(ºX³½)¡C Orz. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/3 ¤W¤È 07:49:48²Ä 2977 ½g¦^À³
|
JP¬O¦Ñ¤ý½æ¥Ê? ¨º»ò¥iµ¥¨ìCYP2E1ªºì¦ì¨x²ÓMFGF21¿E¬¡¡AÀø®Ä¦w¥þµ¥¦P©ÎÀu¹LFGF21Ãþ¦üª«(¤H³yª«)¡A¦A¨Ó¦Y¥Ê¡C ¥Ñ©ó CYP2E1 ¥Dn¦b¥Dnµo¥Í¥NÁªº¨x²ÓM¤¤ªí¹F¡A¹v¦V§í¨î CYP2E1 ¥i¯à¹ê²{ì¦ì¨x²ÓM¤¤ªº PPAR £\¿E¬¡¡A³o¥i¥HÁ× §KÁ{§É¤¤°¸º¸µo¥Íªº«D²Õ´¯S²§©Ê PPAR £\¿E¬¡ªº°Æ§@¥Î--->SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂) ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 02:13:18²Ä 2973 ½g¦^À³ ±q[½è]¨Ó¬Ý: SNP-610/SNP-630§í¨îCYP2E1À³¸Ó¬O¸ûÀu(²×¨s¬Oì¥Äì¨ý¥Ñ¨xŦ¤ÀªcªºFGF21)¡C ±q[¶q]¨Ó¬Ý: AkeroªºEfruxifermin¯à¥[¤JFGF21Ãþ¦üª«¨ì·¸¥X¡C ±EÀu??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 10:28:19²Ä 2976 ½g¦^À³
|
°²³]¦A±NSNP-610ªº¥ÎÃĮɶ¡±q3Ó¤ë©Ôªø¨ì6Ó¤ë¡A¼Æ¾Ú½u·|«ùÄò¤U¦æ?¨«¥?©Î¥i¯à¤Ï¼u¨«¤É? (MadrigalªºResmetirom¦bP2(36¶g)ªºÁ{§Éµ²ªG¡AÅÖºû¤Æªº§ïµ½¬O¨S¦³²Îp¾Ç·N¸q) ------------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/26 ¤W¤È 06:53:17²Ä 2020 ½g¦^À³ www.facebook.com/watch/?v=3194947797458964 5¤À6¬í:Àø®Ä¤ñ¸û¹Ï(ª`·N¹Ïªí®É¶¡¶b): ªYÄ£ /SNP-610¬O(3Ó¤ë) VS. Genfit /Elafibranor(12Ó¤ë) VS. Intercept/Ocaliva(18Ó¤ë) 1. SNP-610 ÃĮį«³t§ó¦w¥þ! 2. Genfit /Elafibranor :4.8»õ¬ü¤¸±ÂÅvªvÀøìµo©ÊÁx¥Ä©ÊÁxºÞª¢(PBC)¸ÕÅç (¤w²×¤îNASHÁ{§É) ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/21 ¤U¤È 09:30:24²Ä 2949 ½g¦^À³ Resmetirom¤T´Á临§É设计¤¤¡AMadrigal°µ¹ï¤F¤°»ò¡H ..µ²½×:调¾ã¤F¨x纤维¤Æ««×±wªÌªº¤ñ¨Ò+ ¥[ªøªvÀø´Á (¤G´ÁªvÀø´Á 36¶g ¡A¤T´ÁªvÀø´Á 52¶g)¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 05:16:00²Ä 2975 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 04:55:45²Ä 2974 ½g¦^À³ CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21 SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂) --------------------------------------------------------------------------------------------------- www.x-mol.com/paper/1492209434695598080?adv ¥Ø«eªº结ªG«Ø¥ß¤F PPAR £\©M CYP2E1¤§间ªº¥N谢¦êÊð¡A [³q过¹v¦V CYP2E1 来调节内·½©Ê¥N谢ª«¡A¶W¥X¨ä¦b¥~·½©Ê¥N谢¤¤ªº¨å«¬§@¥Î] <--->¤j¥Õ¸Ü¬O[SNP-610§í¨îCYP2E1¡A¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[¦Ó¿E¬¡PPAR£\¡A¶W¥XElafibranor ³oºØ¥~·½©ÊÃĪ«ªº¿E¬¡PPAR£\§@¥Î] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 04:55:45²Ä 2974 ½g¦^À³
|
CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21 SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂) ¦³¨S¦³Àu©óAkeroªºEfruxifermin ? (Akero¦b2019¦~5¤ë©Û¦¬²Ä1¦ìP2±wªÌ¡AP2¼Æ¾Ú¬O¥h¦~¤½¥¬¡AµM«áªYÄ£¤½¥¬ªº¼Æ¾Ú«Ü¤Ö¡AµLªk¿s¤@´³¦Óª¾¥þ°\¡A©Ò¥H¨S±o¤ñ) --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151µoªí®É¶¡¡G2020/7/3¤W¤È08:05:38²Ä35½g¦^Î` 108/07/24 Bio-Asia¨È¬w¥Í§Þ¤j®iÁ|¿ì¤§¤½¥q®i±æ»¡©ú·| mops.twse.com.tw/nas/STR/663420190724M001.pdf Phase II study: - The decreases in several clinical parameters from baseline to the end of treatment were greater in SNP-610-12-week treatment than Ocaliva,Cenicriviroc, Elafibranor, MGL3196 or Selonsertib |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 02:13:18²Ä 2973 ½g¦^À³
|
ªYÄ£¥²nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)¡C -------------------------------------------------------------------------------------------- ±q[½è]¨Ó¬Ý: SNP-610/SNP-630§í¨îCYP2E1À³¸Ó¬O¸ûÀu(²×¨s¬Oì¥Äì¨ý¥Ñ¨xŦ¤ÀªcªºFGF21)¡C ±q[¶q]¨Ó¬Ý: AkeroªºEfruxifermin¯à¥[¤JFGF21Ãþ¦üª«¨ì·¸¥X¡C ±EÀu??? |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/2 ¤U¤È 01:58:53²Ä 2972 ½g¦^À³
|
·PÁÂR¤j»¡©ú ¥\¤Ò¦Ê¦ÊºØ ¦³®Äªº¤~¬O¯u¥\¤Ò ¥Ø«eªºM¤ÎA¤½¥q¸ÕÅ禳®Ä ¾÷Âà¤j·§¬Û¦P ªYÄ£ªº¾÷Âà¤]¸ò¥L̬ۦP ¡u¦³¨S¦³®Ä¡v¸ÕÅç¼Æ¾Ú»¡¸Ü |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 01:56:31²Ä 2971 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT03468556?term=SNP-610&draw=2&rank=1 Gene expression biomarkers [ Time Frame: 12 weeks ] Gene expression biomarkers (ACC1, Adfp, AOX, Cat, CCL20, CCR2, Cpt1£\, CYP2E1, CYP4A11, CYP7A, Dgat1, Dgat2, FAS, Gapdh, Gpx1, Gpx2, Gpx3, Gpx4, GSS, Hadh, Ho1, HSL, IL-10, IL-1£], IL-6, iNOS, LCAD, NF-£eB1, NF-£eB2, Ppar£\, PPAR£]/£_, PPAR£^, SCD-1, Sod1, Sod2, Sod3, SREBP-1c, TGF£], TLR4, TNF£\, Ucp2, VLCAD, £\-SMA, £]-actin) related to NASH changes in blood at Week 12 ----------------------------------------------------------------------------------------------- SNP-610ªºP2 ¡A ¼Ð»xª«¯u¬OµY²wº¡¥Ø¡A´N¬O¨S¦³ÀË´úFGF21. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 01:46:30²Ä 2970 ½g¦^À³
|
¥Ø«e(CYP2E1§í¨î--->¿E¬¡PPAR£\<--->¿E¬¡FGF21)³o±ø³q¹D¥i¯à´N¬ONASH¦¨¥\¤§¸ô!? ¥¿±: 1.Saroglitazar(PPAR-£\/£^ Âù«¿E°Ê¾¯)¬O¥Ø«e¥@¬É°ß¤@¤äNASHÃĪ«¡A¥u¦b¦L«×§åã¤W¥«(¬ü°êÁ{§É¤¤¡AFDAÁÙ¨S§åã) 2.AkeroªºEfruxifermin(FGF21Ãþ¦üª«)¬O¥Ø«eP2¼Æ¾Ú³Ì¨Î 3.MadrigalªºResmetirom(THR-£]¿E°Ê¾¯)-->¤]·|¿E¬¡FGF21 t±:¿E¬¡PPAR£\»P¿E¬¡FGF21ªºÃĪ«¡A³£¦³Á{§É¥¢±ÑªÌ! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 01:28:36²Ä 2969 ½g¦^À³
|
¬ü°ê«n¥dù¨Ó¯Ç¤j¾Ç2016¦~½×¤å--ªýÂ_CYP2E1]¤¶¾ÉªºROS TRPV4 ¿E¬¡¤º¥Ö¤@®ñ¤Æ´á¦X酶³q¹L [ªýÂ_CYP2E1]¤¶¾Éªº®ñ¤ÆÁÙì¬r©Ê¨Ó©è§Ü«D°sºë©Ê¯×ªÕ¨x www.ncbi.nlm.nih.gov/pmc/articles/PMC5989309/ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/2 ¤U¤È 01:26:52²Ä 2968 ½g¦^À³
|
TO N¤j ¥D¤£¥D¬y¨Ã¤£¬O«ÂI ÃĦ³¨S¦³®Ä¤~¬O«ÂI ±zª¾¤£ª¾¹DGALTªº¸ÕÅç¼Æ¾Ú¦p¦ó¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/3/2 ¤U¤È 01:23:29²Ä 2967 ½g¦^À³
|
杨¨q伟团队½×¤å´£¥Xªº¾÷¨î:CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21¡C ¸Ó½×¤å¦³¸g¦P¦æ¼f¬dµoªí(Impact Factor:11.614) 2022.11.28 link.springer.com/article/10.1007/s12272-022-01419-w CYP2E1 ¤ô¥¥i¯à¦b FGF21 ªí¹F¤¤«Ü«n¡FCYP2E1 ªº¯Ê¥F¬O¿E¬¡ PPAR£\-FGF21 ¶b©Ò¥²»Ýªº¡A¨Ã¥B¥i¦³®Ä´î¤ÖªÎD -------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤U¤È 05:22:04²Ä 2031 ½g¦^À³ ªYÄ£¥²nÅçÃÒ³o½g½×¤å´£¥Xªº¾÷¨î:SNP610(CYP2E1§í¨î-->¤º·½©Ê¥NÁª«ÅãµÛ¼W¥[-->¿E¬¡ PPAR£\-FGF21)¡C 2022.5¤ë www.sciencedirect.com/science/article/pii/S2211383522000545 ¥Ñ©ó CYP2E1 ¥Dn¦b¥Dnµo¥Í¥NÁªº¨x²ÓM¤¤ªí¹F¡A¹v¦V§í¨î CYP2E1 ¥i¯à¹ê²{ì¦ì¨x²ÓM¤¤ªº PPAR £\¿E¬¡¡A³o¥i¥HÁ× §KÁ{§É¤¤°¸º¸µo¥Íªº«D²Õ´¯S²§©Ê PPAR £\¿E¬¡ªº°Æ§@¥Î--->SNP-610Àø®Ä¦w¥þÀu©óElafibranor (PPAR£\/£_¿E动剂) |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/3/2 ¤U¤È 12:06:41²Ä 2966 ½g¦^À³
|
To ¦V¤j ¦ôȸòMOAÁÙ¬O«Ü¦³Ãö«Yªº¡A89ªºMOA FGF21 ¬O«D±`¥D¬yªº¡AªYÄ£µLªk¤ñ¡C ¤]¤£¬O©Ò¦³¤½¥q¦b¬ü°ê±¾µP´N¦³°ªªÑ»ù¡A°Ñ¦ÒGALT ¥L°µ¨ì2/3´Á¤F¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/3/2 ¤W¤È 11:39:40²Ä 2965 ½g¦^À³
|
Ó¤H¬Ýªk¡A¶È¨Ñ°Ñ¦Ò¡I ±q¥h¦~©³¡A¨º´µ¹F§J¤W¥«ªºNASH ±Ú¸s¤jº¦´X¿¨Ó¬Ý¡C ¤£ºÞ¬O³Ì»â¥ýªºM¤½¥qªÑ»ù´¿¶W¹L300¬ü¤¸ §Y¨Ï1b/2aªº89³£§Ö14¬ü¤¸ ¤½¥qÁnºÙ¬Y¨Ç¼Æ¾ÚÀu©óM¤½¥q ¥Ø«eªÑ»ù¤U¶^¨ì3¬ü¤¸¥ª¥k¡A¥u¦³M¤½¥qªº¹sÀY¡C ¥ý³£¤£¥h¦C¤J810¼Ï¶s¸ÕÅç¡B±ÂÅv¨Æ©y¡C ¥ú¤ñ¸û89¤½¥q´N¦n¡AªYÄ£¥Ø«eªº»ù®æ©e©}¨ì¤£¦æ¡C ¥HªYÄ£6¤Î8¨t¦C¥Ø«e©Ò¤½¥¬ªº¸ÕÅç¼Æ¾ÚÅã¥Ü¤Î¨â¶µ·sÃÄ¥«³õ³W¼Ò Y¦b¨º´µ¹F§J¤W¥«¡AªÑ»ù¦A«ç»ò®t¤]¤ñ89¦n¡C ©Ò¥H±j¯P«Øij-ªYÄ£¨ì¨º´µ¹F§J¤W¥«¡C ¤]½Ð¤j®a¦h¦h¤ä«ù¡A«Øij¤½¥q¨ì¨º«ü¤W¥«¡C ¦³³\¦h¤£@¤[µ¥ªºµu½uÄw½X¡Aµ¥¤£¨ì±ÂÅv¥X¨Ó¡C ¦A¥[¤WÂà¤WÂd§Y¦³¥i¯à·|©µ«á¡A´N·|ÄÀ¥XÄw½X¡AªÑ»ù¦ÛµM·|¤UסI ¤Uפ£¨£±o¬OÃa¨Æ¡A¸Ó¦³ªº»ùȮɡAªø½u§ë¸ê¤H¦ÛµM´N·|¶R¨«¡C «H¤£«H¡H ªYÄ£¦pªG«Å¥¬±N¨ì¨º´µ¹F§J¤W¥«¡AªÑ»ù´N¨göt¡H |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/3/2 ¤W¤È 10:05:53²Ä 2964 ½g¦^À³
|
§Ú¬Oµuµøªñ§Q¡A¬Ý¨ì¤W¨R¤U¬~¤@³õªÅ¡C¥»¨Ó³o¦¸¦³ÁȨS¥X˽ß~nÅܦsªÑ? |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/2 ¤W¤È 09:21:59²Ä 2963 ½g¦^À³
|
§Ú¦Û¤v¤â¤¤¤]¶R¤F±µªñ50±i,쥻n¶R100±iªº.²{¦bÁY¤â.§ÚˬO§Æ±æ¦p¤j®a©Ò»¡:¨ì¨º«ü¤W¥«ªÑ»ù30-50-100-200 ¬üª÷.©ÎªÌ¬Y¦ì¤j¤jºô¤Í©Ò·Q«Ü§Ö±ÂÅv10»õ¬üª÷,ªÑ»ù¥ß§Y¤jº¦¦Ü500-1000. ¤£¹L¥H¤U°ÝÃDȱo¤j®a«ä¦Ò: 1.¤j§Q¦h¤£º¦¥²¦³ÁôÂçQªÅ,³o¬OªÑ¥«ÅK«ß:a.ªñ¤ë¤j½L¤Î¥Í§Þ¤jº¦,6634¤Ï¶^; b.810¤w¸g¹F¼Ï¯Ã¶¥¬q,±ÂÅv¤]¥Ñ2020´N¶}©l½Í. 2.¤½¥q¥DºÞ¦b½æªÑ²¼. ¤º³¡¥DºÞ³Ì¤F¸Ñ¤½¥qÀç¹B. ªÑ»ù¬O©Ò¦³¥«³õ²³¤H¹ï¤½¥q¬Ýªk.©Ò¦³§ë¸ê¤H³£¥²¶·´L«¥«³õ. ¨ä¦¸§Ú¦A¦¸±j½Õ°ê»Ú°Ó°È½Í§P¬O«D±`±M·~§Þ¯à,¨Ã¤£¾A¦X¥Ñ¨S¦³°ê»Ú½Í§P¸gÅç§Þ³N¤Hû¥D½Í. ªÑ¥«·s³Ð¤½¥q¤×¨ä¬O¥Í§Þ¤½¥q, ¦b²£«~2-3´ÁÁ{§É¸êª÷¥R¨¬«á©¹©¹Â§¸u²£·~°ê»Ú¤H¤~¥D«ù°ê»Ú¤Æ½Í§P±ÂÅv. ¦A±j½Õ¤@¦¸. ¤j®a³£¬O6634§ë¸ê«ùªÑªÌ.§Ṳ́@°_·þ«P¤½¥q¥úÄ£,¤j®a¤@°_ÁÈ¿ú.¤]¤@°_µ¹¤½¥q«Ø¨¥Åý¤½¥q§ó¦n.§Ú¤]ÁÙ¬Oºû«ù·í®É¶R¶i®É¬Ýªk: ±ÂÅv¥i¯àn1¦~«á, §Ú·|«ùªÑ2¦~. |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/3/2 ¤W¤È 07:42:53²Ä 2962 ½g¦^À³
|
©^ÄU§O¥HªÑ»ù¨Ó¿Å¶q¥Í§ÞªÑ¡A¥Ø«e¤@°ï¿³Âd¥Í§ÞªÑ¶Wº¦¡A¤@¤£¤p¤ß´N¬O®M¦b¤s³»¡A¥HÃĪ«¶i«×¡B¼Æ¾Ú¤½¥¬¬°¥D¡A§O½M¾Þ¤ß¤½¥q¤F¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/3/1 ¤U¤È 12:07:04²Ä 2961 ½g¦^À³
|
ªÑ»ù·|»¡¸Ü. ¥h½Í¤£¨£±o¦³¯à¤O½Í. ±ÂÅv½Í§P¬O«Ü±M·~ªº, ¤£¬O¬ãµo§Þ³N¤Hû©Î¤½¥q¦ÑÁó¤@©w¯à³Ó¥ô. §Ú»¡n§ë¸ê«ù¦³2¦~, ²{¦b«ù¦³¤¤. |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/3/1 ¤W¤È 09:45:31²Ä 2960 ½g¦^À³
|
«¢«¢«¢«¢«¢ JP³£¥hNew JerseyÁ`³¡°Ó½Í±ÂÅv¨Æ©y¤FÁٯʥF½Í§P¤H¤~? »¡n§ë¸ê¤¦~¥H¤Wµ²ªG¦Ñ¬OÃöª`µu´ÁªÑ»ùµo®i¡AÁ`¬O®³ªñ´Áªí¥ýÀu²§ªºªÑ²¼¨Ó¤ñ¸û¡A§ë¸êÁÙ¬O§ë¾÷? ªÑ»ù¨Sªí²{´N»¡¸gÀç¼h¦³°ÝÃDn¦V¨ä¥L¤½¥q¾Ç²ß¡A«¢«¢«¢«¢«¢ |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/27 ¤U¤È 06:05:36²Ä 2959 ½g¦^À³
|
6634 À³¸Ó¬O¥´ºâ±ÂÅv¦Ó«D¾P°â. 610 2a¨Ã¥¼§¹¥þ§¹¦¨, À³¸Ó¤£¬O¥Dn±ÂÅv¼Ðªº. 810 ¤w¨ì¼Ï¯Ã¶¥¬q, §¹¥þ¥i¥H±ÂÅv¤F. À³¸Ó¬O°ê»Ú½Í§P¤H¤~¯Ê¥F. 6885 ³Ìªñ´N¸u¶±°ê»Ú½Í§P¤H¤~±M³d±ÂÅv¨Æ©y. |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/2/27 ¤U¤È 04:26:32²Ä 2958 ½g¦^À³
|
开发进«×¤ÓºC¡A¦n¦nªº¯Ê药时É󳣪£¤£°_来¡C学学¬P¦t§r¡A¦ÑK¸³还¬O给¤O |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/26 ¤U¤È 03:18:16²Ä 2957 ½g¦^À³
|
¬ü°êªñ´Á¥Ñ©ó·s«aªÍª¢¡B©I§l¹D¦XM¯f¬r©M¬y·P¤T¯f¬r§¨À»¡A°h¿N¤îµhÃįʫܤj!(¤AñQÓi×ô»P¥¬¬¥ªâ¥X²{³Ð¬ö¿ýªº»Ý¨D) ¬°ÓV¸Ñ¯Ê³f±¡¶Õ¡AFDA¦b1¤ë»P2¤ëµo¥¬§ó·s¥¬¬¥ªâ¤fªA²VÄa²G[½Æ¤è]ªºÂ²¤Æ«ü«n¡A¦Ó¤AñQÓi×ô½Æ¤è¦][¨x¬r©Ê]¡A¤£¯Ç¤J! 1. 2023.1.23 www.fda.gov/drugs/human-drug-compounding/questions-and-answers-compounded-oral-suspension-medications-pain-and-fever 2.2023.2.23 -ijû©IÆ~ FDA ¸Ñ¨M¥¬¬¥ªâ©M¹ï¤A酰®ò°ò×ôµu¯Ê°ÝÃD khanna.house.gov/media/press-releases/release-ro-khanna-calls-fda-tackle-ibuprofen-and-acetaminophen-shortages 3.2023.1.30 ®õ¿Õµu¯Ê:¬°¤°»ò¥¦¨Ñ¤£À³¨D parade.com/health/tylenol-shortage |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/26 ¤W¤È 08:56:19²Ä 2956 ½g¦^À³
|
J&J ¥¿¦bµo¥Í½¤ÑÂЦaªºÅܤÆ! ´X¦~«eJ&J¦bª÷¤s«Ø¥ß¤F¶Ç¬V¯f¬ãµo¤¤¤ß¡AµM«á¥h¦~§â¥þ²y¬ãµoR&D¤j³¡¤À³£·h¨ì¤Fª÷¤s¡C¦ý¤µ¦~¶}¦~J&J§â¾ãÓèè«Ø¥ß¨S¦h¤[ªº¶Ç¬V¯f³¡ªù´X¥G¥þµô¤F¡C 2023.2.21--¦Ê»õ³W¼ÒªºNASH¥«³õ¡A¯à§_«P¦¨MNCªº²Ä¤G¼Wªø¦±½u¡H zhuanlan.zhihu.com/p/608286704 01 ¶r¯à¤O¡G¶R¨ÓªºNASH¬G¨Æ ¥¤ß¦Ó½×¡A±j¥Í¤§©óNASHµLºÃ¬O·s¤â¡C ...¬°¤F¹ê²{Ås¹D¶W¨®¡A±j¥Í³Ìªì¿ï¾Ü¤@ºØ1«¬¤j³Â¯À¡]CB1¡^¨üÅéÃĪ«Namacizumab¡]RYI-018¡^... 02 RNAiÀøªk¡A¨ì©³¦æ¤£¦æ¡H ...¨º»ò¡A°ÝÃD¤S¶¤F¦^¨Ó¡C¬JµM²£«~¨ã³Æ¼ç¤O©M®t²§¤Æ¡A±j¥Í¬°¦ó¿ï¾Ü¦b¦¹¨è°h¥X¡H 03 §Ú¡AMNC¡A2023¨DÓ¦wà ...°²¦pAD¬O°h¦æ©Ê¯«¸g¯e¯f»â°ìªº¡§¬ãµo¶Â¬}¡¨¡ANASH«h¬O¥NÁ¯e¯fªº¡§¼X³õ¡¨¡C ...·íµM¡ANASH³o¶ô³J¿|¤£¬O¤£¦Y¡A¤£±Æ°£±j¥Í¦b®É¾÷¦¨¼ô«á¥b¸ô±þ¦^¡AÂǵۻP¦X§@Biotechªº«á´Á¦¨¼ô¸ê²£¸ó¤JÂÅ®ü¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/25 ¤W¤È 08:53:52²Ä 2955 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/17 ¤W¤È 10:16:43²Ä 2933 ½g¦^À³ 1. 2023.2.14--NASH©ö·P©Êªº¿ò¶Ç®t²§(¸ê§UªÌ:Janssen Pharmaceuticals¼b¥Í¶°¹Î) ...§ÚÌ´ú¸Õ¤F¤CºØ¤p¹««~«Y¹ï NASH ªº©ö·P©Ê...[ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C] [ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C]«nªº¡APWK/PhJ ¤p¹«ªº NASH °ò¦]ªí¹FÃлP¤HÃþNASH ¯S¼xªº« Å|«×³Ì°ª¡C --------------------------------------------------------------------------------------------------- actu.epfl.ch/news/modeling-liver-and-kidney-disease/ EPFLªºAuwerx¹Î¶¤»PJanssen Pharmaceuticals ªº¬ì¾Ç®a¤@°_¶}®i¤F¤@¶µ¬ã¨s¡A¥H«Ø¥ß¤CºØ¤p¹«µÇ·l¶Ë¼Ò«¬ªº¤ÏÀ³ ...PWK/PhJ «~¨tªº¤p¹«¹ï NAFLD/NASH ³Ì±Ó·P¡A¤]¬O°ß¤@Åã¥Ü¥X¶i®i¬°ÅÖºû¤Æ NASH ªº«~¨t¡C ------------------------------------------------------------------------------------- ¶R®a±N½æ®aªºÃĪ«¾É¤J¤WzªºNASH°Êª«¼Ò«¬¡A¨ÓÓ[ÀY¹ïÀY]°Êª«¹êÅç¡AÅý¥¦Ìª½±µPK¡A±EÀu¶R½Ö! |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/24 ¤U¤È 07:40:22²Ä 2954 ½g¦^À³
|
¡]¤¤¥¡ªÀ°OªÌÁú´@´@¥x¥_2022¦~10¤ë30¤é¹q¡^ªYÄ£¥ÍÂå (6634) ¬ãµo¥@¬Éº¨ÒµL¨x¬r©Ê¤îµh·sÃÄ¡A¸³¨ÆªøÝÁ`¸g²z¦¶³Í¥Áªí¥Ü¡AÀò±o²Ä¤T¤èÅçÃÒ³æ¦ìÃÒ¹êµL¨x¬r©Ê¡A¥i¬°Acetaminophen¡]´¶®³¯k¦¨¤À¡^40¦h¦~¨Ó¨x¬r©Êªº°ÝÃD´£¨Ñ¸Ñ¤è¡A´Á«Ý«Ü§Ö¶i¤J±ÂÅv°ê»Ú¤j¼t·s¨½µ{¸O¡C ¦¶³Í¥Á±µ¨ü¤¤¥¡ªÀ°OªÌ±M³X®Éªí¥Ü¡A¦b¬ü°ê¦³600¦hºØ¡B¥xÆW¦³ªñ300ºØ·P«_ÃÄ¡B¤îµhÃÄ¡A§t¦³Acetaminophen¡]¤AñQÓi×ô¡^¦¨¤À¡A¬O¥þ²y¨Ï¥Î³Ì¼sªº¸Ñ¼öÂíµh¾¯¡A¦ý¤]¬O¥þ¥@¬É³y¦¨ÃĪ«¨x¬r©Ê²Ä1¦WªºÃĪ«¡CªYÄ£¹Î¶¤¸Ñ¶}¤F³oÓªø¹F40¦~ªºÃøÃD¡C ¬ü°ê¹«~º[ÃĪ«ºÞ²z§½¡]FDA¡^ªñ40¦~¨Ó«ùÄòn¨D¬ÛÃöÃļt¿n·¥¸Ñ¨M¨x¬r©Ê°Æ§@¥Îªº°ÝÃD¡A¨´¤µ©|¥¼§¹¥þ¸Ñ¨M¡C¤AñQÓi×ô¬O¾ÉP¥þ²yÃĪ««æ©Ê¨x°IºÜªº¥Dnì¦]¤§¤@¡A¥e^°ê«æ©Ê¨x°IºÜ±wªÌ¬ù57%¡]1200¤H¡^¡A¥e¬ü°ê«æ©Ê¨x°IºÜ±wªÌ¬ù39%¡]2000¤H¡^¡C ¦¶³Í¥Áªí¥Ü¡AµL¨x¬r©Ê¤îµhÃÄSNP-810¡]¦w®õ®³¯k¡^©ó2020¦~¡B2021¦~¤À§O»P2®a°ê»Ú¯ÅÃļtñq¦X§@¨óij¡AµL©`´Á¶¡¨ä¤¤¤@®a¦X§@¼t°Ó½T»{¸ÕÅçµ²ªG¤£¦p¹w´Á¡A¥HP¦X§@¤¤¤î¡C ¤£¹L¡AªYÄ£¹Î¶¤¨S¦³©ñ±ó¡A§ä¥X°ÝÃD¡Bקï¬ã¨spµe¤¤ªº¤@¶µ±ø¥ó«á¡A¦b¦P¤@®a¸ÕÅ礽¥q«±Ò¸ÕÅç¡A9¤ë22¤éÀò±o¥¿¦¡¸ÕÅç³ø§i¡AÃÒ¹êSNP-810¬°µL¨x¬r©Ê¡C¤é«e¤w´£¨Ñ°Êª«¸ÕÅçµ²ªGµ¹»P¤½¥qñq¦³Àv¦X¬ùªº°ê»Ú¤îµhÃļt°Ó¡C ªYÄ£¬ãµoªº¤îµhÃÄ«·s½T»{ÃҹꬰµL¨x¬r©Ê¡A¤]Åýº®a°ê»Ú¤j¼t¦X§@®×¦³¾÷·|¡u±Ñ³¡´_¬¡¡v¡C ¾¨ºÞ«±Ò¦X§@±ÂÅv®×¬¢½Íªº¶i«×µLªk³zÅS¡A¤£¹L¦¶³Í¥Á»{¬°¡AªYÄ£¸Ñ¶}¤F¤î¯kÃÄ40¦h¦~¨Ó©l²×¸Ñ¤£¤Fªº¶Ë¨xÃøÃD¡A¥¼¨Ó¦³¼Æ¦ÊºØ§t¦³¦¹¦¨¤ÀÃĪ«»Ý³Q´À¥N¡F¬Û«H«Ü§Ö´N¯à¦b°ê»Ú»R¥x¤Wµo¥ú¡A¹ê²{¥ø·~¤T¤jÄ@´º¤¤ªº²Ä¤@¶µ¥Ø¼Ð¡u¶}µo·sÃÄ¡Aµn¤W°ê»Ú»R¥x¡v¡AÁÚ¦VÀò§Q¤§¸ô¤w¶V¨Ó¶V±µªñ¡C ¦¶³Í¥Áªí¥Ü¡A¥Ñ©ó¦³®ÄÃIJzªº¥D¦¨¤À¨S¦³§ïÅÜ¡AY¦¨¥\±NSNP-810±ÂÅvµ¹¥Ø«e¾P°â¤AñQÓi×ô¦¨¤À¤îµhÃĪº¤j¼t¡A¤£¥Î«·s°µÁ{§É¥Ó½ÐÃÄÃÒ¡A¥u»Ýn§ó§ï¥]¸Ë¤Î¥é³æ¡A´N¯à¥H³Ì§Öªº³t«×¾P°â¶i¶¥ª©¡]¤£¶Ë¨x¡^²£«~¡C ¦Ü©ó±ÂÅv¼Ò¦¡¡A¦¶³Í¥Á»¡¡A¥@¬É¯Å¤jÃļt³£¬O¥H¡u¤½¦@½Ã¥Íªº»ùÈ¡v¬°³Ì¤j©v¦®¡A¦]¦¹¥¼¨Ó±N±Ä«D±MÄÝ¡B¤À°Ï±ÂÅvµ¦²¤¡A²{¶¥¬q±ÂÅvºN¦¡¤£³]±Ä¨ú¶}©ñºA«×¡ASNP-810¤]¤w¨ú±o¬ü°êOTC¡]«D³B¤èÃÄ¡^¥«³õ¾P°âÅv¡C ¡u¿ïÃD¡B¤H¤~¡B´¼¼z°]²£«OÅ@¦n¤£¦n¡B°]°È±Ã©w«×¡A³£¬O·sÃĤ½¥q¦¨¥\ªº¥ý¨M±ø¥ó¡v¡C¦¶³Í¥Á«ü¥X¡AªYÄ£±Mª`¥H¤HÅé¥NÁȕÀ¬¡©Ê½Õ±±µ¥¬ÛÃö±M§Q§Þ³N¡A¶}µo¤îµh¤Î¨xŦ¯e¯f·sÃÄ¡AP¤O¸Ñ¨M¥Ø«eÁ{§ÉªvÀø¤W©Ò¾D¹J¦Ó©|«E«Ý¸Ñ¨MªºÃøÃD¡C ¦¶³Í¥Áªí¥Ü¡A¦bµL¨x¬r©Ê¤îµhÃÄSNP-810ÁÚ¤J·sªº¨½µ{¸O«á¡A¤]±N¶i¦æ¤îµh¥[³Â¾K¾¯ªº½Æ¤è¤fªAÃÄ«~¬ãµo¡A¥Î¥H¦]À³¤¤«¯f¯kµh¡A¸Ñ¨M¥Ø«eÃþ¾~¤ù¤îµhÃĪ«¶Ü°Øµ¥¦¨Å}°ÝÃD¡F¦P®É±N¥[³t¯×ªÕ¨x·sÃÄSNP-610¶}µo¡Aº¥ý±NÂX¼W1¿ªº¬ãµo¤Hû¡C ®Ú¾Ú¼w·N§Ó»È¦æ¤ÎÂåÃÄ¥«½Õ¤½¥qEvaluate Pharmaªº¹w´ú¡A¥þ²y«D°sºë©Ê¯×ªÕ¨xª¢¡]NASH¡^ÃĪ«ªº¥«³õ³W¼Ò¦b2025¦~¤W¬Ý350»õ¦Ü400»õ¬ü¤¸¡C¦¶³Í¥Á»{¬°¡A¥Ø«eNASH©|µL¼Ð·ÇªvÀøÃĪ«¡A¼ç¦b°Ó¾÷Ãe¤j¡A¥i¦P®É®e¯Ç¦hÓ·sÃÄ¡C¥L«ü¥X¡AªYÄ£¥¿¿n·¥´M¨D»P°ê¥~¤j¼t¦@¦P¦X§@©Î±ÂÅvµ¥¨Æ©y¡C |
|
|
·|û¡G¤p¨k¤H10151116 µoªí®É¶¡:2023/2/23 ¤U¤È 07:05:17²Ä 2953 ½g¦^À³
|
½Ð°Ý¦³¤Hª¾¹D¤½¥qºô¯¸ªº¬ãµo¨½µ{¸O¨º¶«ç»ò¤F¡H¦n´X¶g¹L¥h¤F¡A¨ÌªŪšI¡I¡I |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/23 ¤U¤È 03:20:20²Ä 2952 ½g¦^À³
|
³o¤@ªi¿³Âd¤Î¥Í§Þ¤jº¦, 6634¯h®z¤Ï¶^. º¥ý¬O¤½¥q¤£¦b·NªÑªFÅv¯q¤ÎªÑ»ù. ¨ä¦¸¥i¯à¬O¦³¥~¤H¤£ª¾¹Dªº°ÝÃD. «Øij¤j®a¦h¤À¨É810 ¼Ï¯Ã¶i«×¤Î±ÂÅv¥i¯à»Ùê¤Î¶i®i. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/23 ¤W¤È 11:09:46²Ä 2951 ½g¦^À³
|
ÅU¦Ó¤£°Ý? Richard C. Dart, MD, PhD: 1.McNeil Consumer HealthcareÅU°Ý 2. RMPDS ¥D¥ô www.rmpds.org/about-rmpds/leadership-team.html 60 ¦h¦~¨Ó¡ARMPDS ¤@ª½¬°¤½¦@©M¨pÀ糡ªù´£¨Ñ±M®aÂåÀø«Øij¡C¦b¨º¬q®É¶¡¸Ì¡A§Ṳ́w¸g¦¨¬°¬ü°ê³Ì¤jªº¬rª«¤¤¤ß¤§¤@¡A¨Ã¥B¬O¬r©Ê¡B¶Ë®`©M¯e¯f¬ã¨sªº»â¾ÉªÌ¡C§Ú̬°¥@¬É¤W¤@¨Ç³Ì¤jªº»sÃĤ½¥q´£¨ÑÂåÀø«H®§©M¼i¦æ¡BÃĪ«¦w¥þ³ø§i©MÀݥκʴúªA°È¡C§ÚÌÁÙ¦b¸Ñ¬r¾¯¶}µo¤è±¶}ÅP¤F¹D¸ô¡A¨Ã¬°©t¨àÃĤ½¥q©M¤j«¬»sÃĤ½¥qºÞ²z¤F³\¦h¦h¤¤¤ßÁ{§É¸ÕÅ綵¥Ø¡C ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/23 ¤W¤È 07:26:33²Ä 2950 ½g¦^À³ SNP-810 Á{§É¼Æ¾Ú´îNAPQI§Î¦¨:Dr. Richard C. Dartªí¥Ü¡A [¤AñQÓi×ô¦b«ØijªvÀø¾¯¶q(4g)¤U¡A¤]´¿¦³µu¼È¤þÓi»ÄÓi°òÂಾ酶¡]ALT¡^¤É°ª¡B¥Nªí¨x²ÓM¨ü·l±¡§Î¡C] [¤AñQÓi×ô¦b«ØijªvÀø¾¯¶q(4g)¤U¡A¤]´¿¦³µu¼È¤þÓi»ÄÓi°òÂಾ酶¡]ALT¡^¤É°ª¡B¥Nªí¨x²ÓM¨ü·l±¡§Î¡C] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/23 ¤W¤È 07:26:33²Ä 2950 ½g¦^À³
|
Richard Dart, MD, PhD¦³»P·|¦X·Ó¡I 2022.11.19¸Ñ¼öÂíµh¤AñQÓi×ô¹L¶q¶Ë¨x ¥x¬ãµo·s°t¤è¦³®Ä°¨x¬rhealth.ltn.com.tw/article/paper/1552287 SNP-810 Á{§É¼Æ¾Ú´îNAPQI§Î¦¨:Dr. Richard C. Dartªí¥Ü¡A¤AñQÓi×ô¦b«ØijªvÀø¾¯¶q¤U¡A¤]´¿¦³µu¼È¤þÓi»ÄÓi°òÂಾ酶¡]ALT¡^¤É°ª¡B¥Nªí¨x²ÓM¨ü·l±¡§Î¡C Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Sponsor:Richard Dart, MD, PhD Collaborator:Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division Information provided by (Responsible Party):Richard Dart, MD, PhD, Denver Health and Hospital Authority --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/10/20 ¤U¤È 07:42:55²Ä 2627 ½g¦^À³ ¦n©_TYNADOTE®(SNP-820)±q¤¤¤î(¼È°±)¦Ó«±ÒÁ{§É¸ÕÅ窺½t¥Ñ? ²ö«D·Qµ¹J&Jªº¸Ñ¬r¾¯ FomepizoleÀ£¤O? Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose clinicaltrials.gov/ct2/show/NCT05517668?term=Fomepizole&draw=2&rank=2 --------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/9/14 ¤W¤È 09:46:29²Ä 350 ½g¦^À³ ªYÄ£SNP-820(¹ï¤AñQÓi×ô¸Ñ¬r¾¯)¨Ã«D°ò©ó¥«³õ§Q¼í¦Ò¶q(¥Õ¸Ü´N¬OÁȤ£¤F¿ú)¡A¦Ó¬O±q¤½¦@½Ã¥Íªº¨¤«×«ä¦Ò¡A§Æ±æ¥H¬ãµo·sÃijyºÖ¯f±w¡A¥HºÉ¨ì¤½¥q¤§ªÀ·|³d¥ô¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/21 ¤U¤È 09:30:24²Ä 2949 ½g¦^À³
|
Resmetirom¤T´Á临§É设计¤¤¡AMadrigal°µ¹ï¤F¤°»ò¡H www.vbdata.cn/1518896904 Madrigal¤½¥q¦b¢»´Á临§É时调¾ã¤F¨x纤维¤Æ««×±wªÌªº¤ñ¨Ò¡CMadrigal¤½¥q¦b¢º´Á临§É时©Û¶Òªº±wªÌ§ó¦h处¤_¨x纤维¤ÆF1©MF2´Á¡A¦Ó¦b [临§É¢»´Á时¡AMadrigal¤½¥q©Û¶Òªº±wªÌ¤j¦h处¤_¨x纤维¤ÆF3´Á¡A¦b这¨Ç««×±wªÌ¤¤¦w¼¢剂§@¥Î´N¬Û对®z¤F«Ü¦h¡C] [临§É¢»´Á时¡AMadrigal¤½¥q©Û¶Òªº±wªÌ¤j¦h处¤_¨x纤维¤ÆF3´Á¡A¦b这¨Ç««×±wªÌ¤¤¦w¼¢剂§@¥Î´N¬Û对®z¤F«Ü¦h¡C] 当µM¡A还¦³§ó¦y锐ªº问题©|¥¼¸Ñú¨¡GMadrigal¤½¥q§Y¨Ï¬O¦b临§É设计¤W°µ¤Fɬ¤Æ¡A [¦ý¤´¦³70%¥H¤W±wªÌ¦b¥Dn终点¤W没¦³©ú显§ïµ½¡A药®Ä还¦³«Ü¤jªº´£¤ÉªÅ间¡C] [¦ý¤´¦³70%¥H¤W±wªÌ¦b¥Dn终点¤W没¦³©ú显§ïµ½¡A药®Ä还¦³«Ü¤jªº´£¤ÉªÅ间¡C] [¦ý¤´¦³70%¥H¤W±wªÌ¦b¥Dn终点¤W没¦³©ú显§ïµ½¡A药®Ä还¦³«Ü¤jªº´£¤ÉªÅ间¡C] ---------------------------------------------------------------------------------------- µ²½×:调¾ã¤F¨x纤维¤Æ««×±wªÌªº¤ñ¨Ò+ ¥[ªøªvÀø´Á (¤G´ÁªvÀø´Á 36¶g ¡A¤T´ÁªvÀø´Á 52¶g)¡C ¥t¥~¡A¥h¦~¤~¥[¶}ªº¨x纤维¤ÆF4´ÁªvÀø´Á 3¦~! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2023/2/20 ¤U¤È 10:22:10²Ä 2948 ½g¦^À³
|
¨Sp¿ù ³o¦ì¥Ûs ¤W¦¸¨SÂ৹ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/20 ¤U¤È 07:38:43²Ä 2947 ½g¦^À³
|
goodinfo.tw/tw/EquityTransfer.asp?STOCK_ID=6634 2020.10.19 ¥ÛªF줧°t°¸ -¥Ó³øÂàÅý±i¼Æ100 ÂàÅý´Á¶¡10/22~11/21 ¥ÛªFì -¥Ó³øÂàÅý±i¼Æ 227 ÂàÅý´Á¶¡10/22~11/21 -------------------------------------------------------------------------------- 2020.12.21¤½§iSNP-810·sÃÄ»P°ê»ÚÃļtñq·sÃĬãµo¦X§@¨óij¡C ´Á¶¡ªÑ»ù¨«¶Õ?¨Æ¹ê¤]¤£ºÉµM¡A³Ì¦n¥h¹qµo¨¥¤H°Ý°Ý! |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/20 ¤U¤È 07:02:06²Ä 2946 ½g¦^À³
|
¤µ¤é¿³Âd¥Í§ÞªÑ¿Wºñ¡A¤@¤ë¥÷¥ÛªFì¨ó²z¥X³f117±i. __________________________________________ ÁÂÁ¾¾¤j®ø®§. ²{¦b¶¥¬q³oÃþ®ø®§¤ñ¹êÅç½×¤å«¬¤Î¥«³õ¦h¤j»·´º¦h¬ü¦nÃþ°T®§¹ê»Ú. ¦pªG¤º³¡¥DºÞ¦b½æ, ¥i¤£¬O¦n¨Æ. |
|
|
·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2023/2/20 ¤U¤È 06:20:15²Ä 2945 ½g¦^À³
|
¤µ¤é¿³Âd¥Í§ÞªÑ¿Wºñ¡A¤@¤ë¥÷¥ÛªFì¨ó²z¥X³f117±i |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/2/20 ¤U¤È 02:46:09²Ä 2944 ½g¦^À³
|
¤é¦³©Ò«ä©]ÁÙ¯u¦³¹Ú¡F«e±ß°µ¹Ú¹Ú¹ÒªYÄ£¤îµh¾¯8¨t¥þ²y¤À¤T°Ï°ì±ÂÅv¤À§O3¡B3¡B4»õ¬ü¤¸¡F¹Ú¹Ò¤¤¦³³o®ø®§©M¼Æ¦r¥X²{¡A¬O¤@ÁûÁÙ¬O2Áû¤£ª¾¹D¡A¨S¦³ªÑ²¼¶R½æ©Î¥ô¦ó±¡ºü¤ÏÀ³¡C¿ô¨Ó·PıÁ`±ÂÅvª÷10»õ¬ü¤¸ÁÙ¯u¦³ÂI¦X²z¡C¥H¤W¹Ú¹Ò¯ù¾l¯Â²á¤Ñ¡A®¤¤£t³d¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/19 ¤U¤È 08:08:50²Ä 2943 ½g¦^À³
|
§Ñ°O»¡140³o¤äªÑ²¼. ¦b½Íªº²£«~¥«³õ³W¼Ò$25»õ¬üª÷. ¤j®a¥i·Q¦pªG810 »{¯u¿n·¥½Í±ÂÅv, ªÑ»ù¸Ó¦h¤Ö. ¦pªG½ÍÓ2-3»õ±ÂÅvª÷¤U¨Ó,ªÑ»ù¸Ó¦h¤Ö. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/19 ¤U¤È 07:54:55²Ä 2942 ½g¦^À³
|
¥«³õ¤W¦³¤@ªÑ²¼. ¥h¦~7¤ë©³Á{3 ÁÙ¨S°µ§¹. ¥Ø«e¿n·¥½Í±ÂÅv¤¤. ¤W©PªÑ»ù¦¬140. ¤j®a°Ñ¦Ò. »P810 ¤ñ¸û¥«³õ³W¼Ò, ¥Ø«eÁ{§É¶i«×. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/19 ¤W¤È 10:17:40²Ä 2941 ½g¦^À³
|
¨xÅÖºû¤Æªºµo¥Í¾÷¨î¡]£\-SMA¡BCol1a1¡BCol3a1©MTimp-1) ¨xÅÖºû¤Æ¬O¦hºØ¯f¦]¾ÉPªººC©Ê¨xŦ¯e¯f¡C¨ä¥Dn¯S¼x¬O¨xŦ¤ºÄjº©©Êªº¡B¹L¶qªº²ÓM¥~°ò½èECM(¯S§O¬O½¦ì)¨I¿n¡Cªñ´Á¬ã¨sªí©ú¡A¦pªG¯àµ¹¤©¦³®Äªº¯f¦]ªvÀø¡A©Î¯àª½±µ[§í¨î]ECMªº¦X¦¨©M©Î[«P¶i]ECM°¸Ñ¡A¤w¸g§Î¦¨ªº¨xÅÖºû¤Æ¬Æ¦Ü¬O¥i¥H°fÂ઺! m.medsci.cn/article/show_article.do?id=1f6fe550173d ¦b进®i©Ê¨xºC©Ê损伤¤¤¡AECMªº¥Í¦¨°¸Ñ[¥¿Å状态]³Q¥´¯}¦Ó¤j¶q¨I积¬O¨x纤维¤Æªº«n¯S©º¡C ...TGF-£]1 ¬O诱导纤维胶ì(¥Dn¬OI«¬©MIII«¬)¡B£\-SMA¡B ¨x损伤´Á间ª÷属³J¥Õ酶组织§í¨î剂(Timp)ªº«ù续产¥Í¥i¥H§í¨î°ò质ª÷属³J¥Õ酶(MMP)ªº¬¡©Ê¡A¨Ï±oª÷属³J¥Õ酶对¦h§Eªº纤维胶ì¥h°£®Ä²v°§C¡A¥´¯}°ò质°¸Ñ¦X¦¨ªº¥¿Å¡A从¦Ó«P进细M¥~°ò质ªº¨I积¡C --------------------------------------------------------------------------------------------------- ¾Ú¦¹2018¦~Gileadªá15»õ¬ü¤¸±ÂÅvTGF£]ÃĪ« finance.yahoo.com/news/gilead-partners-scholar-rock-fibrotic-225910808.html ...³o¨Ç¶µ¥Ø°w¹ï¤@ºØºÙ¬°Âà¤Æ¥Íªø¦]¤l £] ©Î TGF£] ªº²ÓM«H¸¹³J¥Õ¡A¥Î©óªvÀøÅÖºû¤Æ¯e¯f¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/18 ¤U¤È 09:06:04²Ä 2940 ½g¦^À³
|
ªYÄ£ªºNASHªº¼Æ¾ÚÅã¥ÜÀu¶V «D±`¥i±¤ªº¸ÕÅç¶i«×½wºC ªÑ»ùµL¤O¸ò¤W°ê»Ú¸}¨B ¥h¦~¤w§ï¿ï¸³ºÊ¨Æ ¦pªG¬O¤µ¦~§ï¿ï´N¥þ¤O¤ä«ùR¤j¶i¸³¨Æ·| ¬ÝR¤j¦p¦¹¥Î¤ß¡B¿n·¥ªº§ä´M»PªYÄ£¬ÛÃö¸ê®Æ ¯u¬OÅý¤H·P°Ê |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/18 ¤U¤È 05:17:54²Ä 2939 ½g¦^À³
|
2021.2.5 www.sciencedirect.com/science/article/pii/S0753332221001116#bib0035 ...¼Æ¾ÚÅã¥Ü¡ACYP2E1 ¨Ì¿à©Ê ROS ¼W¥[¤F¨x²ÓM©M HSC ¦@°ö¾iª«¤¤ªº½¦ì³J¥Õ¦X¦¨¡A [ªí©ú CYP2E1 »P¨xÅÖºû¤Æ±K¤Á¬ÛÃö [ 54 ] [ªí©ú CYP2E1 »P¨xÅÖºû¤Æ±K¤Á¬ÛÃö [ 54 ] ------------------------------------------------------------------------------------------------- ¨xÅÖºû¤Æ: Col1a1:I«¬½¦ì³J¥Õ / Col3a1:III«¬½¦ì³J¥Õ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/18 ¤U¤È 05:09:32²Ä 2938 ½g¦^À³
|
Æ[¹î3®aªº[ÅÖºû¤Æ] ¥Íª«¼Ð°O¡]£\-SMA¡BCol1a1¡BCol3a1©MTimp-1)¼Æ¾Ú? 1.ªYÄ£:£\-SMA-SMA¡BCol1a1¡BCol3a1©MTimp-1§¡ÅãµÛ°§C¡C 2.Intercept(OCA) www.ncbi.nlm.nih.gov/pmc/articles/PMC5025787/ £\-SMA¡BCol1a1¡B Timp-1--->ÅãµÛ°§C 3.Madrigal(Resmetirom) bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15427 ...ResmetiromªvÀø«á¡A¨xŦcol1a1¡B£\-SMA©Mgal-3§t¶q°§C¡]¹Ï4¡^¡C»P¸üÅéªvÀøªºDIO-NASH¤p¹«¬Û¤ñ¡A [£\-SMAªº®t²§¦bÂk¤@¤Æ¬°¨xŦ«¶q«á¤´¦³²Îp¾Ç·N¸q¡A¦ýcol1a1ªº®t²§«h¨S¦³¡]¥¼Åã¥Ü¡^]-¦pªG®É¶¡©ÔªøÀ³¸Ó¦³²Îp¾Ç·N¸q [£\-SMAªº®t²§¦bÂk¤@¤Æ¬°¨xŦ«¶q«á¤´¦³²Îp¾Ç·N¸q¡A¦ýcol1a1ªº®t²§«h¨S¦³¡]¥¼Åã¥Ü¡^]-¦pªG®É¶¡©ÔªøÀ³¸Ó¦³²Îp¾Ç·N¸q -------------------------------------------------------------------------------------------------- ·|û¡GRock00910149258 µoªí®É¶¡:2022/10/19 ¤U¤È 05:04:37²Ä 2619 ½g¦^À³ 1.¨Æ¹êµo¥Í¤é:111/10/19...¤@¡BSNP-630ªvÀøªº¤p¹«ªº¨xµoª¢¡B¨x¯×ªÕÅÜ©Ê©MÅÖºû¤Æ±o¨ìÅãµÛ§ïµ½¡A¨äALT¤ô¥¡B ÅÖºû¤Æ¬ÛÃö¥Íª«¼Ð°O¡]§Yalpha-SMA¡BCol1a1¡BCol3a1©MTimp-1¡^§¡ÅãµÛ°§C¡C ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/7/3 ¤W¤È 08:30:15²Ä 2172 ½g¦^À³ F4°ò¥»ºâ¬O¥Ø«eÃĪ«¬ãµoªº¸T°Ï¡A¯e¯f¶i®i¨ì¨xµw¤Æ¤§«á¦A°fÂà¬O«D±`§xÃøªº¡A¦pªG¯à°µ¥XÀø®Ä¡A¯uªº´N¤jº¡³e¤F¡C ©Ò¥HSNP-610´Á¤¤¤ÀªR:F4ªº²Õ¡AªvÀø«e«á¦³[ÅãµÛ®t²§] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/18 ¤U¤È 04:28:24²Ä 2937 ½g¦^À³
|
Madrigal¤G´Á¼Æ¾Ú¥X¨Ó«á¡A¬°¦ó¤@°ï¶R®a¬Ý¨«²´³ø»ù¤Ó§C? ì¦]:Á{§É¤G´Áªº[ÅÖºû¤Æ]§ïµ½¼Æ¾Ú¤£¨Î(«á¨Óªº¤T´ÁÁ{§É¦³©ÔªøªvÀø®É¶¡) bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15427 4.°Q½× ...¥Ø«e©|¤£²M·¡³o¬O¥Ñ©ó¯Ê¥FÀø®ÄÁÙ¬O 36 ¶gªºªvÀø«ùÄò®É¶¡¤Óµu¦ÓµLªk¤Þ°_¥iÆ[¹î¨ìªº¨xÅÖºû¤Æ§ïµ½...¨Ã¥B¨Ï¥Î·ç¬ü´Àù¥¼Æ[¹î¨ìÅÖºû¤Æµû¤À¦³ÅãµÛ§ïµ½¡C ...³ÌªñÆ[¹î¨ìÅÖºû¤Æ§ïµ½ªºÃĪ«¬O¶ø¨©Áx»Ä(OCA)¡G¦b³Ìªñ³ø§iªº¤@¶µ III ´Á¸ÕÅ窺¤¤´Á¤ÀªR¤¤¡A¦b±µ¨üªvÀøªºÓÅ餤Æ[¹î¨ìÅÖºû¤Æ¦Ü¤Ö§ïµ½¤F¤@Ó¶¥¬q¨Ï¥Î OCA¡A»P¦w¼¢¾¯¬Û¤ñ¡A18 Ó¤ë«á¤j¬ù¬O resmetirom II ´Á¸ÕÅ窺¨â¿ ...[©ÎªÌ¦P¼Ë¡A§óªø®É¶¡ªºresmetiromªvÀø¥i¯à¾ÉP±wªÌÅÖºû¤Æ§ïµ½¡C] [©ÎªÌ¦P¼Ë¡A§óªø®É¶¡ªºresmetiromªvÀø¥i¯à¾ÉP±wªÌÅÖºû¤Æ§ïµ½¡C] ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/20 ¤W¤È 08:39:24²Ä 2739 ½g¦^À³ Madrigal¤½¥qªº³Ð©l¤H¤Ò°ü±qRoche§â³oÓ²£«~®³¥X¨Óªº®ÉÔ¡A´N¨Sp¹ºµÛ§â²£«~°µ¨ì¤W¥«¾P°â¡C§{¶¡¶Ç»D»¡¥»¨Óp¹ºµÛ¤G´Á¼Æ¾Ú¥X¨Ó¤§«á´N¥X¤â¡A¦ý¬O¶û¦UÓ¶R®a³øªº»ù®æ¤Ó§C.... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/17 ¤U¤È 09:49:08²Ä 2936 ½g¦^À³
|
¥Ø«e2¤äNASHÁ{§É¼Æ¾Ú³Ì¦nªºÃĪ«:Madrigal(Resmetirom) /Akero(Efruxifermin) cyp2e1§í¨î¤]¦³µÛ¬Û¦Pªº§@¥Î¾÷¨î¡A¦Ü©ó¬O¹v¦V¤W´å©Î¤U´åªº®ÄªG¤j¡A´Nµ¥¸ÕÅçÅçÃÒ! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/17 ¤U¤È 09:06:07²Ä 2935 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/17 ¤W¤È 10:16:43²Ä 2933 ½g¦^À³ ½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î! rupress.org/jem/article/220/4/e20221738/213867/The-genetic-background-shapes-the- susceptibility ----------------------------------------------------------------------------------------------- ¤d¨¥¸U»y¤£¦p¤@±i¹Ï¨ÓªºÂ²³æ©úÁA! Graphical Abstract---¦³7°¦ mice¡APWK/PhJ ¬O¥kÃäÂŦâ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/17 ¤U¤È 08:58:23²Ä 2934 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/17 ¤W¤È 10:16:43²Ä 2933 ½g¦^À³ ½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î! ---------------------------------------------------------------------------------------------- Madrigal¤½¥qªºResmetirom: www.madrigalpharma.com/our-programs/resmetirom/ THR-£] §@¥Î¬O¥¿±`¨x¥\¯àªºÃöÁä¡A¥]¬A½Õ¸`½u²ÉÅ鬡©Ê¡]¨Ò¦p¨x¯×ªÕ¤À¸Ñ¡^©M±±¨î¥¿±`¡B°·±dªº½u²ÉÅé¤ô¥¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/17 ¤W¤È 10:16:43²Ä 2933 ½g¦^À³
|
½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î! 1. 2023.2.14--NASH©ö·P©Êªº¿ò¶Ç®t²§(¸ê§UªÌ:Janssen Pharmaceuticals¼b¥Í¶°¹Î) rupress.org/jem/article/220/4/e20221738/213867/The-genetic-background-shapes-the- susceptibility ...§ÚÌ´ú¸Õ¤F¤CºØ¤p¹««~«Y¹ï NASH ªº©ö·P©Ê... [ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C] [ªí©ú½u²ÉÅé¥\¯à»Ùê¦b NASH ¶i®i¤¤°_µÛ®Ö¤ß§@¥Î¡C]«nªº¡APWK/PhJ ¤p¹«ªº NASH °ò¦]ªí¹FÃлP¤HÃþNASH ¯S¼xªº« Å|«×³Ì°ª¡C 2.2017.5.1--CYP2E1 ½u²ÉÅé©w¦ìªº¬r²z¾Ç·N¸q www.ncbi.nlm.nih.gov/pmc/articles/PMC5627779/ ¦ì©ó½u²ÉÅ餺½¤¤Wªº CYP2E1 ¥i³q¹L©³ª«®ñ¤Æ²£¥Í¤ÏÀ³©Ê¥NÁª«©M/©Î¦b¨ä¶Ê¤Æ´`Àô¸Ñ°¸Áp®É²£¥Í ROS¡A±q¦Ó¯}Ãa½u²ÉÅé DNA¡B³J¥Õ½è©M¯×½è¡C¤Ï¹L¨Ó¡A³oºØ·l¶Ë·|¾ÉP½u²ÉÅé¹q¤l¶Ç»¼Ã줤 ROS ªº²£¥Í¼W¥[¡A±q¦Ó¶i¤@¨B·l¶Ë½u²ÉÅé¡A³Ì²×¾É P²ÓM¤¤ªº½u²ÉÅé¥\¯à»Ùê¡C ---------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/10 ¤W¤È 08:50:01²Ä 2876 ½g¦^À³ ªYÄ£¦b§í¨îCYP2E1¬O±j¶µ¡AÂX±i©Ê¤ß¦Ù¯fDCM¤]¦n¦nµo´§§a!(¾Ú§ÚÌ©Òª¾¡A¨ì¥Ø«e¬°¤îÁÙ¨S¦³¬ÛÃö¬ã¨sªº³ø¾É) 2022.11.1 ¼b¥Í¤½¥q¥H166»õ¬ü¤¸¦¬ÁÊAbiomed ¥HÂX¤j¨ä¤ß¦åºÞ·~°È(°w¹ï«æ©Ê¤ßŦ°IºÜ±wªÌ´£¨Ñ¤ßŦ´_µd´`Àô¤ä«ù¤Î«ùÄò·ÓÅ@¤§ÂåÀø¾¹§÷ªº¬ã¨s¡B¶}µo¤Î¾P°â) .... CYP2E1 ¬O²ÓM©M½u²ÉÅé ROS/RNS ªº¥Dn¨Ó·½ |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/16 ¤U¤È 07:20:54²Ä 2932 ½g¦^À³
|
§Ú§ëªº¥t¤@®a¥Í§Þ¤½¥q. ¦ÑÁó´Á±æ©ú¦~2´Á°µ§¹±ÂÅvª÷6-8.8»õ¬üª÷. ²{¦b¦pªG³Q¨ÖÁÊ, ¯à¦h¤Ö¿ú? 3-5»õ¬üª÷¦n¤F. ¦ÑÁó«ùªÑ20%, Àò±o0.6-1»õ¬üª÷. ¦ÑÁó¸òªk¤H»¡, ´Á±æ¥¼¨Ó(¤]³\10¦~§a)¥H100»õ¬üª÷³Q¨ÖÁÊ. ©Ò¥H¦ÑÁ󪺴Á±æȬO³Ð·~¦³¦¨Àò±o $20»õ¬üª÷¦^õX, ¦Ó«D0.6-1»õ¬üª÷. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/16 ¤U¤È 06:30:31²Ä 2931 ½g¦^À³
|
³Q¨ÖÁÊ¥i¯à©Ê¤p: 1. ¥xÆW¦ÑÁó¤£Ä@¦¨¬°¥t¤@®a¤j¤½¥q¨Æ·~¸sÁ`¸g²z; 2. ²{¦b¥«È§C, µLªkÀò¹ï¤è¸³¨Æ·|¦P·N°ª»ù; 3. ÁÙ¦³6¨t¦C¦p¦óp»ù? n8¨t¦Cªº¥¼¥²·R6¨t¦C. §Úı±o²{¦b¤Wµ¦, ÁÙ¬O½Í±ÂÅv810. µM«á±ÂÅv§¹IPO. ¦U¦ì$25¶Rªº¨S°ÝÃD,«ç¼Ë³£¤jÁÈ. §Ú¤µ¦~¶i³õÀ£¤O¸û¤j. ¨ä¹ê쥻´N¹wp1¦~«á§¹¦¨±ÂÅv. ªÑ²¼«ù¦³2¦~. ¤£¹L³Ì¾á¤ßªº¬O¨ä¶¡¤j¼t¦¨¥\±À¥XÃþ¦ü²£«~. ¥H«e§Ú§ëªº¤@®a¥Í§Þ´N¹J¨ì³oºØª¬ªp. ÁÙ¬Oı±o¤j®a¦hª`·N810¼Ï¶s¤Î±ÂÅv¶i«×. |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/16 ¤U¤È 06:00:42²Ä 2930 ½g¦^À³
|
§Ú¤£t³d¥ô:À³¸Ó¬O¤j¼t¶}»ù§C¡A©Ò¥HJP»¡¤£½æ ¡X¡X¡X¡X¡X¡X¡X¡X¡X- ³oÂI§Ú¤]»{¦P ¥Ø«eªº®ÉªÅI´º¤S¤£¤@¼Ë¤F 810¤w¹Gªñ¦¨¥\¶¥¬q §ó¬O³o¨â¤j¼t¦³»Ý¨DªºÃÄ ³B¤è¤Î«D³B¤èÃÄ¡A¨C¦~¶W¹L¦Ê»õ¬ü¤¸¡C ªYÄ£ªº»ùȤw§ó°ª ·Qn§C»ù¨ÖÁÊ¡A§O·Q¤F¡I °£«D¶}¥XÅý¤HµLªk©Úµ´ªº»ù½X |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/16 ¤U¤È 03:06:57²Ä 2929 ½g¦^À³
|
2022.7.16(2011¦~¿Õ¨©º¸¥Í²zÂå¾Ç¼ú±o¥DBruce Beutlerªº½×¤å) www.nature.com/articles/s41467-022-31812-4 ...³Ìªñªº¤@½g½×¤å³ø¾É¤F¤@Ó¤£¦PªºÆ[¹îµ²ªG¡A§YHsd17b13°ò¦]ºV°£¤p¹«¦b´XºØ¯×ªÕ¨x»¤¾Éªº¶¼¹±ø¥ó¤U¡A¦b¨x¯×ªÕÅÜ ©Ê¡B¨x·l¶Ë¡BÅÖºû¤Æ©Mª¢¯g¤è±»P WT ¤p¹«¨S¦³®t²§! --------------------------------------------------------------------------------------------- ¿Õ¨©º¸¥Í²zÂå¾Ç¼ú±o¥DBruce Beutlerªº½×¤å ¤£·|¼vÅTJ&J¨M©w²×¤îArrowheadªºNASH±ÂÅv¬ù? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/16 ¤U¤È 03:01:40²Ä 2928 ½g¦^À³
|
·|û¡G´MÄ_10151381 µoªí®É¶¡:2023/2/16 ¤U¤È 02:35:36²Ä 2926 ½g¦^À³ Ó¤H»{¬°ì¥ýñq¦X§@¨óij¨ì´Á«áªº¨º®a°ê»Ú¤jÃļt¿ð¿ð¨S¦³¤U¤å¡A«áÄò¦n¹³¤]¨S¦³¨ä¥LÃļtñ¦X§@¨óij¡A©Î³\¥i¯à¦³µo²{¬Y¨Ç°ÝÃD¡K. ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/12/2 ¤W¤È 08:20:48²Ä 1497 ½g¦^À³ ....1. ¤G®a¦P¦b2018¦~»PArrowheadñq¦X§@¨óij 2021.11.30´´ËÃļt»P¸¯Äõ¯À¥v§JÃļt¡^¤À§O¦b³Ìªñ¤@¶g¤º«Å¥¬§ë¤J¥Ñ¬ü°êÃļtArrowhead Pharmaceuticals «D°sºë©Ê¯×ªÕ©Ê¨xª¢»â°ìRNA¤zÂZªvÀø¬ãµo¡A¨ä¹ê¨â®aÃļt¬Ò¦¤w©ó2018¦~´N»PArrowheadñq¦X§@¨óij¡C geneonline.news/nash-janssen-gsk-rnai/ .... ------------------------------------------------------------------------------------------ J&J»PGSK³o¤G®a¬O¦b2018¦~¸òArrowheadñq[¦X§@¨óij]¡A3¦~«á¡AJ&J»PGSK¦b2021¦~¸òArrowheadñ[±ÂÅv¬ù]¡C |
|
|
·|û¡GNtumgk10151447 µoªí®É¶¡:2023/2/16 ¤U¤È 02:37:07²Ä 2927 ½g¦^À³
|
¨CÁûÃij£¦³¦Û¤vªº¶i«×®Éµ{¡K ¦X¤@on101°µ§¹¤T´Á³£ÁÙ¨S±ÂÅv¡AÁ{§É°µ¤F7¦~«ç¤£®³¥X¨Ó»¡¡K µu´Á¤º¨S®ø®§ªÑ»ù¤£·|º¦´N¬O¸gÀç°ÝÃD¤F¶Ü¡K¤@ª½®³§O®aÃļtªº±ÂÅv®Éµ{¨Ó¤ñ¸û¥u·|¥¢±æ¦Ó¤w |
|
|
·|û¡G´MÄ_10151381 µoªí®É¶¡:2023/2/16 ¤U¤È 02:35:36²Ä 2926 ½g¦^À³
|
Ó¤H»{¬°ì¥ýñq¦X§@¨óij¨ì´Á«áªº¨º®a°ê»Ú¤jÃļt¿ð¿ð¨S¦³¤U¤å¡A«áÄò¦n¹³¤]¨S¦³¨ä¥LÃļtñ¦X§@¨óij¡A©Î³\¥i¯à¦³µo²{¬Y¨Ç°ÝÃD¡K. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/16 ¤U¤È 01:22:58²Ä 2925 ½g¦^À³
|
¦X¤@¦b2a ÁÙ¨S°µ´Nñ¤F5.3»õ¬üª÷±ÂÅv. 6919 ¤]¥´ºâ2b §¹¦¨´N ñ±ÂÅv. ¹w¦ô6-8.8»õ. ªYÄ£810 ³£¤w¦b°µ¼Ï¶s¤F. À³¸Ó¬OºÞ²zÀç¹B°ÝÃD. |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/16 ¤U¤È 01:11:52²Ä 2924 ½g¦^À³
|
¦A¦h§Q¦h, ªÑ»ù¦u¤£¦í100. ¤£¬O¦³¤j²³¤£ª¾¹Dªº§QªÅ. ´N¬O¦ÑÁó¥u ¨I°g¬ãµo¤£¦b·NÀò§Q. ³Q¨ÖÁÊÀ³¸Ó¾÷·|´ù¯í, ¯à¦b1¦~¤º½Í ¤U±ÂÅv´N¤Ó©¯ºÖ¤F. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/16 ¤U¤È 01:02:02²Ä 2923 ½g¦^À³
|
Jp:...§Ú¿Ë¦Û¨ìheadquarters¥h...¦Ó¥B½Í¨ì³Ì«á...»¡±z̯ण¯à ³o®a.§Ú´N¶R±z̪ºªÑ²¼°Ú.§ë¸ê±z̪ºªÑ²¼°Ú.¥L»¡.... §Ú¤£t³d¥ô:À³¸Ó¬O¤j¼t¶}»ù§C¡A©Ò¥HJP»¡¤£½æ! ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/5/9 ¤U¤È 08:52:57²Ä 1956 ½g¦^À³ 05_·sÃĶ}µo_¿ïÃD J¤j¯«¦b14:15¬í°_:...½Í¨ì³Ì«á ¥L»¡±z̯ण¯à ³o®a.§Ú´N¶R±z̪ºªÑ²¼°Ú.§ë¸ê±z̪ºªÑ²¼°Ú...§Ú»¡ ¥xÆWªºªÑ²¼¤Ó«K©y..¹ï¤£°_ ¤£¦æ ±zn´N¶Rcompound ±z·Q¶R[¤½¥q] §Ṳ́£½æ±z....½Í¨ì³o¼Ë£²... ---------------------------------------------------------------------------------------------------- |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/16 ¤U¤È 12:51:00²Ä 2922 ½g¦^À³
|
2023.2.15---¹ï NASH ªº«¤j·s¨£¸Ñ(¤@ºØÄY«ªº¯×ªÕ¨x¯e¯f) www.labroots.com/trending/cell-and-molecular-biology/24677/major-insights-nash-severe-type-fatty-liver-disease ...¬ã¨s¤Hû¦b¥L̪º¤p¹«¼Ò«¬¤¤¨Ï¥Î siRNA °±¤î¤F RIPK3 ªºªí¹F¡C³oªí©ú¡A [¤@¥¹ RIPK3 ¤£¦Aªí¹F¡A§Y¨Ï¦b±w¦³ÄY«¯×ªÕ¨xªº°Êª«¤¤¡A¨x²ÓMªº¦º¤`©M¨x·l¶Ë¤]·|°¦Ü³Ì§C¡C] [¥¹ RIPK3 ¤£¦Aªí¹F¡A§Y¨Ï¦b±w¦³ÄY«¯×ªÕ¨xªº°Êª«¤¤¡A¨x²ÓMªº¦º¤`©M¨x·l¶Ë¤]·|°¦Ü³Ì§C¡C] 2023.1.23- www.nature.com/articles/s41467-023-35804-w ..§Ú̳q¹L¨x²ÓM RIPK3 ªº¥\¯à³à¥¢½T©w¤FÃa¦º©Êä¤`¦bÄY«¨x¯×ªÕÅܩʤ¤ªº«n©Ê¡C -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/17 ¤W¤È 10:30:19²Ä 2732 ½g¦^À³ ¦A¤@½g²Ï¹êªº¾Ç³N¬ã¨s¡AÅýSNP610/SNP630(CYP2E1)ªºNASHÁ{§É¦¨¥\²v¤j¼W¡C .... ·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/12 ¤W¤È 10:03:20²Ä 2709 ½g¦^À³ ³Ìªñµoªíªº´X½g½×¤å... ¬ã¨sªí©ú¡ACYP2E1 ¹ï RIPK3 ªºªí¹F°µ¥X¤F«¤j°^Äm....ªí©úCYP2E1 §@¬° RIPK3 ªº¤W´å°^ÄmªÌ... |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/16 ¤W¤È 11:12:39²Ä 2921 ½g¦^À³
|
Ãø¹DJ&J¤£·|·Q¨Ó¦¬ÁʪYÄ£¡H ¦³¸Ó¤½¥q·Qnªº¤£¶Ë¨x810 NASHªº610¤Î630 ¦¬ÁÊMadrigal nªá¤j¿ú ¦¬ÁʪYÄ£¬Û¤ñ¥unªá¤p¿ú |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/16 ¤W¤È 10:25:31²Ä 2920 ½g¦^À³
|
µ²½×: ±q©³¤U3½g¬ã¨s¡A±ÀÂ_JNJ-75220795¼Æ¾Ú¤£¦p¹w´Á¾÷²v°ª¡C ARO -HSD °§CºÃ¦ü NASH ±wªÌªº¨xŦHSD17B13 mRNA ªí¹F©M³J¥Õ½è¤ô¥¡C ir.arrowheadpharma.com/static-files/b6b66255-5618-4706-96f2-e0fbfc68ce75 ----------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2022/12/4 ¤U¤È 05:01:34²Ä 2705 ½g¦^À³ NASHªºµo¯f¾÷¨î¤Ó½ÆÂø¡A·sªº¬ã¨sµ²ªG¤£Â_´é²{¡AGSKªá10»õ¬ü¤¸±ÂÅvªºÃĪ«¡A¤p¹«¼Ò«¬²£¥Í¤F¤£¤@Pªºµ²ªG¡AÁÙ¦Ûµoµo®i¬°¿ðµo©Ê¯×ªÕ¨x¡C 1. 2021.3.16 Hsd17b13 ¯Ê³´¤£¯à«OÅ@¤p¹«§K¨üPªÎD©Ê¶¼¹·l¶Ë www.ncbi.nlm.nih.gov/pmc/articles/PMC8627256/ 2. 2022.7.16(2011¦~¿Õ¨©º¸¥Í²zÂå¾Ç¼ú±o¥DBruce Beutlerªº½×¤å) www.nature.com/articles/s41467-022-31812-4 ...³Ìªñªº¤@½g½×¤å³ø¾É¤F¤@Ó¤£¦PªºÆ[¹îµ²ªG¡A§YHsd17b13°ò¦]ºV°£¤p¹«¦b´XºØ¯×ªÕ¨x»¤¾Éªº¶¼¹±ø¥ó¤U¡A¦b¨x¯×ªÕÅÜ ©Ê¡B¨x·l¶Ë¡BÅÖºû¤Æ©Mª¢¯g¤è±»P WT ¤p¹«¨S¦³®t²§! 3. 2022.1.7 («nì³ÐªÌ:Ĭ¤å) www.ncbi.nlm.nih.gov/pmc/articles/PMC8776652/ ¥O¤HÅå³Yªº¬O¡A³Ìªñ¹ï HSD17B13 °ò¦]ºV°£¤p¹«ªº¬ã¨sªí©ú¡AHSD17B13 ¯Ê¥F¯g¥¼¯à«OÅ@¨xŦ§K¨ü°ª¯×ªÕ¶¼¹¡B¦è¤è¶¼ ¹©M°sºë¼ÉÅS¤Þ°_ªº¯×ªÕÅÜ©Ê·l¶Ë¡A³oªí©ú HSD17B13 ¯Ê¥F¯g¥i¯à¹ï¤p¹« NAFLD ¨S¦³«OÅ@§@¥Î¼Ò«¬¡C¦P¼Ë¡A¥t¤@²Õ³ø §i»¡¡A¯Ê¥F HSD17B13 °ò¦]ªº¤p¹«¦b 9 Ó¤ë¤j®É¦b¥¿±`¶¼¹¤U¦Ûµoµo®i¬°¿ðµo©Ê¯×ªÕ¨x.³o¨Ç·N·Q¤£¨ìªºµ²ªG¥Ø«e¯Ê¥F ¾÷¨î¸ÑÄÀ¡A»Ýn¶i¤@¨B¬ã¨s¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/16 ¤W¤È 08:43:30²Ä 2919 ½g¦^À³
|
J&J ¥¿¦bµo¥Í½¤ÑÂЦaªºÅܤÆ(2023.2.15ªð¦^ArrowheadªºÃĪ«±ÂÅv)¡AJ&J¥ô©R¤F¤@¦ì·sªº»â¾ÉªÌ¨Ó»â¾É¨ä»sÃĬãµo¡A§YÁɿյ᪺John Reed¡C §Ú¤£t³d¥ô²q´úì¦]: 1.JNJ-75220795¼Æ¾Ú¤£¦p¹w´Á? 2.¹w³Æ¥X¤â¦¬ÁÊMadrigal©Îintercept? 1. 2023.2.8-- (J&J)¼b¥Í¥þ²y·~°È¤j¾ã¹y¡I 37»õ¬ü¤¸¶R¤UArrowhead B¨xÃÄ®£³Q±ó¡H news.gbimonthly.com/tw/article/show.php?num=56115 2. 2023.2.15-- Janssen ±N I ´Á NASH(JNJ-75220795)Ô¿ïÃĪ«ªð¦^ Arrowhead www.fiercebiotech.com/biotech/jj-strikes-down-nash-pact-arrowhead-hep-b-deal-still-limbo ------------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/11/29 ¤U¤È 05:37:52²Ä 1489 ½g¦^À³ ¬d²z.»X®æ:°ªÃBªº³ø¹S¨Ã«D¨Ó¦Û©ó¶R½æ¡A¦Ó¬O¦s¦b©óµ¥«Ý¤§¤¤¡C 2020.12.22 ªYÄ£»P°ê»ÚÃļtñSNP-810¬ãµo¦X§@¨óij VS 2018.10. 04 Arrowhead »P Janssen ¹F¦¨ 37 »õ¬ü¤¸ªº³\¥i©M¦X§@¨óij (JanssenÀò±o3Ó¦X§@¶µ¥Ø:ARO-JNJ1 ;ARO-JNJ2;ARO-JNJ3) ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-enters-37-billion-license-and-collaboration-agreements ¸g¹L 1¦~2¦~3¦~ 2021 ¦~ 1 ¤ë 17 ¤é-- Arrowhead¤µ¤Ñ«Å¥¬¨ä¦X§@ªÌ¡A ·¨´Ë»sÃĤ½¥q, (Janssen) ±j¥ÍºX¤Uªº Janssen »sÃĤ½¥q¤§¤@¡A¤w©ÜÅS»P Arrowhead ´N¬ã¨s¤Æ¦Xª« JNJ-75220795 ªº¦X§@ |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2023/2/15 ¤U¤È 01:31:33²Ä 2918 ½g¦^À³
|
±q¼ÖÆ[¨¤«×¬Ý¡A¤µ¦~¦X§@¨óij¤w²Ä3¦~¤F¡A¬O¥i¯à±ÂÅv®×ñ©wªº¡C810³B¤è«D³B¤è¥þ²y¥[Á`3»õ¬ü¤¸¸¨«Ë»ù¡A¦X²zªÑ»ù¬O600¤¸¡A©¡®É¯u¥¿ªÑ»ù´N¬Ý¥«³õ»{©w¡C |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/14 ¤U¤È 09:18:12²Ä 2917 ½g¦^À³
|
§ÚÓ¤H·Pı¶¶§Qªº¸Ü: 2024 Q2 ¥H«á8¨t¦C¦³¾÷·|±ÂÅv¦¨¥\. |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/14 ¤U¤È 04:20:56²Ä 2916 ½g¦^À³
|
R¤j ¸g¸ß°Ý¥DºÞ¾÷Ãö¡A®Öã¸ÕÅç®×¥ó§¡µn¸ü©ó»OÆWÃĪ«¸ÕÅç¸ê°Tºô¡C ¸Óºôµn¸üªº²Ä¤@¶µ¦h¾¯¶q¸ÕÅç36¤H¦Ü2023¦~12¤ë31¤é¤î¡C ±©¸Óºô¶Áöµn¸ü¬°¡u¦h¾¯¶q¡v¡A«o¶È¦³500²@§J¡u³æ¾¯¶q¡v¡C ¨Ã¥¼µn¸üÄÝ©ó4-8§J¤§¨ä¥L¾¯¶q¡A¡u¦h¾¯¶q¡v¡B¡u³æ¾¯¶q¡v©úÅ㤣²Å¡C ¡u¥l¶Ò¤¤¡v Ó¤H±À´ú¬O¦P¤@Ó¸ÕÅç ¥t610-2¤]¸ò¤W¤S¤U¬[ºô¶®É¶¡¤@¼Ë¦Ü114¦~¡A¤H¼Æ80¤H¡C |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/14 ¤W¤È 09:50:21²Ä 2915 ½g¦^À³
|
´Nºâ³o¬O810¦b¥xÆWªº¼Ï¯Ã(¤H) §Úı±o2¤j¼tÁÙ¬O¤£·|¶R³æ ¥¦ªùn¬Ýªº¬O¬ü°ê¼Ï¯Ã ¡X¡X¡X¡X ¨â¤j¼t¥»´N¦³Ã±¦X§@¦X¬ù-¸ÕÃÄ®Ä A¤½¥qÃĮĸÕÅç¤w³q¹L B¤½¥q¦X¬ù¨ì´Á¡A¥¼§¹¦¨ÃĮĸÕÅç¡C ¨º¤Ñ¤W¤S¤U¬[ªººô¶ ¦³B¤½¥q¥¿¦b¶i¦æÃĮĽT»{ ³B¤èñªº¼Ï¶s¹LÃö Ó¤H»{¬°»ùȬOOTCÃÄÃÒ©Ò¤£¯à¤ñ |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/14 ¤W¤È 08:49:09²Ä 2914 ½g¦^À³
|
¯È¤j ¬ü°ê¼Ï¶s¸ÕÅç¬O³æ¾¯¶q ì¥Ó½Ð¤ñ¼Ð·Ç¾¯¶q°ª «á¨Ó¬ün¨D¤j¹«¸ÕÅç ¤½¥q¥¼ÁקK¼vÅT¸ÕÅç ¦n¹³§ï¬°¼Ð·Ç¾¯¶q ¥un»OÆW¼Ï¶s¹LÃö ±ÂÅv´N¦n½Í¡A¬ü¸ÕÅç¤]·|§ó¶¶§Q¡C |
|
|
·|û¡G¯È¤W´I¶Q10134993 µoªí®É¶¡:2023/2/14 ¤W¤È 12:52:14²Ä 2913 ½g¦^À³
|
¦h¾¯¶q¤À²Õ¡A¨C²Õ14¤H¡A³Ì¤Ö6¤H¦¸¡A¤w§¹¦¨12¤H¦¸ --------------------------------------- §Ú¤@ª½Ä±±o ¨ä¹ê³o´N¬O¦bÁ¿ª¯ªº¹êÅç ±Ôz¤£²M ³æ¦ì¥Î¿ù ´Nºâ³o¬O810¦b¥xÆWªº¼Ï¯Ã(¤H) §Úı±o2¤j¼tÁÙ¬O¤£·|¶R³æ ¥¦ªùn¬Ýªº¬O¬ü°ê¼Ï¯Ã |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/13 ¤U¤È 08:11:14²Ä 2912 ½g¦^À³
|
R¤j ³o¨Ç±Ôz¬O¤½¥q¨º¤Ñ¤W¬[¨S¦h¤[¤S¤U¬[ªº¤º®e ¨º®É±z¤]po¤F¥ÎÃÄ7¤Ñªº¸ê°T ¨ì©³¬O¤°»ò¡Hn°Ý¦¶¸³¡I ¤S¬°¤°»ò¤S¤U¬[¡H ¬O¤£¬O¥h¦~³oÓ¤½§i¸ÕÅçµ²ªG¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2023/2/13 ¤U¤È 03:23:28²Ä 2911 ½g¦^À³
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2023/2/12 ¤U¤È 08:40:35²Ä 2909 ½g¦^À³ ....810ªº¼Ï¶s¸ÕÅç¡A±q¡u¦h¾¯¶q¤À²Õ¡A¨C²Õ14¤H¡A³Ì¤Ö6¤H¦¸¡A¤w§¹¦¨12¤H¦¸¡v¡u¥ÎÃÄ7¤Ñ¡A¤£¶Ë¨x¡Aµ²ªG²Å¦X¹w´Á¡v ¡u¸ÕÅç³ø§iÄ¡¼g¤¤¡vµ¥µ¥¡A±À¦ô¼Æ¾Ú¥¿¦V¡A·¥¦³¾÷·|¦bµu´Á¶¡¤º¤½§iµ²ªG¡C ------------------------------------------------------------------------------------------------ ¤W±À³¸Ó¬O«ü111/10/20ªº¤½§i: 1.¨Æ¹êµo¥Í¤é:111/10/20 2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¸ÕÅçÄݩ󥻤½¥qSNP-810[¼Ï¯Ã©ÊÁ{§É]ÅçÃÒ¸ÕÅ礧¤@¡A¸ÕÅç³]p¬O¦h¾¯¶q¡B³æª¼¡B³æ¤¤¤ß ¤Î¤fªAµ¹»P´¶®³¯k©ÎµL¨x¬r©Ê¤îµh·sÃÄSNP-810¤§Á{§É¦w¥þÅçÃÒ¸ÕÅç¡A§ë»P¾¯¶q4-8§J¡A ¸Ó¸ÕÅ羯¶q¤w¶W¹L²{¦æ¤AñQÓi×ô(Acetaminophen)ÃÄ«~»¡©ú®Ñ®Öã¨Ï¥Î¨C¤é³Ì¤j¾¯¶q¡A ¹wp§¹¦¨36¦ì¨ü¸ÕªÌ¡A¨ú±oÁ{§É¦w¥þµ²ªG«á¡A¦A¦V½ÃºÖ³¡¹Ãĸp¿Ô¸ß·sÃÄ®Öã¤W¥«¡C -------------------------------- (§Ú¦b¥xÆWÃĪ«Á{§É¸ÕÅç¸ê°Tºô¬d¤£¨ì36¦ì¨ü¸ÕªÌªºÁ{§É?) |
|
|
·|û¡G¤g¾|µf10147850 µoªí®É¶¡:2023/2/12 ¤U¤È 10:32:05²Ä 2910 ½g¦^À³
|
ÁÂÁ¦V«e¤j¤ÎROGER5889¤jªº¸Ñ»¡. ·U¨Ó·U¤F¸Ñ»Ùê¦b¨º¸Ì. ³o¼Ë¬Ý610n±ÂÅvÁÙ»·ªº«Ü. §Y¨Ï2¢ê¹L, ÁÙ¦³°Æ§@¥Î°ÝÃD. ²{¶¥¬q´Á«Ý810±ÂÅv¤ñ¸û°È¹ê.§Ú¬Ý3¤ë¥Ó½ÐIPO¤WÂd¡AÀ³¸Ó¾÷²v¤£¤j¡D¨S¦n»ù¿ú¡D |
|
|
|